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Summary 
Isomerization of L-aspartyl and L-asparaginyl residues to form L-isoaspartyl residues in proteins is one 
type of protein damage that can occur under physiological conditions and can potentially lead to 
conformational change, loss of function and enhanced protein degradation. Protein L-isoaspartyl 
methyltransferase (PCMT or PIMT)1 is a repair enzyme, which allows the reconversion of L-isoaspartyl 
residues to L-aspartyl residues in protein. Although the catalytic function of PCMT is known, its 
physiological roles remain less well understood. Pcmt1 gene knockout in mice leads for example, via 
molecular mechanisms that remain mostly obscure, to activation of insulin/IGF-1 and MAPK signalling 
pathways in the brain, and premature death due to massive epileptic seizure events. 
In this doctoral research project, we have used both mammalian cells and zebrafish models to 
investigate the impact of PCMT deficiency on insulin/IGF-1, MAPK and calcium signalling as well as 
how PCMT may be involved in epilepsy. In mammalian cells we used shRNA and CRISPR/Cas9 
technology to reduce or completely silence PCMT expression, with the main objective being to mimic, 
in cell culture, the activation of the IGF-1 and MAPK signalling pathways observed in Pcmt1 knockout 
mice in the hope to thereby increase the chances to elucidate the underlying molecular mechanisms. 
In zebrafish we used an antisense morpholino-based strategy to knock down both PCMT homologs 
and thereby establish a new whole organism model to further study the physiological functions of 
PCMT, more particularly in the brain. 
Our results indicate that insulin/IGF-1 signalling is not affected by PCMT knockdown or knockout in 
mammalian cells whereas a time-dependent MAPK pathway activation could be detected in a Pcmt1 
knockout mouse hippocampal cell line. In zebrafish, we showed that the two PCMT homologs Pcmt 
and Pcmtl (Pcmt/l) possess isoaspartyl methyltransferase activity. In pcmt/l knockdown (or morphant) 
zebrafish larvae we did not detect abnormal electrical activity in the brain, but we identified 
movement impairment and strongly perturbed brain calcium fluxes. Abnormal calcium responses 
were also observed in the Pcmt1 knockout mouse hippocampal cell line. We concluded that the 
interplay between PCMT and growth signalling pathways is highly dependent on experimental model 
and may not be amenable to investigation in cell culture. Importantly, our results clearly show that 
PCMT plays a pivotal role in calcium signalling and suggest that PCMT-dependent repair mechanisms 
may be important to prevent calcium-related neurological disorders.
                                                          
1 Gene-protein acronym conventions: followed in this thesis: PCMT is used, in an organism-independent way, as 
the general acronym for the L-isoaspartyl protein carboxyl methyltransferase (also known as protein L-
isoaspartyl methyltransferase). As organism-specific acronyms we used: PCMT1, human gene; PCMT1, human 
protein; Pcmt1, mouse gene; Pcmt1, mouse protein; pcmt, zebrafish gene; Pcmt, zebrafish protein. 
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1 Introduction 
1.1 Damage and repair in biology 
Every day human beings are exposed to different environmental stressors, e.g. radiation that leads to 
damage of various molecules in the cells. Nevertheless, cells are still functioning normally due to repair 
mechanisms in charge to maintain cell homeostasis. While DNA damage and repair have been 
intensively studied, only few repair mechanisms for proteins have been described. Even more 
recently, small molecules or metabolites were found to be prone to damage and cellular mechanisms 
for their repair are being uncovered. A considerable body of evidence suggests that cellular inability 
to repair damaged molecules like DNA and proteins plays an important role in neurological disorders 
as well as aging (CAMPISI and VIJG 2009). Therefore, extending our understanding of those cellular 
functions should contribute to gain insights into the physio-pathological processes involved and may 
be key for improving our quality of life. 
1.1.1 DNA damage and repair 
DNA is the keeper of all the genetic information essential for life. Yet, it is continuously subjected to 
damages either by endogenous (e.g. reactive oxygen species (ROS), endonucleases, or defective 
replication machinery) or exogenous sources (e.g. radiation or mutagenic compounds). Excessive, 
uncontrollable damage can lead to accumulation of mutations that can eventually result in cellular 
dysfunctions associated with human diseases such as cancer or neurodegenerative disorders (POIRIER 
2004; COPPEDE and MIGLIORE 2015). In 2015, the Nobel Prize in chemistry was awarded to Tomas 
Lindahl, Paul Modrich and Aziz Sancar for their work on DNA repair. They showed that in order to keep 
DNA integrity, cells developed different repair mechanisms depending on the type of damage (LINDAHL 
et al. 2016). These repair mechanisms include, among others, mismatch repair (MMR), single-strand 
or double-strand break repair, base excision repair (BER) or nucleotide excision repair (NER). 
Deficiency in one of those repair mechanisms can lead to different disorders like Xeroderma 
Pigmentosum, Cockayne syndrome and Huntington disease (JEPPESEN et al. 2011). One example, is the 
MMR deficiency resulting in trinucleotide expansion in the gene encoding huntington protein leading 
to polyglutaminyl residues in Huntington disease (KOVTUN and MCMURRAY 2001). The discoveries in the 
DNA repair mechanisms opened the door for the development of many therapeutic agents such as 
olaparib which targets DNA repair for treatment of ovarian cancer (WIGGANS et al. 2015). Likewise, 
development of drugs modulating repair mechanisms of proteins and metabolites might offer new 
perspectives for therapeutic strategies targeting other diseases. 
Introduction 
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1.1.2 Metabolite damage and repair 
Similarly to DNA, metabolites are also prone to damage, which may appear spontaneously or as a 
result of endogenous processes (mostly enzyme side reactions) (LINSTER et al. 2013). Enzymes, 
particularly in primary metabolism, are proteins that are generally thought to specifically catalyse one 
reaction, allowing the formation of one product. However, it is now known that the specificity of 
metabolic enzymes is weaker than expected and that side activities of various enzymes may lead to 
the production of abnormal or ‘damaged’ metabolites. Accumulation of these potentially harmful 
metabolites in the cell can interfere with normal cell function and lead to development of diseases. A 
growing number of metabolite repair enzymes is being identified and for some of them the 
physiological relevance is well illustrated by the fact that their dysfunction leads to debilitating disease 
(VAN SCHAFTINGEN et al. 2013; KREMER et al. 2016). One example is the production of the neurotoxic 
molecule L-2-hydroxyglutarate (L-2HG) as a side product of L-malate dehydrogenase. L-2HG is 
recognized by the repair enzyme L-2-hydroxyglutarate dehydrogenase (L2HGDH), which converts it to 
the non-toxic α-ketoglutarate. L2HGDH deficiency leads to L-2HG aciduria, a severe neurometabolic 
disorder (VAN SCHAFTINGEN et al. 2009). To illustrate the concept further, (S,S)-adenosyl methionine 
(SAM), the second most used cofactor in the cell, is prone to damage as (R,S)-SAM can form 
spontaneously from (S,S)-SAM (HOFFMAN 1986). A repair mechanism was identified in Saccharomyces 
cerevisiae involving the Mht1 and Sam4 enzymes which transfer the methyl group from (R,S)-SAM to 
homocysteine to form methionine and adenosyl homocysteine, which are both normal metabolites in 
the cell, and by this limiting the accumulation of the abnormal (R,S)-SAM form (VINCI and CLARKE 2007). 
The field of metabolite damage and repair is still young and growing, but the work accomplished 
already so far shows that, similar to DNA, proofreading enzymes are needed also in metabolism to 
correct for unavoidable enzymatic mistakes or reverse unwanted chemical modifications. 
1.1.3 Protein damage and repair 
Protein degradation is known to take place in the cell via two major mechanisms: proteolysis via the 
proteasome or via autophagy. In the former mechanism, misfolded, damaged or unneeded proteins 
are tagged with ubiquitin through enzymatic reactions prior to their degradation by the proteasome 
protein complex. In the latter mechanism, autophagy uses a transport mechanism into the lysosome 
where proteins, protein complexes or organelles can be degraded. In contrast to both proteasome 
and lysosome-based mechanisms, enzyme-based mechanisms exist where damaged proteins are not 
degraded but rather repaired. Indeed, similarly to DNA and metabolites, proteins can acquire damages 
by oxidation reactions or intramolecular rearrangements through which the amino acid sequence is 
altered and proteins can become non-functional. However, repair systems exist that are specific to 
amino acid damages and allow the restoration of functional proteins (CLARKE 2003). Imbalance 
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between protein damages, proteolytic pathways and protein repair systems can lead to accumulation 
of pathological forms of proteins and disease development especially in the nervous system (ROSS and 
POIRIER 2005). Various forms of protein damage and repair are explained in more detail in the following 
section. 
1.2 Forms of protein damage and repair 
1.2.1 Methionine oxidation 
Methionine, either free or in proteins, can be oxidized to methionine sulfoxide by hydrogen peroxide, 
oxygen radicals, or other oxidizing agents. Methionine oxidation (Figure 1-1) was found to affect 
various cell functions. In calmodulin, methionine oxidation leads to structural alteration and declined 
affinity to calcium (GAO et al. 1998). Another example is inactivation of voltage gated K+ channels 
affecting cellular excitability (CHEN et al. 2000). The repair system for this type of protein damage 
involves methionyl-sulfoxide reductases (MsrA and MsrB) that reduce methionyl-sulfoxide back to 
methionine (WEISSBACH et al. 2002). MsrA overexpression was found to extend the lifespan in 
Drosophila melanogaster and increased its ability to resist oxidative stress (RUAN et al. 2002). Similarly, 
MsrA and MsrB overexpression were found to protect mammalian cells against oxidative stress 
induced by H2O2 (MOSKOVITZ et al. 1998). In this regard, Msr enzymes are proposed to not only play a 
role in protein repair but also in ROS scavenging since the reduction reaction is NAD(P)H dependent. 
The cycles of the oxidation by ROS and reduction by Msr, scavenges molecules like H2O2 and drives an 
NAD(P)H oxidation reaction (LEVINE et al. 1996). Finally, MsrA overexpression in mice increased survival 
rate and improved insulin sensitivity in aged mice (SALMON et al. 2016). All the previous findings show 
that the protein damage caused due to methionine oxidation can be repaired directly by the Msr 
enzymes rather than protein degradation and de novo synthesis. 
 
Figure 1-1: Oxidation of methionine and its reduction by methionyl-sulfoxide reductases (Msr A/B). Reactive oxygen species 
(ROS) oxidize methionine, either free or in proteins, to S- or R-methionyl-sulfoxides, which are recognized by MsrA 
or MsrB, respectively, and reduced back to methionine by these enzymes. 
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1.2.2 Tyrosine nitration 
Another form of protein damage due to oxidative stress is tyrosine nitration. Nitric oxide reacts with 
superoxide forming peroxynitrite, which in turn interacts with macromolecules in the cell causing 
modulation of cellular functions. Tyrosine residues in proteins were found to be a potential target of 
peroxynitrite (Figure 1-2), which was confirmed when tyrosine-containing peptides were able to 
rescue PC12 cells from peroxynitrite-induced apoptosis (YE et al. 2007). Later, heat shock protein 90 
(Hsp90) was identified as a major target for nitration and this kind of damage induces neuronal cell 
death (FRANCO et al. 2013). In addition, one noticeable consequence of tyrosine nitration is blocking 
of phosphorylation sites as it has been shown that tyrosine protein kinases were inhibited via 
peroxynitrite-mediated nitration of tyrosine (GOW et al. 1996). Signalling pathways involving 
phospholipase Cγ were found to be inhibited by tyrosine nitration (DREW and LEEUWENBURGH 2002). A 
proposed repair mechanism was assumed to exist when protein extracts from rat spleen and lung 
were able to modify nitrotyrosine-containing peptides but not free nitrotyrosine. However, the 
enzyme responsible for this activity has not been identified yet. (KAMISAKI et al. 1998). Furthermore, 
denitrase activity, from mouse spleen protein crude extract, was found to restore glutamine synthase 
activity inhibited by tyrosine nitration (KAMISAKI et al. 1998; GORG et al. 2007). In summary, tyrosine 
residues in proteins are prone to nitration altering protein function and there is a potential enzymatic 
repair mechanism whose molecular identity remains until now unknown. 
 
Figure 1-2: Tyrosine nitration. Oxygen radicals oxidize NO leading to the formation of peroxynitrite which in turn is able to 
react with tyrosine to form nitrotyrosine. A nitrotyrosine denitrase activity was detected in cellular crude extracts, 
but the enzyme responsible for this activity has not been identified yet. 
1.2.3 Protein glycation 
Unlike controlled, enzymatically catalysed, addition of sugar to protein (protein glycosylation), non-
enzymatic addition of sugar to protein (protein glycation) is another type of protein damage. In 
general, aldehyde or ketone groups can react with free primary amines forming a Schiff base through 
an SN2 nucleophilic attack (JOHNSON et al. 1983). In case of protein glycation, the Schiff base can be 
formed from the interaction between the aldehyde group of glucose and free amine groups in 
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proteins, in particular the ε-amine group of lysine side chains. Although the reaction is reversible, the 
Schiff base can undergo rearrangement giving rise to the more stable Amadori structure (fructosamine 
in case of glucose as the reacting sugar) (Figure 1-3). Glycation at lysine residues in proteins was 
reported as a sort of damage that can affect protein function. For example, RNase A as well as human 
erythrocyte bisphosphoglycerate mutase were found to have lower enzymatic activity when glycated 
(WATKINS et al. 1985; FUJITA et al. 1998). Moreover, glycated calmodulin failed to activate three of its 
downstream kinases (KOWLURU et al. 1989). Recently, protein glycation was found to enhance 
aggregation of β-amyloid (Aβ) and α-synuclein, increasing their pathogenicity (VICENTE MIRANDA and 
OUTEIRO 2010; VICENTE MIRANDA et al. 2016). Fructosamine-3-kinase (FN3K) is a protein repair enzyme 
that phosphorylates fructosamine residues in proteins and facilitates deglycation, restoring the 
original free amine group (DELPIERRE and VAN SCHAFTINGEN 2003). Although, the physiological relevance 
of the repair mechanism of FN3K is still not well understood, it is notably assumed that it might play a 
role in neurodegenerative diseases considering the impact of protein glycation on protein 
aggregation. 
 
Figure 1-3: Protein glycation and repair by fructosamine 3-kinase (FN3K). Unlike enzymatically controlled glycosylation of 
proteins, glucose can react spontaneously with amine groups in proteins forming fructosamines. FN3K 
phosphorylates fructosamine residues in proteins, initiating the repair mechanism (deglycation). Adapted from 
(COLLARD 2004). 
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1.2.4 Proline isomerization 
Although the majority of peptide bonds in proteins are in the trans conformation, those preceding 
prolyl residues are often in the cis conformation. Prolyl residues are however, prone to cis/trans 
interconversion, leading to conformational alterations, which in turn might lead to protein 
aggregation. An example of this process is observed in β-2-microglobulin (β2m) where trans 
conformation preceding prolyl residues together with Cu2+ ions trigger its amyloidogenesis (EAKIN et 
al. 2006). Since the isomerization process can happen spontaneously, an enzymatic system is required 
to maintain the correct conformation of prolyl residues in native proteins. Peptidylprolyl isomerase 
(Pin1) catalyses the cis/trans isomerization of prolyl residues in proteins (SCHIENE and FISCHER 2000). It 
appears that the repair mechanism by Pin1 is important for protein homoeostasis since the two 
hallmark proteins of Alzheimer’s disease, Aβ and tau, were found to be affected by the cellular Pin1 
activity. Pin1 knockout in mammalian cells increased Aβ secretion while overexpression reduced the 
secretion, which was confirmed in a mouse Pin1 knockout as it showed higher levels of insoluble Aβ42 
in the brain (PASTORINO et al. 2006). Moreover, Pin1 was found to restore the ability of phosphorylated 
tau to bind to microtubules and remarkably, Pin1 knockout mice experience motor and behavioural 
deficits (LU et al. 1999; LIOU et al. 2003). Thus, Pin1 is needed for conformational control of proline 
and protein homeostasis and shows interesting links to neurodegenerative disease. 
1.2.5 Aspartyl and asparaginyl isomerization 
Formation of isoaspartyl residues and the repair mechanism by protein L-isoaspartyl 
methyltransferase (PCMT) is the main focus of the work presented in this thesis and will be discussed 
in more detail below. 
Interestingly, all protein repair enzymes discovered so far, i.e. PCMT, Msr, Pin1 and FN3K, are usually 
ubiquitously expressed in all tissues, but show highest expression in the brain (MIZOBUCHI et al. 1994; 
KUSCHEL et al. 1999; COLLARD et al. 2003; FANGHANEL et al. 2006). This suggests that targeted repair of 
proteins in post-mitotic cells such as neurons is essential, in addition to protein degradation and 
resynthesis, to prevent the accumulation of damaged proteins that may otherwise lead to disease 
development and notably neurodegenerative diseases. Protein repair enzymes are therefore also 
potentially promising targets for drug interventions. 
1.3 Protein L-isoaspartyl methyltransferase 
1.3.1 Isoaspartyl formation from aspartyl and asparaginyl residues 
Under physiological conditions, the carbonyl carbons in the side chains of L-aspartyl and L-asparaginyl, 
after deamidation, residues in proteins are prone to a nucleophilic attack by the loan pair of electrons 
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on the nitrogen atom of the peptide bond formed with the next amino acyl residue (Figure 1-4). As a 
result, deamidation, in case of L-asparaginyl, or dehydration, in case of L-aspartyl, takes place leading 
to the formation of an L-succinimide intermediate. At this stage, racemization can take place to form 
D-succinimide. L-succinimide and D-succinimide are unstable and spontaneously form L-isoaspartyl as 
the major product (70%), L-aspartyl (30%), and minor amounts of D-aspartyl and D-isoaspartyl (GEIGER 
and CLARKE 1987). The conversion of aspartyl to isoaspartyl residues leads to an introduction of an 
extra -CH2- group in the peptide backbone with conformational changes in the 3D structure of the 
protein. Remarkably, the rate of isoaspartyl formation from asparaginyl residues was found to be 15 
– 36 times faster in case of asparaginyl than from aspartyl residues (STEPHENSON and CLARKE 1989). 
Furthermore, asparaginyl deamidation was found to be faster when it is followed by an amino acid 
with a relatively small or hydrophilic side chain, such as alanine, glycine, histidine and serine, in 
contrast to bulky amino acids, such as phenylalanine, tyrosine or tryptophan (ROBINSON and ROBINSON 
2001b). Secondary and tertiary protein structures were also found to influence isoaspartyl formation, 
small peptides being for example more prone to isomerization than bigger and highly structured 
proteins. Also, flexible regions in calmodulin were found to accumulate more isoaspartyl residues than 
non-flexible regions (CLARKE 1987; OTA and CLARKE 1989b; OTA and CLARKE 1989a). Additionally, 
asparaginyl residues in α-helices and β-turns were found to be more resistant against isomerization 
(XIE and SCHOWEN 1999). 
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Figure 1-4: Formation of isoaspartyl residues in proteins. L-asparaginyl (L-Asn) and L-aspartyl (L-Asp) residues undergo 
spontaneous modification to form L-succinimide, which in turn can racemiz to D-succinimide. L- and D-succinimide 
are unstable and will eventually form either D-aspartyl (D-Asp), D-isoaspartyl (D-isoAsp), L-aspartyl (L-Asp) or L-
isoaspartyl (L-isoAsp), with the major product being L-isoAsp. The L-Asn or L-Asp conversion to L-isoAsp shifts the 
peptide backbone (blue line) to the side chain, introducing an extra CH2 group into the peptide backbone. 
1.3.2 Influence of isoaspartyl formation on protein structure and function 
Isoaspartyl formation can have different effects on proteins including conformational changes, loss-
of-function, gain-of-function, protein aggregation and higher susceptibility to degradation. Isoaspartyl 
formation is a major concern in the field of therapeutic protein production, where recombinant IgG 
antibodies can lose for example up to 70% of potency due to isoaspartyl formation (HARRIS et al. 2001), 
also recombinant human stem cell factor loses half of the biological activity due to isoaspartyl 
formation (HSU et al. 1998). Another example of functional decline is in creatine kinase B, which loses 
the ability to phosphorylate creatine due to isomerization events (DIMITRIJEVIC et al. 2014). On the 
other hand, isoaspartyl formation was also shown to be a mechanism for gain-of-function. For 
example, conversion of asparaginyl to aspartyl, which involves the intermediate formation of the 
isoaspartyl residue, enables fibronectin to bind to integrin αvβ3 in the process of extracellular matrix 
activation (CURNIS et al. 2006; CORTI and CURNIS 2011). Aggregation is another consequence of 
isoaspartyl formation. Aβ isolated from Alzheimer’s disease patients, was found to contain isoaspartyl 
residues at position 1, 7 and 23 (SARGAEVA et al. 2009); isomerization of Asp23, but not Asp7, enhanced 
Aβ aggregation (ROHER et al. 1993; SHIMIZU et al. 2002). Enhanced degradation due to isoaspartate 
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formation was observed in calmodulin, which during in vitro aging accumulated isoaspartyl residues 
over time and when injected into Xenopus laevis oocytes was degraded faster than a native calmodulin 
as a control (SZYMANSKA et al. 1998). Finally, an in vivo study showed that autoimmune mice strains 
like MRL mice have higher levels of isoaspartyl residues in protein compared to the control strains 
B10.BR nonautoimmune mice and the authors suggested that isoaspartyl formation in protein can 
trigger autoimmunity by T cell hyperproliferation (YANG et al. 2006). It appears that isoaspartyl 
formation can lead to different outcomes under normal physiological or pathological conditions, 
depending on the identity of the protein as well as on the position of the isomerized residue in the 
protein (REISSNER and ASWAD 2003). 
In addition, as already indicated above, isoaspartyl formation has been associated with 
neurodegenerative conditions like Alzheimer’s disease (AD), Parkinson’s disease, and multiple 
sclerosis (MS). In AD patients, higher levels of isoaspartyl residues have been found in plasma proteins, 
tau, and as mentioned above, Aβ (WATANABE et al. 1999; SHIMIZU et al. 2000; YANG et al. 2011). Also in 
MS patients, myelin basic protein was found to accumulate higher isoaspartyl residues than control 
individuals (FRIEDRICH et al. 2016). Finally, α-synuclein, a hallmark in PD, was found to having the 
tendency for isoaspartyl formation, however, this observation is still under debate since another 
group could not confirm this observation (VIGNESWARA et al. 2006; MORRISON et al. 2012; VIGNESWARA 
et al. 2013). Therefore, isoaspartyl formation in proteins can be a risk factor for neurodegenerative 
diseases. 
1.3.3 PCMT transfers a methyl group to isoaspartyl residues initiating their repair to 
aspartyl residues 
Back in 1965, when Axelrod and Daly studied SAM-dependent methyltransferases in bovine pituitary 
gland extracts using radiolabelled S-adenosyl methionine (SAM), they reported the release of 
radiolabelled methanol. The production of radiolabelled methanol was inhibited upon boiling the 
extracts and they concluded that the SAM-dependent methanol production is catalysed enzymatically 
(AXELROD and DALY 1965). Almost ten years later, the methanol-forming enzyme was purified from 
bovine pituitary gland and it was found to methylate hormones secreted from the anterior lobe of the 
pituitary gland (DILIBERTO and AXELROD 1974). This enzyme is identified now as PCMT, which specifically 
recognizes L-isoaspartyl residues and to a lesser extend D-aspartyl residues in proteins and methylates 
them using SAM as the cofactor, thereby initiating their reconversion to L-aspartyl residues (JOHNSON 
et al. 1987b; MCFADDEN and CLARKE 1987; LOWENSON and CLARKE 1992) (Figure 1-5). It can be noted that 
PCMT activity can lead to complete repair if the original residue was an aspartyl residue; if the 
isoaspartyl residue was formed from an asparaginyl residue, the ‘repaired’ residue will also be an 
aspartyl residue, which thus represents a net asparaginyl to aspartyl conversion for the protein. 
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Figure 1-5: Isoaspartyl repair mechanism by PCMT. PCMT catalyses the transfer of a methyl group from the cofactor SAM to 
the carboxyl group in isoaspartyl residues, facilitating the formation of the L-succinimide intermediate. There is 
still a higher chance that L-succinimide will revert to the isoaspartyl form than to form an aspartyl residue, but 
since aspartyl residues are not methylated by PCMT, the reaction equilibrium is shifted towards aspartyl 
formation. 
PCMT is widely conserved from bacteria to humans (JOHNSON et al. 1991a; LI and CLARKE 1992) with 
very few species, such as notably Saccharomyces cerevisiae, lacking a PCMT homolog (Figure 1-6). It 
appears that PCMT1 is the key enzyme to limit the accumulation of isoaspartyl residues in proteins, 
since protein extracted from tissues of Pcmt1 knockout mice contain high levels of isoaspartyl (KIM et 
al. 1997b). Isoaspartyl containing peptides were found to be resistant to peptidase activity, limiting 
their removal through proteolysis and highlighting the importance of PCMT activity not only for 
protein repair but also for efficient protein degradation (JOHNSON and ASWAD 1990). Nevertheless, 
other mechanisms to limit isoaspartyl formation may exist, more particularly in the few species that 
do not encode PCMT, as recently proposed by Patananan et al., (PATANANAN et al. 2014). The authors 
showed indeed that in S. cerevisiae, isoaspartyl accumulation is very low despite the absence of PCMT 
activity in this species and proposed that there is an alternative mechanism for isoaspartyl degradation 
implying metalloproteases. 
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Figure 1-6: PCMT distribution in organisms. PCMT is highly conserved among many species except for a few Gram-positive 
bacteria and fungal species. Adapted from (PATANANAN et al. 2014). 
PCMT being a SAM-dependent methyltransferase, the enzyme possesses a nucleotide-binding 
domain, which is highly conserved among different phyla (KAGAN et al. 1997; SMITH et al. 2002). The 
mechanism by which PCMT1 methylates isoaspartyl was thought earlier to be a random sequential 
mechanism (JOHNSON and ASWAD 1993), but later structural studies showed that it is an ordered 
sequential mechanism where SAM binds first, followed by the isoaspartyl peptide, then release of the 
methyl ester followed by SAH (SMITH et al. 2002; BENNETT et al. 2003). Two isoenzymes were described 
for human PCMT1 (PCMT I and PCMT II) sharing virtually identical primary structure with differing C-
termini arising from alternative splicing resulting in the 226 amino acids PCMT I ending with Arg-Trp-
Lys and the 227 amino acids PCMT II ending with Arg-Asp-Glu-Leu (MACLAREN et al. 1992; TAKEDA et al. 
1995). The PCMT I is more basic than PCMT II and ratio of the second isoform to the first (II/I) varies 
between 0.52 to 1.2 as estimated in human blood samples (OTA et al. 1988). Nevertheless, difference 
in their function has not been reported until now. Human PCMT1 exhibits a polymorphism at residue 
119, with 77% Ile and 23% Val in Caucasian populations (DEVRY and CLARKE 1999). The enzyme 
containing Val119 exhibits lower activity, but higher thermal stability and an increased affinity for 
endogenous substrates (DAVID et al. 1997; RUTHERFORD and DAGGETT 2009). This phenomenon was 
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explained by enforced van der Waals interactions between the residue Val119 and Leu130 (compared 
to Ile119 and Leu 130) (RUTHERFORD and DAGGETT 2010). Overall, PCMT is a SAM-dependent 
methyltransferase widely distributed enzyme with relatively small molecular weight (25 kDa) that 
initiates the conversion of isoaspartyl in proteins to aspartyl residues. 
1.3.4 Tissue distribution and subcellular localization of PCMT 
Different approaches have been used to study the tissue distribution and subcellular localization of 
PCMT including measuring transcript levels, enzyme activity levels or immunostaining techniques. It 
is accepted that PCMT is a soluble enzyme present in the cytosol (ASWAD and DEIGHT 1983) which is 
also supported by the fact that many of its substrates are cytosolic proteins, as will be described in 
the following section. Using Western blot analysis, Boivin et al showed that PCMT1 is ubiquitously 
expressed in rats in different organs like thymus, heart, pancreas, testes, kidney, spleen, liver, 
intestine, stomach, lung, muscles, and brain (BOIVIN et al. 1995). They also showed that, despite the 
solubility of the enzyme, it was abundant in membranous protein extracts when they tested different 
fractions from kidney including brush border membrane, basolateral membrane, intracellular 
membranes as well as mitochondrial fractions and nuclei (BOIVIN et al. 1995). Although PCMT has 
substrates in the nucleus, the enzyme is lacking a nuclear targeting sequence. However, the small size 
of the enzyme (25 kDa) suggests that it can easily diffuse through the nuclear pores since the cut off 
is about 60 kDa (WANG and BRATTAIN 2007). Finally, as mentioned above, there are two isoenzymes of 
PCMT1 resulting from alternative splicing. One of them ends with the amino acid sequence RDEL 
(POTTER et al. 1992), which is very similar to the endoplasmic reticulum (ER) retention signal KDEL 
(PELHAM 2000). Nevertheless, experimental evidence for ER localization has not been yet reported. 
The presence of this potential ER retention signal suggests the requirement of isoaspartyl repair during 
protein synthesis or a chaperon role for PCMT (KINDRACHUK et al. 2003; SAITO et al. 2016). 
PCMT transcript levels in the brain and testes of rats were the highest in comparison to the other 
organs, which was also confirmed later with enzymatic activity levels. In the brain, the highest 
transcript levels were found more specifically in the cerebral cortex and the hippocampus (MIZOBUCHI 
et al. 1994; KIM et al. 1997b). Immunostaining results were consistent with the enzymatic assays, but 
expanded the expression levels to potential other brain regions by showing high staining in the 
substantia nigra, locus coeruleus and paraventricular nucleus as well (BILLINGSLEY and BALABAN 1985). 
Interestingly, neuronal cells expressed more PCMT1 compared to glial cells as indicated by the 
immunostaining intensity (BILLINGSLEY and BALABAN 1985; BILLINGSLEY et al. 1985a). PCMT activity was 
also detected in synaptosomes, but whether this activity is membrane-associated or soluble inside the 
synaptosomes remains unknown (DILIBERTO and AXELROD 1976). The second highest expression levels 
for PCMT was found in the reproductive organs, especially in germinal cells. Testes depleted from 
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sperm from rats, either by X-ray or genetically in infertile rats, have lower enzyme isoaspartyl 
methyltransferase activity than control, suggesting higher levels in germ cells than somatic cells 
(GAGNON et al. 1979; O'CONNOR et al. 1989). PCMT1 activity increases with the spermatogenesis 
process, most likely to limit protein damage during sperm storage and preserve damage free gametes 
for fecundation. In agreement with this assumption, low levels of PCMT1 were found in the sperm tail 
in asthenozoospermia, reduced sperm motility, compared to normozoospermia (HASHEMITABAR et al. 
2015). Thus, PCMT has the potential to also be involved in a kind of rejuvenation mechanism where 
the molecules in the gametes have to be damage-free (BOUCHARD et al. 1980; CHAVOUS et al. 2000; 
UNAL et al. 2011). 
1.3.5 PCMT substrates 
In principle, any aspartyl or asparaginyl residue in a peptide chain can potentially undergo 
isomerization; in practice, it was observed, however, that certain residues in certain proteins are more 
prone to isoaspartyl formation than others (ROBINSON and ROBINSON 2001b; ROBINSON and ROBINSON 
2001a). Since the discovery of the catalytic activity of PCMT1 in 1974, many proteins have been 
identified to be methyl accepting substrates for this enzyme and many of them, including hormones 
secreted from the pituitary gland, the hormonal carrier proteins neurophysins, calmodulin and 
epidermal growth factor (EGF), were identified independently in several studies (DILIBERTO and AXELROD 
1974; EDGAR and HOPE 1974; GAGNON et al. 1981; DIAUGUSTINE et al. 1987). In 2006, two different groups 
independently used a proteomics approach to identify Pcmt1 substrates in mouse brains. They 
extracted total proteins from brains of Pcmt1 knockout mice to enrich the potential substrates for 
Pcmt1. While the first group (VIGNESWARA et al. 2006) labelled the protein extract with radioactive SAM 
using exogenous recombinant PCMT and resolved them by 2-D gel electrophoresis, the second group 
(ZHU et al. 2006b) resolved the proteins and then used on-blot labelling with radioactive SAM and 
recombinant PCMT. Finally, both groups analysed the radiolabelled proteins by mass spectrometry. 
The difference in the sequence of their procedures is also important since isoaspartyl formation in the 
protein extracts can be induced in vitro enriching isoaspartyl residues in specific proteins (MORRISON 
et al. 2012) which might explain the differences in the identified substrates in both studies. Both 
groups identified thereby many Pcmt1 substrates for the first time, but also confirmed previously 
reported substrates. The methodology used did, however, not allow for detection of low abundant 
proteins and low molecular weight proteins and peptides (< 14 kDa). The broad functional diversity of 
the PCMT substrates identified so far suggests that PCMT deficiency has the potential to affect 
numerous different cellular pathways and that PCMT plays an overall housekeeping function in the 
cell. 
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Table 1-1: Pcmt1 substrates identified in the Zhu et al. (2006) and the Vigneswara et al. (2006) proteomic studies. 
Substrate Reference 
α-Synuclein (VIGNESWARA et al. 2006) 
β-Synuclein (VIGNESWARA et al. 2006) 
Calreticulin (VIGNESWARA et al. 2006) 
Clathrin light chains a and b (VIGNESWARA et al. 2006) 
Collapsin response mediator protein 2 
(CRMP2/ULIP2/DRP-2) 
(ZHU et al. 2006b) 
Dynamin 1 (ZHU et al. 2006b) 
Microtubule-associated protein-2 (VIGNESWARA et al. 2006) 
Phosphatidylethanolamine-binding protein 
(PEBP or RKIP) 
(VIGNESWARA et al. 2006) 
Stathmin (VIGNESWARA et al. 2006) 
Synapsin I (PARANANDI and ASWAD 1995; REISSNER et al. 
2006; ZHU et al. 2006b) 
Synapsin II (ZHU et al. 2006b) 
Tubulin (ZHU et al. 2006b) 
Ubiquitin carboxyl-terminal hydrolase L1 (VIGNESWARA et al. 2006) 
 
1.3.6 Physiological roles of PCMT 
As mentioned above, given its broad tissue distribution and the wide range of substrates, PCMT may 
potentially interact with many biochemical pathways and cellular processes. Previous studies indicate 
that PCMT plays a role in aging, autoimmunity, various disease conditions, apoptosis and growth 
signalling pathways (JOHNSON et al. 1991b; DOYLE et al. 2003; FARRAR et al. 2005a; ZHU et al. 2006a). 
However, the molecular mechanisms underlying these interactions are generally not understood. So 
far, the well-documented biochemical function of PCMT is the catalytic transfer of a methyl group 
from SAM to isoaspartyl residues in proteins. To add to the complexity of its biological role, a PCMT 
protein engineered to lack this catalytic function was able to increase the survival of E. coli cells under 
stress induced by heat shock (KINDRACHUK et al. 2003). This observation suggested an additional, more 
chaperone-like role for PCMT. Given the focus of this thesis work on the cross-talk between PCMT and 
cell signalling, this section describes more specifically current knowledge on how this protein is 
involved in apoptosis as well as the MAPK, insulin/IGF-1, and calcium signalling pathways. 
Introduction 
15 
 
1.3.6.1 PCMT1 protects against apoptosis 
Several studies have reported a role of PCMT in apoptosis. Overexpression of PCMT was first 
demonstrated to protect primary mouse cortical neurons against apoptosis when treated with Bax, a 
proapoptotic protein (HUEBSCHER et al. 1999). PCMT1 overexpression was also found to protect SH-
SY5Y neuroblastoma cells from dopamine-mediated apoptosis (OUAZIA et al. 2015). Several 
mechanisms were suggested for the anti-apoptotic role of PCMT1. The first involves the Bcl-xL protein, 
which had been reported to lose its anti-apoptotic function upon deamidation of two critical 
asparaginyl residues (with formation of isoaspartyl residues); this protein was found to be a substrate 
of PCMT1, methylation of the isoaspartyl residues by PCMT1 in the Bcl-xL protein being proposed to 
allow for recovery of its anti-apoptotic function (CIMMINO et al. 2008). This was later confirmed by 
showing that microRNAs 15a and 16-1 downregulated PCMT1 expression, a down-regulation which 
was associated with increased susceptibility to apoptosis due to non-repaired (deamidated and 
isomerized) and therefore non-functional through Bcl-xL (SAMBRI et al. 2011). A second proposed 
mechanism involves the inhibition of the proapoptotic mammalian sterile 20-like kinase 1 (Mst1). In a 
yeast-two hybrid system screen looking for binding partners of Mst1, PCMT1 was identified as an 
Mst1-interacting protein. Follow-up work showed that PCMT1 binds to the kinase domain of Mst1 
based on co-immunoprecipitation experiments and that overexpression of PCMT1 attenuates Mst1 
activity in response to apoptosis inducing conditions like hypoxia (YAN et al. 2013). A third proposed 
mechanism, implicates a potential regulation of the genome guardian (and pro-apoptotic) p53. It has 
been observed that p53 protein levels in the cell are inversely proportional to PCMT1 levels and that 
Asn29 and Asn30 in p53 are prone to deamidation. These and other observations led the authors to 
suggest that higher PCMT1 activity could lead to deactivation of p53 and cell death inhibition via 
isoaspartyl methylation (LEE et al. 2012). These conclusions should, however, be taken with caution 
since Asn29 and Asn30 are not among the hotspots for deamidation in p53, and could have been 
induced artificially (ROBINSON and ROBINSON 2001b; MORRISON et al. 2012). In conclusion, several lines 
of evidence show that PCMT1 plays a role in negative regulation of apoptosis and some mechanistic 
interactions have been proposed with Bcl-xL, Mst1 and p53. 
1.3.6.2 PCMT1 downregulation leads to activation of the Mitogen-activated protein kinase 
(MAPK) pathway 
Protein phosphorylation is a major regulatory mechanism for many cellular functions, including 
signalling cascades mediating extracellular stimuli to the cell nucleus (COHEN 2000). Among the latter, 
the MAPK signalling pathway was found to be affected by PCMT1 activity. Kosugi et al knocked down 
PCMT1 in HEK293 cells and analysed phosphorylation levels of three intermediates in the MAPK 
pathway (MEK, ERK, and Raf) (Figure 1-7) upon stimulation with EGF. They found that the MAPK 
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pathway was hyperactivated in response to EGF stimulation by showing higher phosphorylation levels 
of the three intermediates in the PCMT1 knockdown cells as compared to control cells (KOSUGI et al. 
2008). In apparent contradiction with the observations by Kosugi et al (2008), PCMT1 knockdown in 
MDA-MB-231 epithelial cells under detachment conditions led to lower phosphorylation levels of 
Erk1/2 (RYU et al. 2011). One potential mechanism underlying the interaction between PCMT1 and 
MAPK signalling could be through the Raf inhibitor phosphatidylethanolamine-binding protein (PEBP) 
(also known as Raf kinase inhibitory protein RKIP), which is a PCMT substrate (VIGNESWARA et al. 2006). 
Whether the function of RKIP is affected by isoaspartyl formation has not been investigated yet, but 
one could assume a decrease in activity under PCMT1 deficiency (resulting in a lack of isoaspartyl 
repair in RKIP), leading to hyperactivation of the MAPK signalling pathway at least under certain 
conditions and in certain cell types. Another possibility is through increase of the total protein levels 
of Erk1/2 as reported by Yang et al (YANG et al. 2013) in a proteomics study in Pcmt1 knockout mice. 
However, this wouldn’t explain the increase in phosphorylation levels of intermediates upstream to 
Erk1/2 and would contradict other observations Kosugi et al (2008) showing the same levels of total 
Erk1/2 in PCMT1 knockdown and control cells. Thus, while several lines of evidence suggest a 
regulation of the MAPK pathway by PCMT activity, this interaction appears to be strongly dependent 
on cell type and physiological state of the cell and the molecular mechanism(s) involved remain 
completely obscure. 
1.3.6.3 PCMT1 downregulation leads to activation of the Insulin signalling (IGF-1) pathway 
Components of insulin/insulin-like growth factor I (IGF-1) signalling pathway (hereafter designated as 
IGF-1 pathway) have emerged in the past two decades as being critically involved in the regulation of 
lifespan, and this in a conserved way from yeast to humans (BARBIERI et al. 2003). A key observation 
that was followed by an avalanche of research activity in this direction in the aging field was that 
Caenorhabditis elegans worms deficient in the DAF-2 (insulin-like receptor homolog) live twice as long 
as wild type worms (KENYON et al. 1993). IGF-1 pathway downregulation was subsequently found to 
extend lifespan in other model organisms including Saccharomyces cerevisiase (yeast), Drosophila 
melanogaster (fruit fly), and mice (HOLZENBERGER et al. 2003; KENYON 2010). 
In this context, two interesting observations were made in the course of the characterization of the 
Pcmt1 knockout mice: (1) the drastically shortened lifespan of these mice and (2) an increase in the 
size of their brains. More than 95% of Pcmt1 knockout mice die before day 60 and the remaining 
animals do not make it beyond day 100 (KIM et al. 1997b). On the other hand, overexpression of Pcmt 
in D. melanogaster extended their lifespan by about 35% under stress conditions (CHAVOUS et al. 2001). 
Similar results were obtained in C. elegans where overexpression of Pcmt led to a lifespan extension 
under heat stress (BANFIELD et al. 2008; KHARE et al. 2011). Concerning the second key observation 
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mentioned above, despite the small body weight of the Pcmt1 knockout mice, their brains were found 
to be 10% – 30% larger than the wild type brains (YAMAMOTO et al. 1998; FARRAR et al. 2005a). This 
enlargement was proposed to be due to increased cell proliferation, since CD4+ cells deficient in Pcmt1 
showed higher proliferation rates in response to stimulators (DOYLE et al. 2003; FARRAR et al. 2005b) 
and subsequently evidence was presented in Pcmt1 knockout mice for increased neurogenesis (FARRAR 
et al. 2005b). 
The effects on lifespan and the brain enlargement, which phenocopy IGF-1 overexpression in mice 
(CARSON et al. 1993), suggested a possible interaction between PCMT1 and IGF-1 signalling. This 
hypothesis was supported by findings by Farrar et al (2005) as they found higher phosphorylation 
levels of intermediates in the IGF-1 signalling pathway, including Akt and GSK3β, in Pcmt1 knockout 
mouse brains by Western blot analysis. Further investigation by immunohistochemistry showed the 
highest increases in phosphorylation levels of IGF-1 pathway intermediates in the Pcmt1 knockout 
mice to be localized in the hippocampus (FARRAR et al. 2005a). Additional support for the PCMT/IGF-1 
pathway/aging connection was provided by MacKay et al (2012) (MACKAY et al. 2012), who showed 
that Wortmannin (inhibitor of the phosphoinositide 3-kinase PI3K, an early intermediate in the IGF-1 
pathway) administration to Pcmt1 knockout mice increased their lifespan and decreased brain weight. 
Pcmt-dependent regulation of lifespan via insulin-like signalling may be a conserved feature as the 
lifespan extension observed in C. elegans animals overexpressing PCMT was shown to depend on DAF-
16, the downstream transcription factor of the insulin-like signalling pathway in worms (KHARE et al. 
2011). 
Taken together, the evidence supporting a cross-talk between PCMT and the IGF-1 signalling pathway 
is thus strong, but the molecular mechanism behind this interaction remains completely unknown. It 
could be that, as proposed for the interaction with apoptosis, one of the IGF-1 pathway intermediates 
has an isoaspartyl molecular switch through which PCMT1 could modulate protein function via 
methylation. Another possibility, in the context of the damage theory, is that in the absence of PCMT1, 
the overall accumulation of isoaspartyl residues in proteins leads to inactivation of one or several 
protein phosphatases that are more susceptible to this kind of damage, resulting in increased protein 
phosphorylation levels across several signalling pathways, including the MAPK and IGF-1 pathways. 
Reproducing these effects of PCMT1 deficiency on signalling in cell culture models to investigate the 
molecular mechanisms in play was a major focus of the first part of this thesis. 
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Figure 1-7: (a) Insulin/IGF-1 signalling pathway. (b) MAPK pathway adapted from (FARRAR et al. 2005a) 
1.3.6.4 PCMT1 and calcium signalling 
Similar to phosphorylation, calcium regulates many functions in the cell. Free cytosolic calcium 
concentrations are very low and tightly controlled to remain around a 100 nM basal levels. Different 
calcium regulator proteins were identified as substrates for PCMT1 including, among others, 
calmodulin (VIGNESWARA et al. 2006). Calmodulin was first reported as an exceptionally good substrate 
for enzymatic carboxyl methylation by Gagnon et al in 1981 (GAGNON et al. 1981), before even the 
molecular identification of PCMT, and they showed that this post-translational methylation inhibits 
the stimulatory effect of calmodulin on cyclic nucleotide phosphodiesterase. It has later been 
confirmed by different groups that calmodulin is among the major substrates for PCMT  (BILLINGSLEY et 
al. 1985c; JOHNSON et al. 1985; JOHNSON et al. 1987a). Isoaspartyl residues were identified in the 
calcium binding motifs as well as in flexible regions of the calmodulin protein. (JOHNSON et al. 1985; 
OTA and CLARKE 1989a; POTTER et al. 1993). Furthermore, it has been shown that calcium binding affects 
methylation of calmodulin by PCMT1 (OTA and CLARKE 1989a) and this observation has been confirmed 
in vivo by simultaneous injection of aged calmodulin and [methyl-3H]SAM into Xenopus oocytes, as 
the authors showed that calmodulin pre-incubated with EDTA was a better substrate than calmodulin 
pre-incubated with CaCl2 for carboxyl methylation in these experiments (DESROSIERS et al. 1990). 
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Calmodulin was also identified as an interaction partner binding PCMT1 in a yeast two-hybrid screen 
and here, an effector function of calmodulin on PCMT1 was proposed in addition to the enzyme-
substrate interaction, as calmodulin was found to stimulate the activity of PCMT1 (O'CONNOR and 
O'CONNOR 1998). During the phenotyping of the new PCMT-deficient cell and animal models created 
in this thesis, important perturbations in calcium signalling were observed, providing further in vivo 
evidence for a role of PCMT in this process. 
1.4 Zebrafish as a model organism in biomedical research 
1.4.1 General considerations 
Danio rerio – zebrafish – is a freshwater teleost fish belonging to the Cyprinid family, which has 
emerged as a new vertebrate animal model organism (Figure 1-8a). Over the past 35 years, it has been 
used more and more frequently in diverse areas of developmental biology, biomedical research, 
toxicology, and as an excellent in vivo platform for drug discovery (ZON and PETERSON 2005), as 
indicated by the increasing number of zebrafish-related publications during that period (Figure 1-8b). 
The prominent starting point of zebrafish as a model organism in research goes back to 1994, when 
two highly ambitious projects aimed to generate a large-scale ethyl-N-nitrosourea (ENU) genome-
wide mutational screen in zebrafish. This ENU screen led to the identification of important genes for 
development and organogenesis and subsequent description and characterization of the mutations 
were published in an historic special issue – exclusive to zebrafish – of Development (MULLINS et al. 
1994; DRIEVER et al. 1996; HAFFTER et al. 1996). This represented the first implementation of such a 
large genetic screen in a vertebrate organism, putting the zebrafish model intro the spotlight. 
a                                               b 
 
Figure 1-8: Zebrafish model (a) Adult zebrafish, female on the left and male on the right (Copyright Thierry Marysael) (b) 
Increasing number of publications retrieved from PubMed using ‘zebrafish’ as the search keyword for the period 
going from 1980 to 2016. 
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1.4.2 Advantages setting zebrafish apart as a model organism 
Zebrafish has become an attractive model organism in biomedical research due to several reasons. 
First, its genome was fully sequenced revealing high similarity to the human genome (~70%) and 
suggesting high conservation in many biochemical pathways and cellular processes between humans 
and zebrafish (HOWE et al. 2013). Second, zebrafish develops very fast from a single cell zygote to an 
early larva in only 3 days (Figure 1-9), which allows to efficiently study the impact of genetic 
manipulation on early stages of development, and reaches adulthood to become sexually mature in 
three months, also speeding up experiments compared to many other vertebrate models (KIMMEL et 
al. 1995). Third, many diseases have been already modelled in zebrafish, offering platforms for disease 
mechanism identification (LIESCHKE and CURRIE 2007). Fourth, the small size of embryos and larvae (0.5 
– 5 mm depending on the developmental stage) enables high-throughput, whole animal in vivo 
screenings (MURPHEY and ZON 2006). Fifth, there is an increasing number of genetic and molecular 
methods and tools (antisense morpholino oligonucleotides, Tol2 transgenesis, CRISPR-Cas9 genome 
editing, a well-established cDNA library (TON et al. 2002)) and of publically available online database 
resources (see for example http://zfin.org/) for zebrafish. Finally, the ex-uterus development, the high 
number of progeny (100 – 300 eggs per week), the ease of genetic manipulation, the transparency at 
early developmental stages, and its cost-effective husbandry are other important aspects that make 
zebrafish an excellent vertebrate model. 
The advantages of working with zebrafish appear substantial; nevertheless, some overall limitations 
of this model should be mentioned as well. Phylogenetic studies have shown that early during teleost 
lineage (more than 150 million years ago), zebrafish underwent a teleost-specific genome duplication. 
From an anatomical and physiological point of view, although being a vertebrate, there are relevant 
differences between zebrafish and mammals, such as for example the lack of lungs, limbs, synovial 
joints, and heart separations. 
Introduction 
21 
 
 
Figure 1-9: Zebrafish at different early developmental stages. hfp: hours post fertilization 
1.4.3 Zebrafish as a model for neurological disorders 
Epilepsy is one of the most common chronic neurological disorders affecting about 1% of the world 
population, with up to 30% - 40% of cases presenting resistance to available treatments (GO and SNEAD 
2008; THURMAN et al. 2011). Although zebrafish was originally used primarily as a model to study 
embryogenesis and development, it is becoming a valuable in vivo tool to study many other 
physiological and patho-physiological processes like angiogenesis, cardiovascular diseases, cancer 
(WHITE et al. 2013) and neurological disorders (MARTIN-JIMENEZ et al. 2015). Particularly in the field of 
neurobiology, zebrafish has proven to be a good vertebrate model to study diseases affecting the 
central nervous system, and it has become a well-established model for epilepsy (CUNLIFFE 2016). 
Pentylenetetrazol (PTZ) for example, a gamma-aminobutyric acid receptor antagonist that is used 
widely to induce epilepsy in animals, was found to elicit an epileptic response in zebrafish 
characterized by behavioural, electrographic, and molecular changes reminiscent of the ones 
observed in rodent seizure models  (BARABAN et al. 2005). The PTZ-induced electrical discharges were 
also attenuated by the commonly used anti-convulsant drugs valproate and diazepam in zebrafish. 
Since Pcmt1 knockout mice experience epileptic seizures (KIM et al. 1997b; YAMAMOTO et al. 1998) for 
reasons that remain poorly understood, it seemed tempting to try using a simpler vertebrate model 
to investigate the connection between PCMT1 and epilepsy. We identified two PCMT1 homologs in 
zebrafish and after establishing and validating a PCMT-deficient zebrafish model, we used it to 
investigate, amongst other things, its response to PTZ exposure. 
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1.5 Reverse genetic approaches 
Different reverse genetic approaches were used in the present thesis to downregulate PCMT 
expression levels either in mammalian cells in culture or in zebrafish. 
1.5.1 Lentiviral transduction of shRNA for gene knockdown in mammalian cells 
RNA interference (RNAi) is an endogenous regulatory process through which cells control gene 
transcription (FIRE et al. 1998). Short hairpin RNAs (shRNAs) imitate RNAi and can be used to 
specifically knock down genes of interest. After transcription of shRNA constructs, the Dicer enzyme 
cleaves the generated RNA molecules to release 21 – 23 oligo small interfering RNAs (siRNAs) that will 
specifically bind a target mRNA through base pair complementarity. The siRNA/mRNA complexes are 
then incorporated into RNA-induced silencing complex (RISC) that will degrade them (Figure 1-10). 
 
Figure 1-10: Schematic representation of lentiviral delivery of shRNA for gene knockdown in a mammalian cell. After insertion 
of the viral genetic material (RNA) into the cell, the viral reverse transcriptase (RT) converts it to DNA. which is 
transported into the nucleus and integrated into the genome by homologous recombination. The encoded shRNA 
is then transcribed, processed by Dicer to guide the RISC complex and finally degrade the target mRNA transcript. 
Lentiviral technology provides a highly efficient method for delivery of nucleic acids into cells with 
genome integration of the desired DNA sequence. Unlike other transient gene knockdown techniques, 
integration of shRNA into the genome of a cell allows generating stable cell line with lower 
transcription levels of the target gene. ViraPower™ (ThermoFisher Scientific) is a mix of three plasmids 
(pLP1, pLP2 and pLP/VSVG) that, combined with the pLenti6/BLOCK-iT™-DEST plasmid, encode all the 
components (Section 6.1.1) necessary to form lentiviral particles having the ability to transduce 
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mammalian cells and integrate encapsulated cloned shRNA constructs into the cell genome for 
constitutive expression and efficient knockdown of the target gene. 
1.5.2 CRISPR/Cas9 technology for gene knockout in mammalian cells 
Clustered regularly interspaced short palindromic repeats (CRISPR) was discovered in prokaryotes as 
an acquired immune system against viruses (HORVATH and BARRANGOU 2010). Indeed, it has been 
shown that some bacteria and archaea become resistant to a virus after their first exposure. Those 
prokaryotes can keep a short viral DNA sequence and integrate them into their genome. This latter 
DNA sequence can then be transcribed to act as a guide RNA (gRNA). Upon the second exposure to 
the same virus, a CRISPR-associated (Cas) nuclease, guided by the gRNA, recognizes the invading DNA 
and causes a double strand break (DSB). Those acquired sequences from foreign DNA are always 
associated with a protospacer adjacent motif (PAM), which can vary depending on the specific CRISPR 
system (FENG et al. 2016).  
The CRISPR/Cas9 system has been exploited to develop the current state-of-the-art methodology for 
precise genome editing. It relies on the co-expression of the Cas9 endonuclease, initially isolated from 
Streptococcus pyogenes, with a gRNA targeting a specific DNA sequence in the genome to edit. In this 
specific genome location, the Cas9 endonuclease generates a DSB that will be repaired through either 
Non-Homologous End Joining (NHEJ) or Homology-Directed Repair (HDR). The HDR mechanism 
requires a repair template and is used to insert a desired mutation into the target genomic locus 
(Figure 1-11). In contrast, NHEJ does not require any template and may lead to the insertion or 
deletion (InDel mutation) of several nucleotides at the DSB site. The acquisition of such indel 
mutations has the potential of leading to a frameshift that could generate a non-functional protein 
and thereby result in gene silencing or knockout. 
 
Figure 1-11: Schematic representation of the CRISPR/Cas9 strategy for gene knockout or editing. Cas9: CRISPR associated 
protein; DSB: double strand break; HDR: Homology-directed repair; NHEJ: Nonhomologous end joining Adapted 
from (RAN et al. 2013) 
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1.5.3 Morpholino oligomers for gene knockdown in zebrafish 
Morpholinos (MOs) are of nucleic acid analogs where the ribose or deoxyribose sugar ring is replaced 
by a 6-membered morpholine ring and the polar phosphodiester linkage by a nonpolar 
phosphorodiamidate linkage. They contain the same four default bases that can bind to nucleic acids 
(SUMMERTON and WELLER 1997). They can be chemically synthesized to specifically target a gene of 
interest in order to decrease the amount of the encoded protein. They have been developed as a 
standard and efficient tool for gene knockdown in zebrafish (EKKER 2000; DRAPER et al. 2001). 
The chemical structure of MOs confers a higher chemical stability compared to DNA or RNA and a 
higher resistance to nucleases. MOs can exert their knockdown effect through two mechanisms. The 
first one corresponds to the binding of the MO at the translational initiation site in the 5’UTR region 
of the target mRNA transcript to inhibit protein translation. The second corresponds to the binding of 
the MO either at the intron-exon or exon-intron junction interfering thereby with the correct splicing 
of the target transcript leading ultimately to the skipping of an exon or inclusion of an intron (Figure 
1-12).  
 
Figure 1-12: MO mechanism of action for gene downregulation. MOs can interfere with correct transcript splicing when 
binding at the exon/intron or intro/exon junction. They can also lead to translation blocking through binding to 
the translational initiation site in the target transcript. 
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Aims 
The main aims of the presented thesis work were to 1) a) establish a mammalian cell culture model 
that mimics the effects of PCMT deficiency on the IGF-1 signalling pathway that was observed in Pcmt1 
knockout mice and b) use that model to elucidate the molecular mechanism underlying the crosstalk 
between PCMT and IGF-1 signalling 2) establish a more simple whole animal model of PCMT deficiency 
in zebrafish to better understand the role of PCMT in epilepsy that was also observed in the more 
difficult to handle mouse model and 3) use the cell culture and zebrafish models to investigate the 
influence of PCMT on calcium signalling in vivo. 
In the frame of the first objective, we used lentiviral transduction of shRNAs to establish a stable 
PCMT1 knockdown human HEK293 cell line and the CRISPR/Cas9 system to knock out Pcmt1 in the 
mouse hippocampal cell line HT22. Following model establishment and validation, we compared the 
activation status of the MAPK and IGF-1 signalling pathways after various stimuli in the PCMT deficient 
and control cells. 
For the second aim, as isoaspartyl methyltransferase activity had never been reported in zebrafish 
before, we started by identifying PCMT homolog gene candidates in the zebrafish genome and validate 
them by testing the enzymatic activity of their expression products in vitro. We then proceeded to 
knock down the identified PCMT orthologs using morpholino technology, validated PCMT deficiency 
in the generated morphant larvae and started phenotyping them by performing morphological 
analyses. Finally, we studied their suitability to develop seizures by tracking their locomotor behaviour 
and recording the electrical activity of their brains. 
In the third aim, we wanted to take advantage of the newly established PCMT deficient cell culture 
and animal models to study the interaction between the isoaspartyl methyltransferase and calcium 
signalling in vivo. A strong body of evidence for such an interaction has been gathered through in vitro 
studies, but in vivo evidence remained more scarce. We notably took advantage of the transgenic 
zebrafish line that expresses the fluorescent calcium sensor GCaMP6F to monitor calcium fluxes and 
confirmed that PCMT activity also heavily interferes with intracellular calcium movements and 
therefore most likely signalling in vivo. Similar observations were done on the mouse hippocampal 
cells in culture, which now puts us in a position to take investigations of this physiological role of PCMT 
to the next level. 
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2 Materials and methods 
2.1 Materials 
2.1.1 Antibodies used in the present thesis 
Table 2-1: Antibodies used for Western blot analysis 
Antibody Species Clonality Company Catalog 
# 
MW of 
target 
protein 
(kDa) 
β-Actin (13E5) Rabbit IgG Monoclonal Cell Signalling 4970 45 
Akt (pan) (C67E7) Rabbit IgG Monoclonal Cell Signalling 4691 60 
p44/42 MAPK (Erk1/2)  Rabbit Polyclonal Cell Signalling 3264 42, 44 
GAPDH (D16H11) XP® (HRP 
Conjugate) 
Rabbit Monoclonal Cell Signalling 8884 37 
MEK1/2 (47E6)  Rabbit Monoclonal Cell Signalling 9126 45 
Phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) 
(D13.14.4E) XP® 
Rabbit IgG Monoclonal Cell Signalling 4370 44, 42 
Phospho-Akt (Ser473) (D9E) 
XP®  
Rabbit IgG Monoclonal Cell Signalling 4060 60 
Phospho-GSK3β (Ser9) (5B3) Rabbit Monoclonal Cell Signalling 9323 46 
Phospho-MEK1/2 
(Ser217/221) (41G9) 
Rabbit IgG Monoclonal Cell Signalling 9154 45 
Anti-PCMT1 Rabbit Polyclonal Abcam ab97446 25 
Anti-rabbit IgG HRP-linked Goat IgG Polyclonal Cell Signalling 7074 N/A 
2.1.2 Mammalian cell lines used in the present thesis 
Table 2-2: Mammalian cell lines 
Cell line Purpose Source 
Human embryonic kidney 
cells (HEK293) 
Study of the interplay between 
PCMT1 and growth signalling 
pathways. 
the American Type Culture 
Collection (ATCC) 
Human embryonic kidney 
fast-growing cells (HEK293FT) 
Production of lentiviral 
particles carrying shRNA for 
PCMT1 knockdown 
experiments. 
ThermoFisher Scientific 
Catalog number: K4944 
Human glioblastoma cells (U-
87 MG) 
Study of the interplay between 
PCMT1 and growth signalling 
pathways. 
the American Type Culture 
Collection (ATCC) 
Murine hippocampal cells 
(HT22) 
Study of the interplay between 
PCMT1 and growth signalling 
pathways as well as calcium 
signalling. 
a generous gift from Dr. David 
Schubert at the Salk institute, 
La Jolla, San Diego, California, 
USA 
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2.1.3 Chemicals used in the present thesis 
2-Propanol      Sigma-Aldrich Belgium 
5-Bromo 4-chloro 3-indolyl phosphate   Sigma-Aldrich Belgium 
Agarose      Sigma-Aldrich Belgium 
Bis-Tris       Sigma-Aldrich Belgium 
Blasticidin S HCl      ThermoFisher 
Bovine serum albumin     Sigma-Aldrich Belgium 
Bromophenol blue     Sigma-Aldrich Belgium 
Carbenicillin      Sigma-Aldrich Belgium 
Chloroform      Sigma-Aldrich Belgium 
Epidermal growth factor    Sigma-Aldrich Belgium 
Ethanol       VWR/Merk 
Ethyl 3-aminobenzoate methanesulfonate (Tricaine) Sigma-Aldrich Belgium 
Formamide      ThermoFisher Scientific 
Glycerol      Sigma-Aldrich Belgium 
Glycine       Sigma-Aldrich Belgium 
Heparin       Sigma-Aldrich Belgium 
Imidazole      VWR 
Insulin       Sigma-Aldrich Belgium 
Insulin growth factor-1     Sigma-Aldrich Belgium 
Liquid scintillation cocktail    PerkinElmer 
Methanol      VWR 
Methyl cellulose     Sigma-Aldrich Belgium  
Nitro blue tetrazolium     Sigma-Aldrich Belgium 
Pentylenetetrazol     Sigma-Aldrich Belgium 
Phenylthiourea      Sigma-Aldrich Belgium 
Polyethylene glycol     Sigma-Aldrich Belgium 
Polybrene      Sigma-Aldrich Belgium 
Protease inhibitor cocktail    Roche 
Proteinase K      Prophac/Roche 
Phosphatase inhibitor cocktail    Sigma-Aldrich Belgium 
Resazurin      Sigma-Aldrich Belgium 
S-Adenosyl methionine     Sigma-Aldrich Belgium 
S-[Methyl-3H]Adenosyl methionine   PerkinElmer 
Sodium chloride     Sigma-Aldrich Belgium 
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Sodium deoxycholate     Sigma-Aldrich Belgium 
Sodium dodecyl sulfate     Sigma-Aldrich Belgium 
Sodium fluoride     Sigma-Aldrich Belgium 
Sodium orthovanadate     Sigma-Aldrich Belgium 
Triton X-100      Sigma-Aldrich Belgium 
Trizma       Sigma-Aldrich Belgium 
Tween 20      Sigma-Aldrich Belgium 
2.1.4 Plasmids used in the present thesis 
Table 2-3: Description of the different plasmids, for which purpose they are used and their source 
Plasmid Purpose Source 
pCS2+ Used for cloning of pcmt and pcmtl 
coding sequence for further IVT 
production of transcripts of both genes. 
A kind gift from Dr. Uwe Irion, Max 
Planck Institute for Developmental 
Biology, Tübingen, Germany 
pENTR™/U6 Used for transient expression of shRNA 
sequence for PCMT1 knockdown in 
HEK293 and U-87 MG cells. 
ThermoFisher Scientific 
Catalog number: K4945 
pET100D Used for Pcmt and Pcmtl recombinant 
protein expression. 
ThermoFisher Scientific 
Catalog number: K100-01 
pGEM-T Used for rescue experiments in zebrafish 
by exogenous expression of pcmt and 
pcmtl under the control of the ubiquitous 
promoter eef1α. 
A kind gift from Dr. Simon 
Perathoner (PERATHONER et al. 2014) 
pLenti6/BLOCK-
iT™-DEST 
Used in combination with ViraPower™ 
plasmid mixture for production of 
lentiviral particles carrying shRNA 
ThermoFisher Scientific 
Catalog number: K4944 
pZFF001 Used for rescue experiments in zebrafish 
by exogenous expression of pcmt and 
pcmtl under the control of the neuronal 
promoter Her4 
A kind gift from prof Gilbert 
Weidinger, institute of biochemistry 
and molecular biology, university of 
Ulm, Germany 
pX459 Used for cloning gRNA and expression of 
the Cas9 nuclease for CRISPR/Cas9 
mediated knockout of Pcmt1 in HT22 cells 
Addgene, plasmid #48139 
(RAN et al. 2013) 
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ViraPower™ 
plasmid mix 
A mixture of three plasmids pLP1, pLP2 
and pLP/VSV-G contain the necessary 
elements for production of lentiviral 
particles in HEK293FT cells 
ThermoFisher Scientific 
Catalog number: K4944 
 
2.1.5 Morpholino oligomers used in the present thesis 
Table 2-4: Sequence of splice-blocking morpholinos used for knockdown experiments in zebrafish 
Name Sequence 
PCMT i2e3 GCTTGATAACCTGCATGAAATGAAC 
PCMTL e1i1 AGAGCGGAGCAAAAATCTTACTCGT 
PCMT e5i5 AAGATGGATGAGCAGACCAACCGAT 
PCMTL e4i4 CATGTGTTTTTCTGACCTACCATAT 
Control MO CCTCTTACCTCAGTTACAATTTATA 
 
2.1.6 Primers used in the present thesis 
2.1.6.1 Primers for qPCR 
Table 2-5: Primers used in qPCR for transcript level quantification of target genes 
Target gene Sequence 5’  3’ Amplicon Size 
H. sapiens PCMT1 FWD: AGAAGCCCCTTATGATGCCA 
REV: TGCTGCCATCTTGTAGCTTG 
161 
H. sapiens ACTB FWD: AGAAAATCTGGCACCACACC 
REV: AGCACAGCCTGGATAGCAA 
173 
H. sapiens GAPDH FWD: GCTCTCTGCTCCTCCTGTT 
REV: GCGCCCAATACGACCAAAT 
124 
M. musculus Pcmt1 FWD: TCTTTCCTCCTCCACACAGTC 
REV: GTCCAAAACAAGCTGTGATGC 
135 
M. musculus Actb FWD: GGCTGTATTCCCCTCCATCG 
REV: CCAGTTGGTAACAATGCCATGT 
154 
M. musculus Gapdh FWD: TGCGACTTCAACAGCAACTC 
REV: CTTGCTCAGTGTCCTTGCTG 
200 
D. rerio Pcmt FWD: CCACAGACCGTTCCCATTTC 
REV: GCTCCTTCATAGAGGTGGTCA 
139 
D. rerio Pcmtl FWD: CATGGAGTCATTCACAACGACA 
REV: TATCCACTTCCAGACCCCACA 
215 
D. rerio Rpl13-alpha FWD: TCTGGAGGACTGTAAGAGGTATGC 
REV: AGACGCACAATCTTGAGAGCAG 
148 
D. rerio eEf1-alpha FWD: CTGGAGGCCAGCTCAAACAT 
REV: ATCAAGAAGAGTAGTACCGCTAGCATTAC 
87 
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2.1.6.2 Primers for cloning 
Table 2-6: Primers used for cloning 
Name Sequence 5’  3’ Melting 
temperature °C 
Purpose 
hPCMT1-His FWD: ATATAAGCTTATGCACCATCACCATCACCATGCCTGGAAATCCGGCGGC 
REV: ATATCTCGAGTTACAATTCATCCCTGGACCAC 
58 Cloning of N-terminally His-tagged 
human PCMT1 into pCMV6 
drPcmt FWD FWD: CACCATGGCCTGGAAATCCGGAG 
REV: TCAAAGTTCATCCCTTGACCACTG 
55 Cloning of pcmt into pET100 
drPcmtl FWD FWD: CACCATGGCATGGATGTCTAGTGGC 
REV: TCAGAGCTCATCGCCCGGCCAC 
55 Cloning of pcmtl into pET100 
Pcmt as FWD: GACATTAATACGACTCACTATAGGGTCATTGCTTAGCAGTGAGTTTATTG 
REV: GCTGGATTTTGTAGCAGGGAAACAAC 
50 Preparation of in situ hybridization 
template for pcmt antisense probe 
Pcmt s GACATTAATACGACTCACTATAGGGGCTGGATTTTGTAGCAGGGAAAC 
TCATTGCTTAGCAGTGAGTTTATTGG 
50 Preparation of in situ hybridization 
template for pcmt sense probe 
Pcmtl as GACATTAATACGACTCACTATAGGGCG 
GTCCCACTGACAGACAAGCAACACC 
50 Preparation of in situ hybridization 
template for pcmtl antisense probe 
Pcmtl s GACATTAATACGACTCACTATAGGGATGTCCCACTGACAGACAAG 
CGAATTGGGTACCGGGCCCCCCC 
50 Preparation of in situ hybridization 
template for pcmtl sense probe 
drPcmt_pCS2 FWD: CTTGTTCTTTTTGCAGGATCCGCCGCCACCATGGCCTGGAAATCCGGAGG 
REV: CTATAGTTCTAGAGGCTCGAGTCAAAGTTCATCCCTTG 
58 Cloning of pcmt into pCS2+ plasmid 
drPcmtl_pCS2 FWD: CTTGTTCTTTTTGCAGGATCCGCCGCCACCATGGCATGGATGTCTAGTGG 
REV: CTATAGTTCTAGAGGCTCGAGTCAGAGCTCATCGCCCG 
58 Cloning of pcmtl into pCS2+ plasmid 
drPcmt_pZFF FWD: CAAGACACACAGCAATCATGGCCTGGAAATCCGGAGG 
REV: CAGGCTGAAGTTTGTAGCAAGTTCATCCCTTGACCAC 
58 Cloning of pcmt into pZFF001 plasmid 
drPcmtl_pZFF FWD: CAAGACACACAGCAATCATGGCATGGATGTCTAGTGG 
REV: CAGGCTGAAGTTTGTAGCGAGCTCATCGCCCGGCCA 
58 Cloning of pcmtl into pZFF001 plasmid 
SDM_Pcmt_D-V FWD: GGAGCAAAGGCTCTGGTGGTGGGATCGGGCTCC 
REV: GGAGCCCGATCCCACCACCAGAGCCTTTGCTCC 
60 Site directed mutagenesis of pcmt to 
replace Asp83 with Val 
SDM_Pcmtl_D-V FWD: GGAGCCTCAGCGCTGGTGGTGGGGTCTGGAAGT 
REV: ACTTCCAGACCCCACCACCAGCGCTGAGGCTCC 
60 Site directed mutagenesis of pcmtl to 
replace Asp83 with Val 
mPcmtCRISPRcheck FWD: AAGGATGACCCAATGCTCCT 
REV: GGGCTGCTGTTTCTACTTGG 
58 Validation of Pcmt1 gene deletion 
after CRISPR-mutated HT22 cells 
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2.1.7 Restriction enzymes used in the present thesis 
• BamHI  New England Biolabs 
• BbSI  New England Biolabs 
• BsmBI  New England Biolabs 
• DpnI  Agilent Technologies 
• HindIII  New England Biolabs 
• NheI  New England Biolabs 
• NotI  New England Biolabs 
• SacII  New England Biolabs 
• XhoI  New England Biolabs 
2.1.8 Kits used in the present thesis 
Kit Purpose Company  
AccuPrime™ Pfx PCR amplification of DNA ThermoFischer Scientific 
BLOCK-iT™ U6 RNAi 
Entry Vector kit 
Transient expression of shRNA for PCMT1 
knockdown in mammalian cells 
ThermoFischer Scientific 
BLOCK-iT™ Lentiviral 
RNAi expression system 
kit 
Stable integration of shRNA in mammalian 
cell genome for PCMT1 knockdown in 
mammalian cells 
ThermoFischer Scientific 
Champion™ pET 
Directional TOPO® 
Expression kit 
Cloning of Pcmt and Pcmtl for recombinant 
protein expression. 
ThermoFischer Scientific 
Fluo-4 AM Intracellular calcium detection in 
mammalian cells. 
ThermoFischer Scientific 
Gel extraction kit DNA extraction and purification from 
agarose gel 
Qiagen 
In-Fusion Cloning of pcmt and pcmtl into pZFF001 
plasmid 
Clontech 
MEGAclear™ kit Purification of RNA after in vitro 
transcription reaction 
Ambion 
mMESSAGE 
mMACHINE® SP6 
Transcription kit 
In vitro transcription for production of pcmt 
and pcmtl for rescue experiments 
Ambion 
NucleoBond Xtra Maxi 
kit 
Purification of plasmid DNA from 50 – 
100 ml bacterial culture. 
MACHEREY-NAGEL 
PCR purification kit DNA purification Qiagen 
Plasmid Miniprep kit Purification of plasmid DNA from 1 – 5 ml 
bacterial culture. 
Qiagen 
Rapid DNA Dephos & 
Ligation kit 
Dephosphorylation of DNA during cloning Roche 
RED Taq premix kit Colony check for PCR Sigma-Aldrich Belgium 
RevertAid H Minus First 
Strand cDNA synthesis 
kit 
Synthesis of first strand cDNA from total 
RNA template. 
ThermoFischer Scientific 
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2.2 Methods 
2.2.1 Handling of cellular and whole organism models 
2.2.1.1 Mammalian cell culture 
All cells were maintained in culture medium composed of Dulbecco's Modified Eagle Medium (DMEM) 
(Table 2-7), 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) Penicillin-Streptomycin (100 units/ml of 
penicillin and 100 µg/ml of streptomycin final concentration). Cells were stored as aliquots of 1×106 
cells in 1 ml culture medium supplemented with 5% DMSO at -150°C. When fresh cells were needed 
they were thawed, washed with culture medium to remove DMSO and passaged at least 2 times 
before using them in experiments. Cells were cultivated at 37°C and 5% CO2 at 70 – 90 % confluency 
and passaged two times a week (except for HT22 cell passages 3 times a week). Experiments in this 
thesis were performed with cells that had been passaged 10 – 28 times. 
Table 2-7: Dulbecco's Modified Eagle Medium (DMEM) composition 
Components Concentration 
[mg/l] 
Concentration 
[mM] 
AMINO ACIDS 
  
Glycine 30 0.400 
L-Arginine hydrochloride 84 0.398 
L-Cystine 2HCl 63 0.201 
L-Glutamine 584 4.000 
L-Histidine hydrochloride-H2O 42 0.200 
L-Isoleucine 105 0.802 
L-Leucine 105 0.802 
L-Lysine hydrochloride 146 0.798 
L-Methionine 30 0.201 
L-Phenylalanine 66 0.400 
L-Serine 42 0.400 
L-Threonine 95 0.798 
L-Tryptophan 16 0.078 
L-Tyrosine disodium salt dihydrate 104 0.398 
L-Valine 94 0.803 
VITAMINS 
  
Choline chloride 4 0.029 
D-Calcium pantothenate 4 0.008 
Folic Acid 4 0.009 
Niacinamide 4 0.033 
Pyridoxine hydrochloride 4 0.019 
Riboflavin 0.4 0.001 
Thiamine hydrochloride 4 0.012 
i-Inositol 7.2 0.040 
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INORGANIC SALTS 
  
Calcium Chloride (CaCl2) (anhyd.) 200 1.802 
Ferric Nitrate (Fe(NO3)3*9H2O) 0.1 0.000 
Magnesium Sulfate (MgSO4) (anhyd.) 97.67 0.814 
Potassium Chloride (KCl) 400 5.333 
Sodium Bicarbonate (NaHCO3) 3700 44.048 
Sodium Chloride (NaCl) 6400 110.345 
Sodium Phosphate monobasic (NaH2PO4-H2O) 125 0.906 
OTHER COMPONENTS 
  
D-Glucose (Dextrose) 4500 25.000 
Phenol Red 15 0.040 
 
2.2.1.2 Zebrafish (Danio rerio) maintenance 
The zebrafish strains used in this thesis were the AB strain (wild type) and the nacre and beta-
actin:GCaMP6f transgenic lines. The AB strain (Figure 2-1) was originally offspring of two lines named 
A and B, which were initially bought by Prof. George Streisinger from a pet shop in Albany, Oregon, 
USA. The nacre transgenic line (Figure 2-1) is lacking the microphthalmia-associated transcription 
factor a (mitfa) gene in the AB background, leading to deficiency in melanocytes and transparency of 
the animals (LISTER et al. 1999). 
 
Figure 2-1: Wild type strain (top) and nacre strain (mitfa-/- mutant) lacking melanocytes (bottom) of adult zebrafish (A) and 3 
dpf larvae (B). Adapted from (LISTER et al. 1999) 
The beta-actin:GCaMP6f transgenic zebrafish line was a generous gift from Dr. Francesca Peri, head 
of the Developmental Biology Unit at EMBL, Heidelberg, Germany. This transgenic line expresses 
calmodulin (CaM) fused to a circularly permuted green fluorescent protein (GFP) through an M13 
peptide in the cytoplasm of the cells (CHEN et al. 2013) under the control of the beta-actin promoter, 
expected to lead to ubiquitous expression in all cell types of the body. Upon binding of calcium to 
CaM, the CaM/M13 domain undergoes conformational changes leading to increase in the 
fluorescence intensity of the GFP. Transparency is essential to obtain a good visualization of 
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fluorescent signal. To achieve transparency, the beta-actin:GCaMP6f strain was crossed with the nacre 
strain and their non-pigmented, green fluorescent heart progeny were selected for the experiments. 
The beta-actin:GCaMP6f positive larvae shows green fluorescence in the heart due to continues 
calcium release for contractility. 
Adult zebrafish and embryos were raised and maintained in the LCSB Zebrafish Core Facility at 28 
(±0.5) °C  with light/dark cycles of 14/10 hours, respectively, according to standard protocols 
(WESTERFIELD 2000). Embryos were obtained by natural spawning and after collection and sorting out 
unfertilized eggs, they were reared in 0.3 × Danieau’s solution (17 mM NaCl, 2 mM KCl, 0.12 mM 
MgSO4, 1.8 mM Ca(NO3)2, 1.5 mM HEPES pH 7.5 and 0.03 M methylene blue) until needed for 
experiments. 
2.2.1.2.1 Ethics statement for animal experimentation 
In this project, all procedures with zebrafish were performed in accordance with European laws, 
guidelines and policies for animal experimentation, housing and care (European Directive 2010/63/EU 
on the protection of animals used for scientific purposes of 20 October 2010), and following the 
principles of the Three Rs – to replace, reduce and refine the use of animals used for scientific 
purposes. By using non-mammalian vertebrates (zebrafish embryos and larvae) for in vivo 
experiments, the use of mammalian models (e.g. adult rodents such as mice and rats) is minimized.  
The operation of the Luxembourg Centre for Systems Biomedicine (LCSB) Zebrafish Core Facility and 
the performance of the aforementioned experiments with zebrafish embryos and larvae in the LCSB 
has been allowed, with regard to European Directive 2010/63/EU, by the relevant agencies of the 
Government of Luxembourg, both the Ministère de la Santé and the Ministère de l'Agriculture, de la 
Viticulture et du Développement Rural (Arrêté ministériel du 20 décembre 2012). 
2.2.2 Molecular biology 
2.2.2.1 Genomic DNA (gDNA) extraction 
Extraction of gDNA from mammalian cells was adapted from Meeker et al. (MEEKER et al. 2007). Briefly, 
1×106 cells were disrupted by vortexing in 100 µl of 50 mM NaOH and boiling for 10 minutes at 95°C. 
Subsequently, samples were put on ice and 10 µl of 1 M Tris/HCl pH 8.0 were added to neutralize the 
pH. Finally, samples were centrifuged for 5 minutes at 16 100 × g at 4°C and the supernatants were 
used for PCR analysis. 
2.2.2.2 Total RNA extraction 
RNA extraction, either from mammalian cells or zebrafish, was carried out using TriPure reagent 
according to the supplier’s protocol. One ml of TriPure reagent was added to either 1×106 cells, 15 – 
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20 larvae or dissected adult zebrafish organ. In case of the larvae and dissected organs, tissues were 
homogenized using the Precellys-24 homogenizer (3 cycles each of 10 seconds at 6000 rpm and 15 
seconds off between each cycle) while mammalian cells were homogenized by pipetting. Regardless 
of the sample origin, all samples were treated the same for subsequent steps. Homogenates were left 
5 minutes at room temperature, transferred to 2-ml tubes containing 200 µl chloroform, shaken 
vigorously for 15 seconds and then centrifuged at 12 000 × g for 15 minutes at 4°C for phase 
separation. The upper aqueous phase, containing RNA, was transferred to a new tube containing 500 
µl isopropanol for RNA precipitation. Tubes were left at room temperature for 5 minutes for the 
precipitate to form, followed by centrifugation at 12 000 × g for 10 minutes at 4°C. The pellet was then 
washed with 1 ml of 70% ethanol and left to air-dry. Finally, the pellet was solubilized in 50 µl nuclease-
free H2O and incubation for 10 minutes at 55°C. RNA samples were stored at -80°C until used. 
2.2.2.3 In vitro transcription 
In vitro transcription (IVT) was performed using the mMESSAGE mMACHINE® SP6 Transcription kit to 
produce full sequence capped mRNA for injection into zebrafish eggs. Prior to IVT, the coding 
sequences of target genes were cloned into the pCS2+ plasmid, which was then linearized using NotI 
restriction enzyme and purified using the Qiagen PCR purification kit. IVT reactions (20 µl total volume) 
contained 10 µl 2× NTP/CAP (mixture of NTPs and capped GTP), 2 µl 10× reaction buffer, 2 µg of 
linearized and purified plasmid and 2 µl of SP6 enzyme mix. The reaction mixture was incubated for 
2 hours at 37°C. Residual plasmid DNA was removed by the addition of 1 µl of TURBO DNase and 
incubation at 37°C for 15 minutes. Finally, transcribed RNA was purified using the MEGAclear™ kit. 
2.2.2.4 Complementary DNA (cDNA) synthesis 
The RevertAid H Minus First Strand cDNA synthesis kit from ThermoFisher was used following the 
manufacturer’s protocol for cDNA synthesis. Briefly, 1 µg total RNA was used as a template in 20 µl 
reactions containing 1 µl of dT10 primer (stock 100 µM), 4 µl 5× reaction buffer, 1 µl RiboLock (RNase 
inhibitor 20 U/µl), 2 µl of dNTPs (stock 10 mM) and 1 µl of RevertAid enzyme (stock 200 U/µl). The 
reaction mixtures were incubated at 42°C for 1 hour followed by 15 minutes at 70°C for enzyme 
deactivation. cDNA samples were stored at -20°C until further analysis. 
2.2.2.5 Transformation of chemically competent E. coli cells 
Transformation of Stbl3, TOP10 or BL21(DE3) chemically competent E. coli cells (Table 2-8) was 
performed by incubating the cells with either 50 – 100 ng purified plasmid or 2 µl of a ligation product 
following cloning (Section 2.2.2.9) for 5 minutes on ice, followed by 30 seconds at 42°C and 2 minutes 
back on ice. Cells were regenerated in 250 µl of SOC medium (20 g/l Tryptone, 5 g/l yeast extract, 
4.8 g/l MgSO4, 3.603 g/l dextrose, 0.5 g/l NaCl, 0.186 g/l KCl) at 37°C for 1 hour with constant agitation 
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(225 rpm). Finally, cells were spread on LB-agar plates supplemented with the appropriate antibiotic 
for selection. 
Table 2-8: Bacterial strains used for cloning and recombinant protein expression 
Strain Purpose Company 
E. coli BL21(DE3) Recombinant protein expression TermoFischer 
Scientific 
E. coli Stbl3 Propagation of plasmids containing direct repeats found 
in lentiviral expression vectors 
TermoFischer 
Scientific 
E. coli TOP10 Propagation of plasmids TermoFischer 
Scientific 
 
2.2.2.6 Plasmid purification 
Depending on the desired quantity of the purified plasmid, either the Qiagen MiniPrep kit (to produce 
5 – 10 µg of DNA) or the NucleoBond MaxiPrep kit (to produce 500 – 1000 µg of DNA) were used. 5 
ml or 100 ml bacterial culture hosting the plasmid to be purified were prepared for the MiniPrep or 
MaxiPrep kits, respectively. Cells were cultivated overnight with constant shaking (200 rpm) at 37°C 
in LB medium supplemented with the appropriate antibiotic for selection (ampicillin was used at 100 
µg/ml and kanamycin at 50 µg/ml). Cells were harvested by centrifugation at 4000 × g and pellets 
were used for plasmid purification following the manufacturers’ protocols, with final elution of 
plasmid in nuclease-free H2O. 
2.2.2.7 Polymerase chain reaction (PCR), colony PCR and qPCR 
A standard PCR protocol was used for amplification of genes of interest prior to cloning. Briefly, the 
AccuPrime™ Pfx DNA polymerase was used in a 50 µl reaction mixture containing 5 µl of 10 × reaction 
buffer () supplied with the enzyme kit, 25 pmol of each forward and reverse primers, 10 – 100 ng DNA 
template and 1 unit of the enzyme. The template was denatured at 98°C for 2 minutes followed by 30 
cycles of 98°C for 15 seconds; X°C for 15 seconds; and 72°C for 1 min/kb for extension (where X is the 
annealing temperature specific to each primer pair (Table 2-6)). An additional final extension step at 
72°C for 10 minutes was used after these 30 cycles.  
For colony PCR, Taq DNA polymerase was used, where 20 µl reaction mixtures were set up containing 
10 µl of 2× REDTaq premix and 5 pmol of each forward and reverse primers. By opposition to the 
standard PCR where purified DNA served as a template, a freshly picked bacterial colony, resuspended 
in the reaction mixture, was here used as the DNA source. Thermocycler parameters were similar to 
the ones described for standard PCR but an initial step (98°C for 5 minutes) was added to allow for cell 
lysis. 
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A qPCR approach was used to quantify transcript levels of genes of interest. Briefly, 2 µl of 1:5 diluted 
cDNA, prepared from 1 µg RNA as described before (Section 2.2.2.4), were used as a template. In each 
qPCR reaction (total volume of 20 µl), the cDNA was mixed with 5 pmol of each forward and reverse 
primers specific for the target gene and 10 µl 2× iQ SYBR green mix from BioRad. A denaturation step 
at 95°C for 5 minutes was followed by 40 cycles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C 
for 30 seconds for extension, with acquisition of fluorescence information followed by a melting curve. 
Calculation of relative fold changes in expression of a target gene normalized to expression of a 
reference gene was done using the 2-∆∆Ct method (PFAFFL 2001). 
2.2.2.8 Quality and quantification of nucleic acid 
The concentration of DNA and RNA samples were evaluated by UV absorbance measured on a 
NanoDrop2000 from ThermoFisher Scientific. Concentration was estimated based on UV absorbance 
at 260 nm where 1 absorbance unite corresponded to 50 ng/µl for DNA and 40 ng/µl for RNA. 
2.2.2.9 Cloning 
During this thesis work, various DNA fragments had to be cloned into plasmids. Based on the desired 
application and the plasmid, different cloning strategies and different bacterial strains were used. 
2.2.2.9.1 Restriction-ligation cloning 
Standard restriction-ligation cloning was done by amplification of the target DNA with primers 
containing restriction site sequences compatible with the restriction sites available in the plasmid. PCR 
products were purified using the Qiagen PCR purification kit and incubated with the restriction 
enzymes and the respective buffer at the recommended temperature. In parallel, destination plasmids 
were also incubated with compatible restriction enzymes and buffer. Restricted plasmids were 
dephosphorylated using the Rapid Dephos kit. Restricted PCR fragments and plasmids were mixed 
together at 1:3 molar ratio in ligation buffer with T4 DNA ligase and incubated at room temperature 
for 15 minutes. The ligation reactions were stopped by placing the reaction tubes on ice and 2 µl of 
ligation reaction were used for chemical transformation of E. coli TOP10 cells (Section 2.2.2.5). 
2.2.2.9.2 TOPO cloning 
The Champion™ pET100 Directional TOPO® Expression Kit was used to insert an ORF of interest into a 
pET100 plasmid downstream to a His-tag for recombinant protein expression in E. coli and for later 
affinity purification on His-Trap Ni-column (GE Healthcare). 
Cloning was carried out according to the manufacturer’s protocol. Briefly, primers were designed 
including the 4 bp sequence CACC in 5’ of the forward primer necessary for directional cloning. The 
ORF of interest was amplified using the respective primers by the standard PCR protocol (Section 
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2.2.2.7) from clones obtained from SourceBioscience clone IRBOp991B0677D for pcmt and clone 
IRBOp991C012D for pcmtl. The PCR product was loaded into a 1% agarose gel for separation by 
electrophoresis and the DNA band migrating at the correct size was excised out of the gel for 
subsequent purification using the Qiagen gel extraction kit. The purified PCR product was mixed with 
the pET100 vector at a 2:1 molar ratio, 1 µl salt solution (provided with the kit) and H2O to reach a 
total volume of 10 µl. The reaction mixture was incubated for 15 minutes at room temperature and 
then kept on ice until used (2 µl) for transformation of E. coli TOP10 cells. 
2.2.2.9.3 In-Fusion cloning 
In-Fusion Enzyme fuses DNA fragments (e.g. PCR-amplified DNA sequences) with linearized vectors by 
recognizing a 15 bp overlap at their ends. PCR was done using the standard protocol followed by 
loading into a 1% agarose gel and amplicon purification using the Qiagen gel extraction kit. An In-
Fusion cloning reaction was set up by mixing 2 μl of 5× In-Fusion HD Enzyme Premix with 100 ng 
linearized plasmid, 30 ng insert and nuclease-free H2O up to 10 µl. The reaction was incubated for 15 
min at 50°C, then placed on ice. 2.5 µl of this reaction mixture were used to transform chemically 
competent E. coli TOP10 cells (Section 2.2.2.5). 
2.2.2.9.4 shRNA cloning into pENTR™/U6 vector 
shRNAs against human PCMT1 were designed using the BLOCK-iT™ RNAi Designer web tool from 
ThermoFisher Scientific and default parameters. The shRNA was aimed to be inserted into the 
pENTR™/U6 vector with a sense-loop-antisense orientation and the default loop sequence CGAA. The 
designer tool returned 8 different regions to target in the transcript and the three with the highest 
score were selected for further use. Top and bottom strand oligonucleotides were ordered from 
Eurofins with HPLC grade of purification. 
Table 2-9: shRNA design for the human PCMT1 gene: sequence of the three targeted regions in the PCMT1 transcript and the 
corresponding top and bottom strands for shRNA synthesis 
 Target sequence in 
PCMT1 transcript 
Top Strand 
5'  3' 
Bottom Strand 
5'  3' 
shRNA1 GCTAGTAGATGACT
CAGTAAA 
CACCGCTAGTAGATGACTCAGTAAACGA
ATTTACTGAGTCATCTACTAGC  
AAAAGCTAGTAGATGACTCAGTAAATTC
GTTTACTGAGTCATCTACTAGC 
shRNA2 GCGCTAATAGATCA
GTTAAAG 
CACCGCGCTAATAGATCAGTTAAAGCGA
ACTTTAACTGATCTATTAGCGC 
AAAAGCGCTAATAGATCAGTTAAAGTTC
GCTTTAACTGATCTATTAGCGC 
shRNA3 GCAGTATGACAAGC
TACAAGA 
CACCGCAGTATGACAAGCTACAAGACGA
ATCTTGTAGCTTGTCATACTGC 
AAAAGCAGTATGACAAGCTACAAGATTC
GTCTTGTAGCTTGTCATACTGC 
Ctrl shRNA N/A CACCGAGAAGACATCGTACTGTAATCGA
AATTACAGTACGATGTCTTCTC 
AAAAGAGAAGACATCGTACTGTAATTTC
GATTACAGTACGATGTCTTCTC 
 
Materials and methods 
39 
 
For transient expression of shRNA and to test the efficiency of the three different shRNAs, each was 
cloned into the pENTR™/U6 vector. The top and bottom strand oligonucleotides were mixed together 
at a concentration of 200 µM, heated to 95°C for 4 minutes and then left to anneal at RT for 10 
minutes. 0.0025 pmol of the annealed oligonucleotides were mixed with 0.5 ng pENTR™/U6 vector 
together with 0.5 U of T4 DNA ligase and ligation buffer provided with the kit in a total volume of 10 
µl and incubated for 5 minutes at room temperature. 2 µl of the ligation product were used for 
transformation of chemically competent E. coli TOP10 cells (Section 2.2.2.5). 
2.2.2.9.5 Gateway cloning to generate lentiviral shRNA expression plasmid 
The Gateway® Technology is a universal cloning method that takes advantage of the site-specific 
recombination properties of bacteriophage lambda to provide a rapid and highly efficient way to move 
a DNA sequence of interest into multiple vector systems. Gateway cloning was used to move the 
shRNA sequences cloned into the pENTR™/U6 vector to the pLenti6/BLOCK-iT™-DEST vector by LR 
recombination to create lentiviral shRNA expression vectors. The LR recombination reaction was set 
up by mixing 150 ng of empty pLenti6/BLOCK-iT™-DEST vector with 150 ng of recombinant (shRNA 
containing) the pENTR™/U6 entry construct together with 2 µl of Gateway® LR clonase® II enzyme mix 
in a total volume of 10 µl and the reaction mixture was incubated at 25°C for 1 hour. 2 µg proteinase 
K were then added followed by a 10 minutes incubation at 37°C. 2 µl of this final mixture were used 
for transformation of chemically competent E. coli Stbl3 cells (Section 2.2.2.5). 
2.2.2.9.6 gRNA cloning into the pX459 plasmid 
Guide RNAs (gRNA) were designed using an online tool from the Sanger institute 
(http://www.sanger.ac.uk/htgt/wge/find_crisprs). Since CRISPR/Cas9 was going to be used to knock 
out Pcmt1 in HT22 cells, which are of murine origin, Mouse (GRCm38) was selected as the ‘Species’ 
and the search was focused on exons 1 – 5 of the Pcmt1 gene. As the search returned hundreds of 
results, it was refined by selecting both the ‘paired Crispr’ and ‘best 25%’ at the off-target filters. The 
two gRNAs with the lowest number of putative off-targets were selected. Scrambled gRNA was 
generated by shuffling gRNA1 sequence to be used as a control. Oligonucleotides were ordered from 
Eurogentec. 
Table 2-10: gRNA sequences used in this study to guide the Cas9 nuclease to the Pcmt1 gene in HT22 cells 
Name gRNA sequence Oligos ordered for gRNA cloning into pX459 
Top 5’ 3’ Bottom 5’ 3’ 
gRNA 1 GCCGCACTCGCCCCGAGGAC CACCGCCGCACTCGCCCCGAGGAC AAACGTCCTCGGGGCGAGTGCGGC 
gRNA 2 GTGAGTGGCAGAACGCTTAC CACCGTGAGTGGCAGAACGCTTAC AAACGTAAGCGTTCTGCCACTCAC 
Scramble gRNA GCGCGCACGTCGCACGCACC CACCGCGCGCACGTCGCACGCACC AAACGGTGCGTGCGACGTGCGCGC 
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To clone the gRNAs into the pX459 plasmid, 10 pmol of each the top and bottom oligonucleotides 
were mixed together with 1 µl of T4 Polynucleotide Kinase (PNK) and 1 µl of 10× T4 ligation buffer in 
a final volume of 10 µl reaction. The reaction mixture was incubated at 37°C for 30 minutes for 
phosphorylation of the oligonucleotides. The temperature was increased to 95°C for 5 minutes and 
then decreased to 25°C at a rate of -5°C/minute, allowing annealing of the top and bottom 
oligonucleotides. The phosphorylated annealed oligonucleotides were diluted 1:250. In parallel, the 
pX459 vector was digested with BbSI restriction enzyme followed by purification using the Qiagen gel 
extraction kit. The purified plasmid was dephosphorylated in a reaction mixture containing 22.5 µl of 
gel purified product (i.e. 800 ng), 3 µl H2O, 3 µl 10× rAPid Alkaline Phosphatase buffer and 1.5 µl rAPid 
alkaline phosphatase and incubated for 30 min at 37°C following by deactivation for 2 min at 75 °C. 
Ligation of the phosphorylated annealed oligos with the digested dephosphorylated pX459 plasmid 
was performed using the T4 DNA ligase protocol: a 20 µl reaction mixture containing 2 µl of linearized 
pX459, 1 µl of diluted annealed and phosphorylated oligos, 2 µl of DNA dilution buffer, 5 µl of H2O, 10 
of µl 2× ligation buffer and 1 µl of T4 DNA ligase was incubated for 15 min at room temperature. 2 µl 
of this ligation reaction were used to transform chemically competent E. coli TOP10 cells. 
2.2.2.10 Site-directed mutagenesis 
The D83V non-synonymous mutation was introduced into the coding sequence of both the pcmt and 
pcmtl zebrafish genes by substitution of a GAT codon by a GTT codon through site-directed 
mutagenesis. Plasmids containing either the pcmt or pcmtl coding sequences were used as templates 
and PCR-amplified, using two different pairs of primers designed specifically to introduce the desired 
mutation using PCR standard protocol (Section 2.2.2.7). In contrast to the newly PCR-produced 
plasmids (with the mutation of interest), the template plasmids were methylated at various positions. 
The Dpn I restriction enzyme specifically recognizes and cuts methylated DNA sequences. The addition 
of this enzyme to a mixture containing template plasmid and the newly produced plasmids allowed 
the digestion of only the template plasmid without the mutation. Chemically competent E. coli cells 
were transformed with 2 µl of the resulting point mutated plasmid preparation. 
2.2.3 Biochemical assays 
2.2.3.1 Protein quantification through Bradford assay 
Protein concentration was determined using the Bradford assay. Briefly, Bradford reagent was 
prepared by diluting commercially available Bradford solution from Biorad 5-fold in H2O, followed by 
filtration through a 0.2 µm filter. Bovine serum albumin (BSA) standards were prepared in the range 
of 0.1 – 0.9 mg/ml. For each sample or standard, 20 µl were mixed with 1 ml of Bradford reagent and 
incubated 5 minutes in the dark at room temperature. Absorbance was measured at 595 nm. Protein 
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concentration in the samples was calculated using the standard curve generated based on the BSA 
standard measurements. 
2.2.3.2 SDS-PAGE and Western blot analysis 
Protein extracts or purified protein samples were mixed with SDS sample buffer (63 mM Tris/HCl pH 
6.8, 2% w/v SDS, 10% v/v glycerol, 0.002% w/v bromophenol blue, and 5% β-mercaptoethanol) and 
heated at 95°C for 5 minutes. Unless otherwise mentioned, the equivalent of 20 µg protein of each 
sample was loaded into pre-cast SDS-PAGE gels from BioRad. Separation was achieved at a constant 
voltage (160 V) for 1 hour using migration buffer (25 mM Tris pH 8.3, 192 mM glycine and 1% SDS). 
Following the electrophoretic separation, the gel was either used for protein detection by Coomassie 
blue staining or for Western blot analysis. For Coomassie blue detection, the gel was stained with 
Coomassie blue (ThermoFisher Scientific, catalog no. 24620) in a microwave for 10 seconds followed 
by 15 min at room temperature on a shaker. Several washing steps with water were used to reduce 
background staining. 
For Western blot analysis, the gel, alongside filter papers and methanol-activated PVDF membrane, 
were first equilibrated for 5 minutes in transfer buffer (25 mM Tris pH 8.3, 192 mM glycine, 10% (v/v) 
methanol). Proteins were blotted on the PVDF membrane using a semi-dry method. This membrane 
was washed briefly with TBS-T buffer (20 mM Tris/HCl pH 6.7; 137 mM NaCl 0.1% Tween20) and 
blocked in 5% BSA solution for 1 hour at room temperature on an orbital shaker. Unless otherwise 
indicated, primary antibody was diluted 1:1000 in TBS-T buffer containing 1% BSA and incubated with 
the membrane overnight at 4°C with shaking followed by three washing steps with TBS-T buffer for 
5 minutes. The secondary antibody, diluted 1:5000 in TBS-T containing 1% BSA, was then added to the 
membrane followed by a 1-hour incubation at room temperature. Finally, the membrane was again 
washed 3 times with TBS-T buffer for 5 minutes. Antibody binding was revealed through addition of 
enhanced chemiluminescent (ECL) substrate from Amersham (Catalog no. RPN2232). Band detection 
was carried out on a Li-COR Odyssey FC Imaging System. Band intensity was quantified using Image 
Studio™ software from Li-COR with exposure times ranging from 30 seconds to 2 minutes.  
2.2.3.3 Recombinant protein expression and purification 
E. coli BL21(DE3) cells carrying the pET100 plasmid (containing either pcmt or pcmtl coding sequences) 
were grown on LB agar plates supplemented with 100 µg/ml ampicillin at 37°C. One clone served to 
inoculate a 5 ml starter culture (LB with ampicillin) that was grown for about 10 hours at 37°C. The 
complete starter culture was used to inoculate a 50 ml pre-culture that was grown overnight to obtain 
sufficient biomass for the main culture. This latter consisted in 1 L of LB medium supplemented with 
50 µg/ml carbenicillin to which 20 ml of the pre-culture was added. Cells were grown at 37°C with 
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shaking until OD600 reached 0.7. Protein expression was then induced by addition of IPTG at a final 
concentration of 0.1 mM and cells were incubated with continuous shaking for 10 hours at 18°C. 
Finally, they were harvested by centrifugation at 4816 × g for 20 minutes and pellets were stored at -
80°C until used for protein extraction and purification. 
Cells were resuspended in 50 ml lysis buffer (25 mM Tris/HCl pH 8.0, 300 mM NaCl, 0.5 mM PMSF, 1 
mM DTT, 0.1 mg/ml lysozyme, 1× protease inhibitor cocktail) and sonicated using a BRANSON Digital 
Sonifier 200W S-250D for 3 cycles with 1 minute breaks in between (each cycle was 0.5 second ‘on’, 1 
second ‘off’ during 20 seconds total, with 50% amplitude). Lysates were centrifuged for 40 minutes at 
15,000 × g at 4°C and the supernatant, containing soluble proteins, was filtered through a 5 µm 
cellulose acetate membrane. 
An Äkta purifier system (GE Healthcare) was used for protein purification. The filtered protein extract 
(about 50 ml) was passed on a 1 ml HisTrap column at a constant flow rate of 1 ml/min. This column 
had been previously equilibrated with 10 column volumes (CVs) of buffer A (25 mM Tris/HCl pH8, 300 
mM NaCl, 10 mM imidazole). After loading the cell free extract, buffer A was constantly run through 
the column until absorbance at 280 nm went back to baseline levels, indicating that all non-bound 
proteins had been removed. The column was then washed with another 10 CVs of buffer A followed 
by a second washing step with a buffer with equal composition as buffer A except for imidazole 
concentration (increased to 25 mM). Finally, His-tagged proteins were eluted with a linear gradient of 
imidazole (25 – 300 mM) applied over 20 ml with collection of 1 ml fractions. The fractions showing 
high protein concentration and high purity of the protein of interest by SDS-PAGE analysis were 
pooled. Pooled fractions were dialyzed overnight against a buffer containing 20 mM Tris/HCl pH 7.6, 
25 mM NaCl and 20% glycerol with a 2-step dialysis each of 2 l and stored at -20°C until used. 
2.2.3.4 Methanol vapour diffusion assay 
To assess total isoaspartyl content and isoaspartyl methyltransferase activity in various sample types, 
a methanol vapour diffusion assay was applied as adapted from Patananan et al (PATANANAN et al. 
2014) and illustrated in Figure 2-2. A 100 µl reaction mixture was prepared containing 0.2 M Bis-Tris 
pH 6.0, 73 µM S-adenosyl methionine (SAM), isoaspartyl containing substrate and the 
methyltransferase. The SAM cofactor solution was prepared by diluting 1 part of 7 µM [methyl-
3H]SAM (PerkinElmer, 78 Ci/mmol, 0.55 µCi/µl) in 9 parts 80 µM non-labelled SAM (Sigma-Aldrich). 
For the methyltransferase activity assays in cell extracts, the reaction contained 100 µM of 
KASAisoDLAKY peptide (Lys-Ala-Ser-Ala-isoAsp-Leu-Ala-Lys-Tyr) as the isoaspartyl substrate and 10 – 
30 µg cytosolic protein extract as the isoaspartyl methyltransferase source. For measuring total 
isoaspartyl levels, the assay mixture contained 10 – 30 µg cytosolic protein extract as the isoaspartyl 
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substrate and 5 µg recombinant human protein L-isoaspartyl methyltransferase (rhPCMT1). For both 
types of assay, the reaction mixture was incubated at 30°C for two hours and stopped by addition of 
10 µl of 0.2 M NaOH solution. 100 µl of the stopped reaction mixture were spotted on a filter paper 
(1×2 cm) and placed above 2 ml liquid scintillation cocktail (Ultima Gold XR, Perkin Elmer catalog no. 
6013111) in a 4-ml tube. The closed tube was incubated for 4 hours at room temperature to allow the 
diffusion of radiolabeled methanol into the liquid scintillation cocktail. Finally, the filter paper was 
removed and tubes were placed into a MicroBeta2 plate counter from PerkinElmer. Counts per minute 
(cpm) were converted to moles of isoaspartyl using a standard curve prepared the same way using 
5 µg rhPCMT1 and different concentrations (0.024 – 6.25 µM) of KASAisoDLAKY peptide. 
For kinetic characterization of the purified D. rerio Pcmt and Pcmtl enzymes, the reaction mixture 
contained 2 µg of recombinant Pcmt or Pcmtl and different concentrations (2 – 500 µM) of the of 
KASAisoDLAKY substrate. Reactions were stopped at different time points to determine initial 
velocities. Dependency of enzyme initial velocity on substrate concentration indicated Michaelis-
Menten kinetics. 
 
Figure 2-2: Methanol vapour diffusion assay used to assay L-isoaspartyl methyltransferase activity or L-isoaspartyl content in 
various types of samples. 
2.2.4 Cell culture methods 
2.2.4.1 Mammalian cell transfection 
The mammalian cell transfection protocol described here was carried out to introduce plasmid DNA 
into cells. Cells were seeded 1 day before transfection in a 6-well plate and left to adhere, reaching 50 
– 70% confluency at the time of transfection. Lipofectamine 2000 reagent and plasmid DNA were 
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mixed together at a ratio of 1 µg DNA per 3 µl lipofectamine in a total volume of 250 µl OptiMEM 
medium. The mixture was incubated for 5 minutes at room temperature for the lipid-DNA complex to 
form and then added drop-wise to the cells in the 6-well plate. Experiments were performed 24 to 72 
hours later. For production of recombinant lentiviral particles containing shRNA constructs, the same 
transfection protocol was used (with HEK293FT cells) except that the lipid-DNA complexes were added 
on the same day as the cells were seeded, and lentiviral production was continued as described in the 
following section. 
2.2.4.2 PCMT1 knockdown in human cell lines using lentiviral shRNA transduction 
Lentiviral transduction of shRNAs was used to establish stable human-derived cell lines (HEK293 and 
U-87 MG) with lower transcription levels of PCMT1. 
2.2.4.2.1 Production of lentivirus 
HEK293FT cells were transfected as described before (Section 2.2.4.1) with a plasmid mix composed 
of ViraPower™ (containing pLP1, pLP2 and pLP/VSVG plasmids, see above) and pLenti6/BLOCK-iT™-
shRNA expression vector for the production of recombinant lentiviral particles. After on overnight 
incubation in full growth DMEM medium, this latter was replaced by fresh medium. Virus-containing 
medium was harvested 48 hours post transfection and centrifuged at 3000 rpm for 5 minutes at 4°C. 
Viral particles were concentrated by mixing 40 ml of the resulting supernatant with 8 ml of 40% 
polyethylenglycol 1000 (PEG1000), overnight incubation at 4°C, and 30 minutes centrifugation at 1 
500 × g at 4°C. The supernatant was discarded and the viral pellet was resuspended in 400 µl PBS. 
Aliquots of this concentrated viral preparation were stored at -80°C. 
2.2.4.2.2 Transduction of U-87 MG and HEK293 cells 
Since the lentivirus used introduces a blasticidin resistance to the transduced cells, a kill curve was set 
up for both the HEK293 and U-87 MG cell lines to find the minimum toxic concentration of blasticidin. 
Cells were incubated with 1 to 10 µM blasticidin and media were changed every 3 days for a total 
duration of 10 days. 
HEK293 or U-87 MG cells were seeded in 6-well plates and grown overnight. The medium (2 ml/well) 
was replaced by a fresh one containing 20 µl of the virus preparation described in the previous section. 
Polybrene was added at a final concentration of 6 µg/ml to enhance cell transduction. After one day 
of incubation, the medium containing the virus was changed with fresh complete medium devoid of 
virus. On the third day, selection with blasticidin (at the minimal toxic concentrations determined as 
described above i.e. 2 µg/ml and 4µg/ml for U87 and HEK293 cells, respectively) was started by adding 
the antibiotic followed by renewal of the medium every 3 days during a total duration of 10 days. Six 
blasticidin-resistant colonies were selected and plated in fresh dishes. Total RNA was extracted and 
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the transcription level of PCMT1 was determined by qPCR to identify clones with the highest 
knockdown efficiency.  
2.2.4.3 Pcmt1 knockout in mouse HT22 cells using CRISPR/Cas9 
The CRISPR/Cas9 strategy was used to knock out the Pcmt1 gene in the mouse hippocampal HT22 cell 
line using the method described in Ran et al (RAN et al. 2013). gRNAs were designed and cloned into 
the pX459 plasmid as described before (Section 2.2.2.9.6). HT22 cells were transfected with the 
recombinant plasmid using the standard transfection protocol described earlier (Section 2.2.4.1). 
Puromycin was added one day after transfection at a final concentration of 1 µg/ml for selection of 
plasmid containing cells. Medium was refreshed after 3 days and 3 days later puromycin-resistant cells 
were trypsinized, counted and diluted to a density of 1 cell per 200 µl medium so that when seeding 
100 µl per well in 96-well plates the chances to have only one cell per well is high. Single resistant cells 
were seeded in each well of a 96-well plate followed by clone expansion for one week. Ten wells with 
single clones were selected for genotyping. Clones showing the expected 40 bp deletion in the Pcmt1 
gene were propagated and stored thereafter in DMSO solution at -150°C. 
2.2.4.4 Stimulation of mammalian cells with growth factors  
To study the phosphorylation of different intermediates in growth signalling pathways in the 
established cell models, different growth factors were used to stimulate the different signalling 
pathways. Insulin and insulin growth factor-1 (IGF-1) were used for stimulation of the insulin/IGF-1 
signalling pathway and epidermal growth factor (EGF) was used for stimulation of the MAPK signalling 
pathway. Cells were seeded in 6-well plates in 2 ml culture media and incubated under standard 
conditions for 24 hours. Stimulation was done when the cells were 70 – 80 % confluent and to achieve 
this confluency in 24 hours, HEK293 cells were seeded at 1 × 106 cells/well; U-87 MG cells were seeded 
at 0.4 × 106 cells/well; HT22 cells were seeded at 0.5 × 106 cells/well. Following the 24 hours incubation 
time cells were washed with pre-warmed PBS and then fresh medium without serum supplemented 
with the respective stimulator was added and cells incubated for the desired duration of stimulation. 
Following the desired stimulation time, medium was aspirated and the plates were placed on ice. Cells 
were scraped in 150 µl RIPA buffer and lysed using Bioruptor UCD-300 TO. Lysates were centrifuged 
at 16 100 × g for 20 minutes at 4°C. Protein concentration was determined using Bradford assay and 
phosphorylation analysed by Western blot. 
2.2.4.5 Calcium imaging in HT22 cells 
Pcmt1 knockout or control cells were seeded in 12-well plates at a density of 25,000 cells per well and 
incubated at 37°C and 5% CO2 for 2 days. Cells were then washed with PBS and 1 ml of fresh medium 
was added (the medium used in this case was DMEM without phenol red and supplemented with 25 
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mM glucose, 4 mM glutamine, 10% FB and 1% (v/v)). Cells were stained by adding 250 µl of Fluo-4 AM 
reagent into each well followed by 30 minutes incubation at 37°C and 5% CO2. Cells were then 
stimulated by addition of ATP at final concentrations of 10 – 80 µM and calcium signals were acquired 
using a Nikon widefield microscope in a controlled environment (37°C and 5% CO2). Signals were 
extracted from acquired images using ImageJ and analyzed using CASA software. 
2.2.4.6 Metabolite extraction from mammalian cells 
Cells were seeded in 6-well plates at a density of 50,000 cells per well and grown to 80 % confluency. 
Cells were washed with 1 ml PBS, placed on ice and scraped into 300 µl quenching buffer (50% 
methanol, 10 mM Tris pH 7.5) at -20°C. Quenched cells were transferred to a tube containing 150 µl 
chloroform at -20°C. Tubes were vortexed for 2 hours at -20°C and then centrifuged at 10 000 × g for 
10 minutes at -10°C. The upper aqueous phase was filtered through a 0.2 µm filter and kept at -80°C 
until metabolite analysis by LCMS. 
2.2.4.7 Targeted metabolite analysis with LCMS 
To quantify the nucleotides AMP, ADP, ATP, GMP, GDP, and GTP, a targeted HRES-LC-MS method was 
used. Measurements were performed on a Dionex UltiMate 3000 (Thermo Fisher Scientific) coupled 
to a Qexactive Orbitrap mass spectrometer (Thermo Fisher Scientific) equipped with a HESI 
electrospray ion source. Nitrogen was supplied by a NMG33 generator (CMC). Absolute 
concentrations were calculated based on external calibration curves prepared in 50 % LC-MS-grade 
MeOH. Analyte separation was achieved by hydrophilic interaction chromatography using a Sequant 
zicHilic column (3.5 µm, 100 Å, 150 X 2.1 mm, Merck) equipped with a SecurityGuard ULTRA 
precolumn (UHPLC HILIC for 2.1 ID Columns, Phenomenex) at a constant flow rate of 0.4 ml/min and 
a temperature of 40 °C. Target metabolites were eluted isocratic, using 70 % solvent B where solvent 
A is 100 mM Ammonium acetate pH 4.5 (adjusted by acetic acid addition) and solvent B is acetonitrile. 
5 µl of sample were injected, while the autosampler was cooled down to 10 °C. Mass spectral data 
were obtained in a scheduled single ion monitoring in negative mode. Source settings and accurate 
masses are given in appendix 6.2. 
For the analysis of inositol 1,4,5-trisphosphate a second targeted HRES-LC-MS method was applied 
using the same instrumental setup. Chromatographic separation was achieved in reversed phase 
mode on a C18EVO column (150 × 2.1 mm, 3.5 µm particle size, 100 °A pore size) (Phenomenex) 
connected to a guard column (SecurityGuard ULTRA cartridge, UHPLC C18EVO for 2.1 mm ID columns, 
Phenomenex) that was used at 20 °C and a flow rate of 0.25 ml/min in gradient mode where solvent 
A is 0 mM ammonium acetate pH 7 (adjusted by ammonium hydroxide) and solvent B is acetonitrile, 
according to the following profile: from 0 to 2 minutes, isocratic at 0 % B; 2 to 12 minutes, linear 
gradient to 100 % B; 12 to 15 minutes, isocratic at 100 % B, 15 to 16 minutes, linear gradient to 0 % B  
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followed by an equilibration of  4 minutes at starting condition. 5 µl of sample were injected, while 
the autosampler was cooled down to 10 °C. Mass spectral data were obtained in negative single ion 
monitoring mode. Source settings and mass transitions are given in the appendix 6.2. 
2.2.5 Zebrafish methods 
2.2.5.1 Collecting eggs 
Female and male adult animals were transferred to mating cages with a physical barrier, which was 
removed on the morning of the next day when lights were switched on. At this time, the mating 
process started to take place and females started to lay eggs. Eggs were collected at regular intervals 
of 30 minutes after the beginning of the mating process. 
2.2.5.2 Morpholino injection 
Splice blocking morpholino oligomers (MOs) were designed and synthesized by Gene Tools, LLC 
(Philomath, Oregon, USA). MOs (1 mM stock solutions) were diluted in water with 0.1% phenol red 
and loaded into a glass capillary pulled in house. Pressure and time of injection were adjusted to obtain 
a droplet with 0.15 mm diameter to inject a volume of about 2 nl into eggs at 1 – 2-cell stage. The 
injected eggs were maintained at 28.5°C with standard light/dark cycles and medium exchange was 
done every day until the day of the esperiments. 
2.2.5.3 Larvae deyolking and protein extraction 
Deyolking was done according to a method described by Link et al. (LINK et al. 2006). About 100 larvae 
at 2 days post fertilization (dpf) or 4 dpf were collected in a tube containing 200 µl of deyolking buffer 
(55 mM NaCl, 1.8 mM KCl, 1.25 mM NaHCO3). Larvae were pipetted up and down with a tip cut off at 
the extremity so as to match approximately the diameter of the yolk and favour yolk disruption 
through shear stress. Samples were then washed 3 times with 200 µl wash buffer (110 mM NaCl, 3.5 
mM KCl, 2.7 mM CaCl2, 10 mM Tris/HCl pH8.5) centrifuged briefly to collect the larvae at the bottom 
and pellets stored at -80°C until used. 
For protein extraction, 200 µl of lysis buffer (50 mM Tris/HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 
0.1% SDS, 1 mM EDTA, 1 × protease inhibitor cocktail) were added to about 100 larvae. Tissue 
homogenization was carried out using a Precellys-24 homogenizer for 3 cycles, each cycle consisting 
of vigorous shaking at 3000 rpm for 10 seconds and a 15 seconds break. Samples were then incubated 
on ice for 30 minutes and centrifuged at 16 100 × g for 20 minutes at 4°C. Protein concentration of 
the supernatants was determined using the Bradford assay (Section 2.2.3.1). 
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2.2.5.4 Embryo or larvae fixation 
Embryos or larvae were collected at the desired stage, manually dechorionated with fine forceps if 
applicable, and incubated in 4% paraformaldehyde overnight at 4°C. After this incubation period, 
samples were washed with PBS and stored in methanol at -20°C until used. 
2.2.5.5 In situ hybridization 
In situ hybridization (ISH) was performed to determine the tissue distribution of the pcmt and pcmtl 
transcripts. Procedures were performed according to the protocol developed by Thisse and Thisse 
(THISSE and THISSE 2008) as illustrated in Figure 2-3 and described thereafter. 
2.2.5.5.1 Probe preparation 
Templates for IVT were prepared by PCR amplification of 500 bp for pcmt and 700 bp for pcmtl genes. 
Forward primers used were designed with T7 promoter sequence. IVT reaction contained 2 µg of PCR 
product, 2 µl of 10× reaction buffer DIG-labelling mix, 2 µl of T7 polymerase and 1 µl of RNase inhibitor 
in a final volume of 20 µl. This reaction was incubated 3 hours at 37°C. After this incubation, 1 µl 
DNaseI was added and reaction was incubated again for 15 minutes at 37°C. IVT products were 
purified using ammonium acetate precipitation. To the 20 µl IVT reaction, 10 µl of 7.5 M ammonium 
acetate were added and incubated 30 minutes at room temperature. Probes were centrifuged at 
16,100 × g for 1 hour at 20°C and washed with 1 ml of 80% ethanol. Pellets were air-dried and finally 
re-suspended in 100 µl of RNase-free H2O and stored at -80°C until used. 
2.2.5.5.2 Probe hybridization 
Fixed embryos or larvae stored in 100% methanol were rehydrated gradually with PBS by 5 minutes 
incubation in 25% methanol, 75% PBS and each step reducing the methanol by 25% until the last 
incubation with 100% PBS which was repeated 4 times. Following, rehydration, samples were 
permeablized by incubation in PBS supplemented with 10 µg/ml proteinase K and 0.1% tween 20. 
Incubation time was dependent on the developmental stage. It ranges from 10 second (or minutes) 
for samples harvested after 10 – 36 hpf to 30 minutes for samples harvested after the 36 hpf stage. 
Proteinase K digestion was stopped by transferring samples to 4% paraformaldehyde (PFA) and 
incubation for 20 minutes at RT. Samples were then washed 4 times in PBS, each for 5 minutes. 
Following this, PBS was replaced by 70°C-preheated hybridization buffer (50% deionized formamide, 
5× SSC, 0.1% Tween 20, 50 µg/ml heparin, 500 µg/ml RNase-free tRNA adjusted to pH 6.0 by adding 
citric acid (460 µl of 1 M citric acid solution for 50 ml of HM)) and samples were incubated for 4 hours 
at 70°C. After this incubation, probes were added to a final concentration of 1 ng/µl and hybridization 
was carried out overnight, still at 70°C. After hybridization, probes were recovered and samples were 
gradually washed with increasing concentration of SSC buffer until achieving 100% of 2× SSC. Samples 
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were then washed with 0.2× SSC for 30 minutes and gradually brought to 100% PBS. After that, they 
were incubated during 4 hours at RT in blocking buffer (PBS with 0.1% tween 20, 2% (v/v) sheep serum 
and 2 mg/ml BSA). Further incubation with primary antibody anti-DIG, conjugated to the alkaline 
phosphatase (AP) diluted 1:5000, was done overnight at 4°C. Embryos were washed 6 times with PBST 
at RT each for 15 minutes, then washed 3 times 5 minutes with AP buffer (100 mM Tris HCl, pH 9.5, 
50 mM MgCl2, 100 mM NaCl and 0.1% (v/v) Tween 20). After washing, samples were incubated in 
dark with colouring buffer (AP buffer containing 225 µg/ml of NBT and 175 µg/ml of BCIP). Colour 
development was checked every 10 minutes and stopped as soon as the desired intensity was 
reached. The reaction was stopped by replacement of the colouring buffer with PBS-T and samples 
were washed 4 times for 5 minutes with PBS-T. Samples were fixed for 10 minutes at RT in 4% PFA 
and then washed again 3 times in PBS-T. To decrease background, samples were incubated for 10 
minutes in 100% ethanol and then gradually brought back to PBS-T. Finally, samples were mounted 
into 3% methylcellulose and images were taken using a Zeiss Stereomicroscope Discovery V8. 
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Figure 2-3: Flow chart summarizing steps for in situ hybridization. Adapted from (THISSE and THISSE 2008) 
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2.2.5.6 Locomotor tracking 
Locomotor tracking system is usually used to evaluate changes in locomotor behaviour in zebrafish 
larvae. The system is equipped with a camera that records the movement of larvae and can measure 
the distance they move and their velocity. Larvae at 4 dpf injected with either Ctrl or pcmt/l MO were 
placed in a 96-well plate (1 larva per well) in 100 µl 0.3 × Danieau’s. The plate was incubated in the 
dark for 1 hour and then placed into the DanioVision tracking system, where the exposure to light was 
minimized. Larvae movements were continuously tracked. After 2 cycles of tracking (10 minutes lights 
on followed by 10 minutes lights off), 100 µl 0.3 × Danieau’s supplemented with 40 mM PTZ was added 
to each well (to reach a final concentration of 20 mM PTZ) and tracking was repeated.  
2.2.5.7 Calcium signalling in beta-actin:GCaMP6f transgenic zebrafish 
Larvae at 4 dpf injected with either Ctrl MO, Pcmt/l MO or Pcmt/l MO together with rescue plasmids, 
were incubated in 20 mM PTZ for 5 or 30 minutes at 28.5°C. They were then immobilized in 1.3% low 
melting agarose in 0.3 × Danieau’s without methylene blue on a glass bottom dish (MatTek, MA, USA) 
and covered with Danieau’s supplemented with 20 mM PTZ to avoid dryness of the gel. The 
immobilized larvae were positioned on the Nikon stereomicroscope SMZ25 and imaged for 15 or 30 
minutes using a Nikon SHR Plan Apo 2× WD:60 lens and illuminated by an epi-fluorescence light source 
with a GFP-B filter cube. Images were acquired at 2 Hz (500 msec exposure time), 640×512 resolution, 
8 Bit depth, and 5× zoom. The mean fluorescence intensity (F) of the brain over time was analysed 
using the Fiji software (SCHINDELIN et al. 2012) and expressed as F/F0, where F0 corresponds to the 35th 
percentile of the acquired signal. 
2.2.5.8 Tectal field potential recording 
Larvae at 4dpf were immersed in 2% low melting agarose in artificial cerebrospinal fluid (ACSF - 
124 mM NaCl, 2 mM KCl, 2 mM MgSO4, 2 mM CaCl2, 1.25 mM KH2PO4, 26 mM NaHCO3 and 10 mM 
glucose). A glass electrode, filled with ACSF and connected to a high-impedance amplifier, was 
inserted into the optic tectum of the larval brain. Electrode resistance was set between 2–9 MΩ. 
Recordings were performed in current clamp mode with the following parameters: low-pass filtered 
at 1 kHz, high-pass filtered at 1 Hz, digital gain 10 and sampling interval 10 μs (MultiClamp 700B 
amplifier, Digidata 1550A digitizer, both Axon instruments, USA). Each recording was done for 10 
minutes. Spontaneous epileptiform events were taken into account when the amplitude exceeded 
three times the background noise. The analysis of spikes was carried out using the Clampfit 10.2 
software (Molecular Devices Corporation, USA). 
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2.2.5.9 Statistical analysis 
All statistical analyses were done using the GraphPad Prism 5 software version 5.04 applying two-
tailed, unpaired Student’s t-test in case of comparing two data sets or ANOVA for comparison of more 
than two data sets. 
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3 Results 
3.1 Establishment of PCMT-deficient models to study  
3.1.1 PCMT1 knockdown in HEK293 and U-87 MG cells 
The insulin/IGF-1 signalling pathway (hereafter simply designated IGF-1 pathway) is highly conserved 
among species and one of the major regulators of aging (KENYON et al. 1993). Interestingly, 
phosphorylation levels of intermediates in the IGF-1 pathway (including Akt and GSK3) were found 
to be higher in the brains of Pcmt1 knockout mice (FARRAR et al. 2005a). One of our aims was to 
elucidate the mechanism by which Pcmt1 deficiency affects the phosphorylation levels in IGF-1 
pathway intermediates. Since the highest expression of Pcmt1 is found in the brain, we started using 
U-87 MG and HEK293, which are brain and kidney derived human cell lines, respectively. Although 
HEK293 cells are not derived from brain, they have been reported to express neuronal markers for 
example neurofilament (NF) subunits NF-L, NF-M and NF-H (SHAW et al. 2002). Moreover, 
phosphorylation levels of c-Raf, Erk1/2 and MEK, intermediates of the mitogen-activated protein 
kinase (MAPK) pathway, were found to be higher in PCMT1 knockdown HEK293 cells (KOSUGI et al. 
2008) suggesting that this cell line might be appropriate for studying effects of PCMT1 deficiency on 
other signalling pathways as well. We decided to use lentivirus mediated integration of shRNA to 
knock down PCMT1 in the chosen cell lines since it could potentially result in more efficient gene 
silencing and allow for creation of more easy to handle stable knockdown cell lines as compared to 
transient transfection with siRNAs. 
3.1.1.1 shRNA design and knockdown efficiency test 
As described in the methods (Section 2.2.4.2), lentiviral delivery of shRNA was used to knock down 
the expression of PCMT1 in both the HEK293 and U-87 MG cell lines. shRNA target regions in the 
PCMT1 coding sequence were identified using the freely available BLOCK-iT™ RNAi Designer web tool 
from ThermoFisher. The designer tool returned eight target regions and ranked them according to 
their knockdown probability (Table 3-1). We chose three target sequences (#2, #4 and #8 in Table 3-1) 
and designated them shRNA1, shRNA2 and shRNA3. The decision was based on the fact that #4 and 
#8 had the highest score, and #2 was chosen randomly. Simultaneously, a scrambled shRNA sequence 
was designed by shuffling the sequence of shRNA1. This control shRNA (designated below shCtrl) 
doesn’t target any transcript encoded by the human genome. 
These four shRNAs were independently inserted into the pENTR™/U6 vector to be expressed under 
the control of the U6 promoter. A transient transfection approach was then used to test the 
Results 
54 
 
knockdown efficiency of the different shRNAs in both the HEK293 and U-87 MG cell lines. Cells were 
maintained under standard conditions and harvested for RNA extraction 48 hours after transfection. 
PCMT1 transcript levels were measured by qPCR, the β-actin gene (ACTB) being used as the reference 
gene for normalisation. Cells expressing the control shRNA showed the same levels of PCMT1 
transcript as non-transfected cells (data not show). Cells expressing either of the three PCMT1 
targeting shRNAs showed a reduction in PCMT1 transcript levels (Figure 3-1) with knockdown 
efficiencies of 52%, 59% and 35% (HEK293 cells) and 63%, 56% and 47% (U-87 MG cells) for shRNA1, 
shRNA2, and shRNA3, respectively. Based on these results, we decided to use shRNA2 (hereafter 
designated shPCMT) for subsequent experiments. 
Table 3-1: Different shRNA target regions in the PCMT1 transcript and their rank according to knockdown probabilities. The 
yellow highlighted sequences were tested for PCMT1 knockdown efficiency. 
No. Start (bp) Target sequence (DNA) GC% Rank Name 
1 33 GGAGCTAATCCACAATCTCCG 52.39 
 
 
2 342 GCTAGTAGATGACTCAGTAAA 38.1 
 
shRNA1 
3 501 GGCGCTAATAGATCAGTTAAA 38.1 
 
 
4 502 GCGCTAATAGATCAGTTAAAG 38.1 
 
shRNA2 
5 573 GTTGGAGCAGTATGACAAGCT 47.62 
 
 
6 576 GGAGCAGTATGACAAGCTACA 47.62 
 
 
7 577 GAGCAGTATGACAAGCTACAA 42.86 
 
 
8 579 GCAGTATGACAAGCTACAAGA 42.86 
 
shRNA3 
  GAGAAGACATCGTACTGTAAT 38.1  shCtrl 
 
 
Figure 3-1: Relative PCMT1 transcript levels determined by qPCR following transient knockdown in HEK293 (a) and U-87 MG 
(b) cells by transfection with plasmids for transient expression of different shRNAs against PCMT1 (Ctrl, non-
targeting scrambled shRNA). The values shown are mean ± SEM of 3 biological replicates. The statistical 
significance of the differences between Ctrl and PCMT1 targeting shRNAs was estimated using a Student t-test 
(* p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001). 
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3.1.1.2 Generation of a stable PCMT1 knockdown cell lines  
For stable integration of the shRNA into the genome of the target cells, we first had to produce 
lentiviral particles carrying the shRNA sequence. Recombinant lentivirus production was performed 
as described in details in the methods (Section 2.2.4.2) in HEK293FT cells, after transfection of the cells 
with ViraPower plasmids provided with the kit along with the pLenti6/BLOCK-iT™ expression plasmid 
carrying the sequence of either shCtrl or shPCMT1. Viral particles were purified, concentrated, and 
used for stable integration of shCtrl or shPCMT into the genome of HEK293 and U-87 MG cells. Stable 
cell lines were selected based on blasticidin resistance and tested further. As for the transient shRNA 
expression trials, we estimated the PCMT1 expression levels in blasticidin resistant cell lines stably 
expressing shCtrl or shPCMT through qPCR. Results showed that PCMT1 expression was reduced to 
30% and 20% in the stable knockdown HEK293 and U-87 MG cell lines, respectively, by the PCMT1 
targeting shRNA as compared to cell lines stably expressing shCtrl (Figure 3-2). The knockdown 
efficiency is clearly stronger in the stable cell lines as after transient expression of the shRNA. This 
difference in knockdown efficiency between transient and stable expression of shRNA could be due 
to two reasons. The first is the plasmid dilution taking place in transient expression during cell division, 
where shRNA copy number gets diluted with every cell division, whereas in the stable cell lines the 
genome integrated shRNA is duplicated with each cell division. The second reason may be that in 
transient expression we estimated the knockdown efficiency in a heterogeneous population of cells, 
where some might have had low levels of the shRNA, while for the stable cell lines, generated from 
single clones each, homogenous cell populations are analysed in which each cell in principle expresses 
similar levels of the shRNA. 
 
Figure 3-2: Relative PCMT1 transcript levels in HEK293 (a) or U-87 MG (b) cell lines stably expressing non-targeting control 
shRNA (shCtrl) or PCMT1-targeting shRNA (shPCMT) after lentiviral transduction and selection by blasticidin. The 
values shown are mean ± SEM of 3 biological replicates The values shown are means ± SEM of 3 biological 
replicates (**** p-value < 0.0001). 
We further determined the PCMT1 knockdown efficiency in the two stable cell lines at the protein 
level. We seeded cells expressing shCtrl or shPCMT in a 6-well plate and kept it for 24 hours under 
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standard conditions followed by protein extraction in SDS sample buffer. Protein samples were 
resolved with 12% SDS-PAGE denaturation gel and blotted onto a PVDF membrane. We used two 
primary antibodies (Table 2-1) for protein quantification: an anti-PCMT1 antibody (from Abcam; 
polyclonal antibody raised against a recombinant fragment, corresponding to amino acids 1-197 of 
human PCMT1 (NP_005380)) and an anti-β-Actin antibody (13E5; from Cell Signalling) for loading 
control. 
The Western blot analysis clearly showed a decrease of PCMT1 protein in both knockdown cell lines 
(Figure 3-3 a). Comparison of relative band intensities (PCMT1/ACTB) using the Imagej software 
revealed a decrease in PCMT1 protein levels of 80% and 62% in knockdown HEK293 and U-87 MG 
cells, respectively, compared to control cells (Figure 3-3 b & c). Intriguingly, the transcript and protein 
levels variations in HEK293 and U-87 MG cells were inconsistent. On the one hand, PCMT1 transcript 
levels were higher in HEK293 cells than in U-87 MG cells (Figure 3-2). On the other hand, PCMT1 
protein levels were lower in HEK293 cells than in U-87 MG cells (Figure 3-3 b & c). These results 
suggested either a more efficient translational machinery or higher protein stability in the U-87 MG 
cells. 
 
Figure 3-3: PCMT1 protein levels in HEK293 and U-87 MG cells stably expressing shPCMT. Western blot analysis of protein 
extracts from HEK293 and U-87 MG cells (a). Quantitative analysis of PCMT1 protein levels in HEK293 (b) and U-
87 MG (c) cells. The values shown are means ± SEM of 6 biological replicates (** p-value < 0.01, *** p-
value < 0.001). 
3.1.1.3 Isoaspartyl methyltransferase activity and isoaspartyl levels in stable PCMT1 
knockdown cell lines 
We assumed that lower PCMT1 protein levels in the cells expressing shPCMT would lead to a decrease 
of the activity of the enzyme and subsequent accumulation of the enzyme substrates, isoaspartyl-
containing proteins. To validate this hypothesis, we assayed the isoaspartyl methyltransferase activity 
and isoaspartyl levels in protein extracts derived from the above described HEK293 and U-87 MG cell 
lines using a methanol vapour diffusion assay (PATANANAN et al. 2014). To determine the endogenous 
PCMT1 enzyme activity, we incubated protein extracts with the KASAisoDLAKY peptide as a substrate 
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and S-[3H-methyl]adenosyl methionine ([3H]SAM). KASAisoDLAKY is a nonapeptide of the following 
sequence (Lys-Ala-Ser-Ala-isoAsp-Leu-Ala-Lys-Tyr) where the middle amino acid is an L-isoaspartyl 
residue that serves as a methyl acceptor for the PCMT1 activity. In addition, for isoaspartyl level 
quantification, we incubated the protein extracts with recombinant human PCMT1 and [3H]SAM. In 
both cases, the reactions were run for 2 hours at 37°C and stopped by adding NaOH. The base-labile 
[3H]methanol released from the carboxymethyl ester bond on isoaspartyl residues was measured by 
the vapour diffusion assay described in the methods (Section 2.2.3.4) and illustrated in Figure 2-2. 
In comparison to the control cells, the isoaspartyl methyltransferase activity levels were significantly 
reduced to 17% and 38% in the PCMT1 knockdown HEK293 and U-87 MG cell lines, respectively (Figure 
3-4a, c). This activity analysis is in perfect agreement with the knockdown efficiency at protein level 
(Figure 3-3). Furthermore, the impact of the lower PCMT1 protein and activity levels on isoaspartyl 
accumulation was determined in total protein extracts. Our results show only a slight increase of about 
10% in isoaspartyl levels in both the HEK293 and U-87 MG cell lines (Figure 3-4b, d). These data suggest 
that the low residual PCMT1 activity levels in the PCMT1 knockdown cell lines are sufficient to repair 
the bulk of isoaspartyl residues forming under our cultivations conditions and therefore prevent an 
important isoaspartyl accumulation. Similarly, heterozygous Pcmt1+/- mice did not show a significant 
difference in isoaspartyl levels compared to wild type mice despite the fact that they have only 50% 
of the enzyme activity (KIM et al. 1997b; YAMAMOTO et al. 1998). Given this very moderate effect on 
isoaspartyl levels by the partial PCMT1 deficiency in our stable HEK293 and U-87 MG knockdown cell 
lines, we decided to apply the more recently established CRISPR/Cas9 technology to try to achieve a 
full knockout of PCMT activity in another cell line. 
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Figure 3-4: Isoaspartyl methyltransferase activity and isoaspartyl levels in HEK293 (a, b) and U-87 MG (c, d) PCMT1 
knockdown cells. The methanol vapour diffusion assay was used for quantification of the isoaspartyl 
methyltransferase activity as well as isoaspartyl levels in protein extracts derived from the cells. The values shown 
are means ± SEM of 4 biological replicates (*p-value < 0.05, **p-value < 0.01, **** p-value < 0.0001). 
3.1.2 Pcmt1 knockout in mouse hippocampal HT22 cells 
In Pcmt1 knockout mice, immunostaining of phosphorylated Akt showed most pronounced elevations 
in phosphorylation levels specifically in the hippocampus region of the brain (FARRAR et al. 2005a). We 
decided therefore not only to use CRISPR/Cas9 technology to knock out Pcmt1 (instead of only 
knocking down by shRNA), but to also switch from HEK293 and U-97 MG cells to HT22 cells, which 
have been derived from immortalized murine hippocampal cells (LIU et al. 2009). 
3.1.2.1 CRISPR/Cas9 mediated knockout of Pcmt1 
We designed two guide RNAs (gRNAs) to specifically target the Cas9 nuclease towards two sites in the 
Pcmt1 gene, distant of 40 bp, to induce double strand breaks (DSB). The expected deletion would be 
expected to either interfere with mRNA splicing and maturation or lead to frameshift mutation and in 
both cases this would lead to early stop codon and truncated protein. We cloned these two gRNAs 
into the pX459 plasmid carrying a puromycin resistance gene, as described in the methods section 
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(2.2.4.3), and transfected the recombinant plasmid into the HT22 cells. In parallel, we also transfected 
cells with the same plasmid expressing a scrambled gRNA as control (scrambled gRNA was generated 
by shuffling gRNA1 sequence; see section 2.2.2.9.6). Puromycin-resistant cells were seeded in 96-well 
plates at a density of 1 cell/well for clonal selection. After one week of incubation, we selected 10 
clones from cells transfected with Pcmt1 gRNAs and 3 clones from cells transfected with scrambled 
gRNA for validation of Pcmt1 gene mutation. 
A PCR-based approach was performed using primers pairs surrounding the expected deletion region 
(Table 2-6). The expected amplicon size corresponded to 155 bp for the control HT22 cells and 115 bp 
for cells carrying the correct deletion. While clones 1 – 9 showed only the smaller amplicon, clone 
number 10 showed two amplicons (expected 115 bp amplicon and a second one that is smaller than 
the wild type amplicon, but bigger than the mutated one (Figure 3-5a)). The clone number 10 thus did 
not seem to be a heterozygous cell line (one wild-type and one mutated Pcmt1 allele), but the indel 
mutation might have led, in one of the alleles, to the introduction of extra nucleotides between the 
two DSBs by the repair machinery that performs the nonhomologous end joining (NHEJ) and which is 
prone to mistakes. We randomly selected three of the positive clones (C3, C6 and C7) for further 
experiments and the data shown hereafter are from clone number C6 (designated Pcmt1 knockout 
from here on). 
Similarly, as for the knockdown in HEK293 and U-87 MG cell lines, we next determine the knockout 
efficiency at both mRNA and protein levels in the selected Pcmt1 knockout HT22 line. Using qPCR, we 
found an 82% decrease in the transcript in the Pcmt1 knockout line compared to the control line 
(Figure 3-5b). This difference could be explained by a decrease of the transcription of edited Pcmt1 
gene or a lower stability of the corresponding mRNA. As mentioned previously, the 40-bp deletion is 
predicted to lead to a premature stop codon in the transcript. Thus we may assume that the nonsense-
mediated decay mechanism (BAKER and PARKER 2004), which could take place when translational 
termination is in close proximity to the initiation site, is more pronounced for Pcmt1 carrying the 40-
bp deletion. The difference in expression was even more striking at the protein level. After protein 
separation by SDS-PAGE, Western blot analysis showed that the PCMT1 protein was not detectable in 
the knockout cells even though, the anti-PCMT1 antibody used was raised against the first 197 amino 
acids which are not before the DSB induced by CRISPR/Cas9 (Figure 3-5c). We thus concluded that our 
CRISPR/Cas9 strategy had allowed for the creation of an HT22 cell line with a complete knockout of 
Pcmt1 expression, in which the low but detectable residual Pcmt1 transcripts were not translated into 
Pcmt1 protein levels detectable by Western blot.  
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Figure 3-5: Pcmt1 knockout in HT22 cells. (a) PCR amplicons of genomic Pcmt1 from different CRISPR/Cas9 edited HT22 cell 
lines analysed on a 3% agarose gel. Ten clones were tested (1 – 10) in addition to control cells (C) transfected with 
a scrambled gRNA. Wild type amplicon is 155 bp while CRISPR/Cas9 mutant amplicon is 115 bp (b) Pcmt1 
transcript level in Pcmt1 knockout HT22 cells relative to control cells as determined by qPCR. The values shown 
are means ± SEM of 3 biological replicates (*** p = 0.0005) (c) Pcmt1 protein levels in control and Pcmt1 knockout 
HT22 cells analysed by Western blot. 
3.1.2.2 Isoaspartyl methyltransferase activity and isoaspartyl levels in Pcmt1 knockout 
HT22 cells 
We then also investigated the impact of the Pcmt1 deletion on both the isoaspartyl methyltransferase 
activity and isoaspartyl levels in protein extracts derived from the Pcmt1 knockout HT22 cells, using 
the methanol vapour diffusion assay described above. Cells were seeded in 6-well plates and 
incubated for two days under standard cultivation conditions. Consistent with the total lack of Pcmt1 
protein in the Pcmt1 knockout cells, no residual isoaspartyl methyltransferase activity was detected 
(Figure 3-6). Moreover, we found that the proteins in the Pcmt1 knockout cells contained significantly 
more isoaspartyl residues than the control cells. By comparison to the PCMT1 knockdown HEK293 or 
U87 cell lines, there was a higher accumulation of damaged proteins containing isoaspartyl residues 
in the Pcmt1 knockout HT22 cell line (1.1-fold increase in both the HEK293 or U87 knockdown cells 
compared to control cells versus 1.6-fold increase in the HT22 knockout cells compared to control 
cells). For further comparison, it has been reported previously that Pcmt1 knockout mice accumulate 
4- to 8-fold higher isoaspartyl levels in various tissues than control mice. But it was also shown that 
this accumulation is age-dependent, with a 2.7-fold increase of isoaspartyl levels in proteins extracted 
Results 
61 
 
from red blood cells taken from Pcmt1 knockout mice at the age of 24 or 59 days (KIM et al. 1997b). 
In addition, isoaspartyl levels were found also to increase in response to oxidative stress. Isoaspartyl 
levels increased in membrane proteins of human erythrocytes under oxidative stress due to exposure 
to t-butyl hydroperoxide and H2O2 (INGROSSO et al. 2000). It is therefore possible that higher isoaspartyl 
accumulations can be reached in our HT22 Pcmt1 knockout cell line after more prolonged cultivation 
times (aging) or following exposure to certain stress conditions. In any case, given the complete 
absence of isoaspartyl methyltransferase activity in a cell line of a relevant type (hippocampal origin), 
we concluded that we had now created a promising tool to mimic the effects of Pcmt1 knockout on 
growth signalling pathways previously observed in the hippocampus of Pcmt1 knockout mice. 
 
Figure 3-6: Isoaspartyl methyltransferase activity and isoaspartyl levels in protein extracts of Pcmt1 knockout cells. The values 
shown are means ± SEM of 6 biological replicates (**** p < 0.0001). 
3.1.3 PCMT knockdown in zebrafish 
Pcmt1 knockout mice die prematurely due to fatal epileptic seizures (KIM et al. 1997b), however, the 
mechanism underlying the connection between seizure development and Pcmt1 function is not 
known. Zebrafish is used as a model organism to investigate neurological disorders, including epilepsy 
(BARABAN 2007; MARTIN-JIMENEZ et al. 2015). As the zebrafish model enables in vivo imaging of the 
brain, is amenable to high-throughput approaches (ZON and PETERSON 2005) and is for a number of 
aspects more convenient and easy to handle than the mouse model (Section 1.4.2), we aimed at 
developing a zebrafish model with PCMT deficiency to further study the physiological relevance of the 
isoaspartyl repair mechanism and more particularly its apparent role in seizure development. 
A BLASTp search using the human PCMT1 protein sequence (Accession: AAH07501.1) as query against 
D. rerio (taxid: 7955) and using default parameters (ALTSCHUL et al. 1997; ALTSCHUL et al. 2005) revealed 
5 hits (Table 3-2). Three out of the five protein hits had less than 50% query cover and were excluded. 
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They only shared similarity with the human protein in the methyltransferase domains, which 
suggested that they are methyltransferase enzymes but not specifically related to the isoaspartyl 
methyltransferase family. The other two matches correspond to the expression products of the 
zebrafish pcmt and pcmtl genes, annotated as L-isoaspartyl methyltransferases based on the high 
sequence similarity with established isoaspartyl methyltransferases. Pcmt and Pcmtl are paralogs, 
resulting from an ancient genome duplication event in teleost fishes (TAYLOR et al. 2001), and the share 
85% and 69% amino acid sequence identity, respectively, with the human PCMT1 protein. To see the 
sequence similarity between the three homologues as well as the mouse one, since we are also using 
a mouse derived cells line, a multiple sequence alignment performed with the CLUSTAL Omega 
software version 1.2.4 (SIEVERS et al. 2011) using default settings. The alignment (Figure 3-7) showed 
that the SAM-dependent methyltransferase domains, AdoMet I – III, as well as isoaspartyl 
methyltransferase domains, pre-I and post-III, highlighted in yellow in Figure 3-7 are well conserved 
between the four sequences as well as amino acid residues found to directly interact with S-
adenosylhomocysteine from crystal structure data (PDB: 1I1N) (KAGAN and CLARKE 1994; KAGAN et al. 
1997; SMITH et al. 2002). 
Table 3-2: Blastp results from searching for homologs of human PCMT1 in zebrafish. 
Description Query 
cover 
E 
value 
Ident Accession 
protein-L-isoaspartate(D-aspartate) O-
methyltransferase [Danio rerio] 
100% 5.19E-151 85% NP_571540.1 
l-isoaspartyl protein carboxyl methyltransferase, 
like [Danio rerio] 
100% 4.22E-117 69% NP_957062.1 
Select seq ref|XP_017206506.1| PREDICTED: 
uncharacterized protein LOC767695 isoform X1 
[Danio rerio] 
45% 0.003 32% XP_017206506.1 
Select seq ref|NP_001070101.1| uncharacterized 
protein LOC767695 [Danio rerio] 
45% 0.004 32% NP_001070101.1 
Zgc:153372 [Danio rerio] 20% 0.004 43% AAI52084.1 
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Figure 3-7: Sequence alignment of the human PCMT1, mouse Pcmt1 and their two homologs from zebrafish Pcmt and Pcmtl. 
Residues highlighted in yellow are conserved methyltransferase domains; AdoMet I – III are SAM specific domains 
and pre-I and post-III are isoaspartyl methyltransferase-specific domains (KAGAN et al. 1997). Residues in red were 
found from crystallography data to be directly interacting with S-adenosylhomocysteine (SMITH et al. 2002). An * 
(asterisk) indicates positions which have a single, fully conserved residue. A : (colon) indicates conservation 
between groups of strongly similar properties. A . (period) indicates conservation between groups of weakly 
similar properties. 
3.1.3.1 Biochemical properties of the zebrafish Pcmt and Pcmtl proteins 
Gene duplication is a powerful tool to the acquisition of new function. In 1970, Susumu Ohno has 
presented a new classical view of the evolution of duplicated genes: whereas one gene must conserve 
the function, the second one may acquire mutations, either in the coding or non-coding regions, that 
have the potential to lead to dosage compensation, sub- or neo-functionalization (CONANT and WOLFE 
2008). Pcmt and Pcmtl, arising from the genome duplication of the ancestor of teleost fishes, both 
share high sequence identity with human and mouse PCMT, with virtually total conservation in the 
SAM methyltransferase domains as well as the more isoaspartyl methyltransferase specific domains 
pre-I and post-III (Figure 3-7). Based on this sequence analysis, both Pcmt and Pcmtl thus qualified has 
highly likely ortholog candidates of the mammalian PCMT1 protein. As even single amino acid changes 
in protein sequences can critically affect protein function, however, predictions based on sequence 
similarity should never be taken as granted and need to be verified experimentally. In our case, to 
determine if we had to focus on the pcmt or the pcmtl gene or both for the establishment of our PCMT 
deficient zebrafish model, we first aimed at answering the following two questions: (i) do Pcmt and/or 
Pcmtl catalyse the same enzymatic reaction as their human homologue and (ii) if yes, do the kinetic 
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properties vary significantly between human PCMT1 and zebrafish Pcmt and Pcmtl? A second aspect, 
that we analysed in a second stage, was a comparison of the expression properties of the pcmt and 
pcmtl genes, both in time (when during development?) and in space (in which tissues?). 
3.1.3.1.1 Pcmt and Pcmtl recombinant protein expression and purification 
To answer the first two questions regarding the catalytic function of Pcmt and Pcmtl, we expressed 
both enzymes in E. coli for subsequent purification and in vitro enzymatic characterization. After 
cloning of the coding sequences of both proteins independently into pET100 plasmids downstream of 
a 6×His-tag sequence (Section 2.2.2.9.2), E. coli BL21(DE) cells were transformed with each plasmid 
and transformants were cultivated in LB medium supplemented with 50 µg/ml carbenicillin for 
selection. Protein expression was induced with 0.1 mM IPTG at 18°C for 10 hours. To purify the 
recombinantly expressed proteins, we lysed the cells by sonication and separated soluble proteins 
from cell debris and other insoluble material by centrifugation followed by a filtration step. The 
filtered supernatant was loaded onto a His-trap Ni2+ column for affinity purification of His-tagged 
proteins. 
We started with the purification of Pcmtl. Following protein binding to the His-trap column, the latter 
was washed with 25 mM imidazole, to remove non-specifically bound proteins, followed by gradient 
elution with 25 – 300 mM imidazole over 20 minutes (Figure 3-8 b). Based on SDS-PAGE analysis we 
prepared two pools of fractions, the first corresponding to volumes 179 – 182 ml (contained higher 
Pcmtl amount) and the second corresponding to volumes 182 – 186 ml collected during the elution 
step (Figure 3-8 b&d). As the SDS-PAGE showed some remaining protein impurities in the peak elution 
fractions, we modified our strategy for the Pcmt purification by adding a second washing step in the 
aim of increasing the purity. After the protein binding step, we washed the column with 25 mM and 
50 mM imidazole, followed by protein elution using a linear imidazole gradient (50 – 300 mM 
imidazole) over 20 ml (Figure 3-8 a). Based on SDS-PAGE analysis (Figure 3-8 c) we prepared two pools 
of fractions containing purified Pcmt, the first corresponding to the protein peak that eluted during 
the 50 mM imidazole wash and the second corresponding to the fractions eluted between volumes 
129 – 136 ml during the imidazole gradient. 
Following affinity purification, to desalt our purified enzyme pools we dialyzed them twice against a 
buffer containing 20 mM Tris pH 7.4, 25 mM NaCl and 20% glycerol and stored them in dialysis buffer 
at -20°C.  
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Figure 3-8: Recombinant protein purification of N-terminally His-tagged Pcmt and Pcmtl. Chromatography profile for 
purification of zebrafish Pcmt (a) and Pcmtl (b) protein on nickel affinity column. Protein concentration was 
monitored spectrophotometrically by measuring the absorbance at 280 nm (blue line). Imidazole concentration 
was adjusted into the running buffer for washing and elution of His-tagged protein (red line). (c and d) SDS-PAGE 
analysis of samples collected during the purification MW: molecular weight markers; P: pellet; SN: supernatant 
FT: flow through; W: wash; %B: buffer B percentage used for extra washing steps; F6, F8, F10, F12 in (c) fractions 
collected during gradient elution corresponding to volumes 130, 132, 134 ml in chromatogram (a), respectively; 
F3, F7, F9, F12, F14, F18, F20, F21 in (d) corresponds to volumes 167, 171, 173, 176, 178, 181, 182, 184, 185 ml in 
chromatogram (b), respectively. 
As can be deduced from the chromatograms and SDS-PAGE analyses shown in Figure 3-8, the second 
purification strategy (for Pcmt) was not necessarily more successful than the first one (for Pcmtl), His-
tagged Pcmt protein eluting already during the washing steps at the increased imidazole 
concentrations. Nevertheless, after affinity purification and desalting, SDS-PAGE analysis of the 
desalted protein pools showed that we had obtained highly homogenous protein preparations of both 
enzymes (Figure 3-8e), with a total protein yield of 24 mg and 55 mg of purified Pcmt and Pcmtl, 
respectively. 
3.1.3.1.2 Catalytic activity of Pcmt and Pcmtl 
We used the purified recombinant Pcmt and Pcmtl proteins for in vitro enzymatic characterization 
using the methanol vapour diffusion assay (Section 2.2.3.4). Briefly, we incubated 0.5 µg of either 
enzyme with different concentrations (0.2 – 60 µM) of an isoaspartyl-containing peptide 
(KASAisoDLAKY) and radiolabelled [3H]-S-adenosyl methionine [3H]-SAM in a total volume of 50 µl. The 
assay was in an ‘end-point’ format with the reaction being stopped after 7, 14 and 21 minutes after 
incubation at 30°C. The [3H]-methanol released from the methylated isoaspartyl-containing peptide 
during incubation at basic pH was measured via the vapour diffusion assay and initial velocities were 
determined by the rate of [3H]-methanol formation over time. The determined initial velocities were 
plotted against the substrate concentration and the data were fitted to the Michaelis-Menten kinetics 
model was used to determine the Michaelis-Menten constant (KM) and maximum velocity (Vmax) and 
thereby evaluate the substrate affinity, turnover number (kcat) and catalytic efficiency (kcat/KM) of Pcmt 
and Pcmtl. 
Our results showed that both Pcmt and Pcmtl catalyse the transfer of methyl group from the cofactor 
SAM to the isoaspartyl residue in the tested peptide substrate (Figure 3-9). Based on the KM values 
(4.2 µM and 3.6 µM for Pcmt and Pcmtl, respectively) both enzymes show a high substrate affinity. 
This substrate affinity was intermediate compared to isoaspartyl methyltransferase enzymes from 
other species tested with the same substrate. It was higher compared to Pcmt from A. thaliana (KM = 
21 µM) and lower compared to PCMT1 from H. sapiens (KM = 0.4 µM) (LOWENSON and CLARKE 1991; 
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THAPAR and CLARKE 2000). We found that the maximum velocity is about 1.5-fold higher for Pcmtl 
compared to Pcmt. 
 
Figure 3-9: Substrate saturation curves for zebrafish Pcmt and Pcmtl. Each of the recombinant purified enzymes was 
incubated with different concentrations of the methyl acceptor substrate KASAisoDLAKY and initial reaction 
velocities were determined using methanol vapour diffusion assay. The values shown are mean ± SD of 3 biological 
replicates. 
Table 3-3: Kinetic properties of Pcmt and Pcmtl using KASAisoDLAKY as a methyl acceptor. KM and Vmax values were 
determined from the data shown in Figure 3-9 using nonlinear regression curve fitting in GraphPad Prism 5. 
 KM 
[µM] 
Vmax 
[pmol/min/mg] 
kcat 
[s-1] 
kcat/KM 
[M-1s-1] 
Pcmt 4.2 ± 0.51 9096 ± 313 4.30 ± 0.12 × 10-3 1031 
Pcmtl 3.6 ± 0.48 14112 ± 515 6.72 ± 0.25 × 10-3 1845 
 
3.1.3.2 pcmt and pcmtl expression and tissue distribution 
We first compared the pcmt and pcmtl mRNA expression over time during early larval development 
using qPCR. We next used two approaches to determine the tissue localization of the pcmt and pcmtl 
transcripts: in situ hybridization in embryos and mRNA quantification by qPCR in different organs 
dissected from adult zebrafish. 
3.1.3.2.1 pcmt and pcmtl expression during early development 
To determine if both pcmt and pcmtl genes are expressed during early zebrafish development, total 
RNA was extracted from embryos/larvae collected at different stages: from 7 hours post fertilization 
(hpf) up to 6 days post fertilization (dpf). Using qPCR, we found that both pcmt and pcmtl transcripts 
were detectable as early as 7 hpf, the first time point tested (Figure 3-10). Pcmtl transcript levels were 
stable for the first 3 days and then doubled from the fourth day, while the pcmt transcript levels 
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showed (reproducibly) more variations during the first 3 days and then also started to stabilize at an 
overall higher level. This discrepancy between pcmt and pcmtl transcript levels could be due to 
differential transcription regulation or transcript stability. 
 
Figure 3-10: Pcmt and pcmtl transcript levels during early development of zebrafish as determined by qPCR (Relative fold 
changes compared to 7 hpf. The values shown are mean ± SEM of 3 biological replicates. 
The dynamics observed for pcmt expression, where the transcript levels decreased at 12 hpf and start 
to increase again at 24 hpf were unusual. One possible explanation for the early drop in transcript 
level is that at the first time point there is still a high proportion of maternally transmitted mRNA, 
which then starts to decrease while the endogenous machinery is taking over for the transcript 
production. To test this hypothesis, we collected eggs directly after they were laid for yolk RNA 
extraction. RNA extraction was done as before and in parallel we also extracted RNA from fertilized 
eggs at 12 and 24 hpf followed by first strand cDNA synthesis. Agarose gel electrophoresis analysis 
showed the presence of both transcripts in the eggs confirming the transmission of maternal mRNA 
(Figure 3-11). Our results show that both pcmt and pcmtl are maternally transmitted and both genes 
are expressed during early stages of development. In addition, the results suggest an important role 
of pcmt/l during development since, at least in mice, isoaspartyl levels are low at young age and 
increase with age (KIM et al. 1997b). Therefore, the repair mechanism to limit isoaspartyl accumulation 
is unusable suggesting an alternative function during development. 
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Figure 3-11: Agarose gel showing DNA fragments amplified from pcmt and pcmtl cDNA from zebrafish egg yolk, 12 hpf and 
24 hpf embryos. 
3.1.3.2.2 Tissue distribution of pcmt and pcmtl transcripts at embryonic stage 
For tissue localization of both the pcmt and pcmtl transcripts at embryonic stage, we performed in situ 
hybridization as previously described (Section 2.2.5.5). We prepared sense and anti-sense RNA probes 
for both transcripts by in vitro transcription during which uridine bases were labelled with digoxigenin 
(DIG). The antisense probe should hybridize to endogenous transcript for visualization of the transcript 
localization, while the sense probe should not bind specifically and is used as a negative control. 
Embryos were collected at 1 dpf, fixed in 4% paraformaldehyde and incubated with either sense or 
antisense probes followed by immunodetection using anti-DIG antibody. 
 
Figure 3-12: Tissue distribution analysis by in situ hybridization for pcmt and pcmtl transcripts in 1 dpf embryos. 
Our results showed colour development over the whole embryos using the antisense probes with no 
preferential localization to specific tissues for either pcmt or pcmtl transcripts (Figure 3-12). 
Noticeably, a very slight difference between pcmt and pcmtl can be seen where the pcmt transcript 
showed higher levels in the trunk and tail while pcmtl transcript was more intense in the head region. 
The results suggest a ubiquitous expression of both genes in all tissue of the embryo, but the high 
background detected in the control samples (sense probe) renders the experiment somewhat 
inconclusive. Similar experiments done previously for pcmtl in a high-throughput analysis by Thisse, 
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B. and Thisse, C. also indicated that the transcript is not spatially restricted to a specific tissue in 
zebrafish at stages between 1-cell to 3 dpf (THISSE and THISSE 2004). Experiments in mice also showed 
that Pcmt1 is ubiquitously expressed in all the tissue tested (DILIBERTO and AXELROD 1976; BOIVIN et al. 
1995). 
3.1.3.2.3 Tissue distribution of pcmt and pcmtl transcripts in adult zebrafish 
Tissue-specific localization can also be estimated through gene expression analysis by qPCR in various 
cell types or organs. We dissected different organs (brain, heart, testes/ovaries, spleen, kidney and 
liver) from 2 year-old adult fish (n=3) for RNA extraction and subsequent pcmt and pcmtl transcript 
quantification through qPCR. All gene expression data were normalized to the eukaryotic elongation 
factor 1a (eef1a) housekeeping gene (TANG et al. 2007). Independently of the gender, we found the 
same trend for both the pcmt and pcmtl genes, with the highest expression levels being found in brain 
and testes/ovaries (Figure 3-13). The results are in good agreement with the tissue distribution found 
for Pcmt1 in mice, which also showed ubiquitous expression, but higher expression levels in the brain 
and testes (KIM et al. 1997b; LOWENSON et al. 2001). 
 
Figure 3-13: Pcmt and Pcmtl transcript levels determined by qPCR in different organs of 2-year old adult zebrafish.  Relative 
fold changes compared to the expression levels in brain were determined. The values shown are mean ± SEM of 
3 biological replicates. 
Results 
71 
 
All together, these results suggest that both Pcmt and Pcmtl conserved the same catalytic activity and 
similar expression patterns, suggesting that the two paralogue genes have not functionally diverged 
since the gene duplication event. In practical terms, this meant that both genes had to be targeted in 
zebrafish to achieve efficient knockdown of isoaspartyl methyltransferase function and investigate the 
in vivo impact of a deficiency in this function. The evolution of duplicated genes is still a hot topic in 
biology, especially in zebrafish (ZHONG et al. 2016), and could be investigated further for pcmt and 
pcmtl genes. However, this evolutionary aspect goes beyond the scope of this thesis. 
3.1.3.3 Morpholino mediated knockdown of pcmt and pcmtl in zebrafish 
3.1.3.3.1 Morpholino efficiency and toxicity testing 
Morpholinos (MOs) are oligomers that are often used for gene expression knockdown in zebrafish 
(EKKER 2000; DRAPER et al. 2001). Five different MOs were designed by GeneTools LLC (Philomath, 
Oregon, USA) (Table 2-4): two specific to pcmt (pcmt i2e3 and pcmt e5i5), two specific to pcmtl (pcmtl 
e1i1 and pcmtl e4i4) and one scrambled sequence serving as control MO. The MOs designed for pcmt 
specifically target the intron2-exon3 (pcmt i2e3) and the exon5-intron5 junctions (pcmt e5i5). 
Similarly, MOs designed for pcmtl specifically target the exon1-intron1 (pcmtl e1i1) and the exon4-
intron4 (pcmtl e4i4) junctions. As described previously, MOs binding at the intron-exon or at the exon-
intron junctions should impair mRNA splicing leading to the loss of one exon and eventually to non-
functional protein. Thus the efficiency of MOs can be estimated by PCR analysis at the cDNA level with 
primers located up- and downstream of the predicted skipped exon leading to a smaller amplicon due 
to the missing exon (Figure 3-14). 
 
Figure 3-14: Schematic representation of MO effect on mRNA splicing and of the PCR analysis strategy that can be used to 
check for MO efficiency. 
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To test the efficiency of the MOs, we injected 9 ng of each of the above mentioned five MOs 
independently into wild type AB eggs at 1 – 2 cell stage, followed by total RNA extraction at 2 dpf. 
After cDNA synthesis and PCR with primers chosen as described above, amplicons were resolved by 
on a 3% agarose gel. Depending on the MO, the size of the PCR amplicon was expected to vary from 
100 to 225 bp or to be totally absent in case of pcmtl e1i1 since the forward primer had been designed 
to bind to MO-target exon 1 (Table 3-4). Figure 3-15 shows the DNA agarose gel analysis of the 
obtained PCR amplicons. In pcmt i2e3 MO-injected larvae, the wild type (wt) amplicon was still 
predominant with a faint band of smaller size representing the morphant amplicon lacking the 32 bp 
exon 3. In contrast, in case of the pcmt e5i5 MO, the wt amplicon was totally absent while two 
morphant smaller bands were observed. Sequencing of the latter two amplicons showed both total 
skipping of the 115 bp exon 5 or partial skipping of 52 bp from the same exon. pcmtl e1i1 did not seem 
to interfere with pcmtl transcript splicing, but pcmtl e4i4 led to skipping of the 32 bp exon 4, with low 
levels of residual wt amplicon. In summary, pcmt e5i5 and pcmtl e4i4 were more efficient than pcmt 
i2e3 and pcmtl e1i1 in interfering with correct splicing of the pcmt and pcmtl pre-mRNAs, respectively. 
We thus decided to use pcmt e5i5 and pcmtl e4i4 for further experiments. 
Table 3-4: Expected amplicon size from wt or morphant transcripts. 
 pcmt i2e3 pcmt e5i5 pcmtl e1i1 pcmtl e4i4 
Target exon (size) Exon 3 in 
pcmt 
(32bp) 
Exon 5 in 
pcmt 
(115 bp) 
Exon 1 in 
pcmtl 
(161 bp) 
Exon 4 in 
pcmtl 
(32bp) 
Wt amplicon size (bp) 139 225 101 215 
Morphant amplicon size (bp) 107 110 0 183 
 
Figure 3-15: Agarose gel electrophoresis analysis for MO efficiency validation. Eggs were injected with either control MO or 
MO targeting pcmt or pcmtl (9 ng of each MO). RNA was extracted at 2dpf, converted into cDNA and used for 
PCR with primers spanning the exon targeted by the MO. 
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To find the efficient MO concentration with the lowest toxicity, we injected different amounts of each 
MO (7, 11, or 14 ng) at 1 – 2-cell stage and followed the development of the injected larvae over time. 
Both MOs resulted in amount-dependent dysmorphology (Figure 3-16). MOs higher than 7 ng in the 
case of pcmt e5i5 and 11 ng in the case of pcmtl e4i4 led to larvae with strong curvature of the trunk 
at 4 dpf, which is reported as a common side-effect of many MOs (KOK et al. 2015).  
Interestingly, the swim bladder was found to be affected by MOs injection. In pcmt e5i5 the swim 
bladder is totally absent even with the lowest concentration, while in the case of pcmtl e4i4, the effect 
is dose-dependent (red arrows in Figure 3-16). It has previously been reported in MO-mediated 
knockdown of genes related to neurological disorders, such as Dravet syndrome and Batten disease 
(ZHANG et al. 2015; WAGER et al. 2016) that the swim bladder development was affected and failed to 
inflate. 
 
Figure 3-16: MO titration: AB eggs were injected with different amounts of either Pcmt e5i5 MO or Pcmtl e4i4 MO to find the 
maximum tolerated concentration. b and e: 7 ng; c and f: 11 ng; d and g: 14 ng. Increasing MO amounts led to 
developmental delay and morphological abnormalities. Swim bladder development was also affected by the MOs 
(red arrows). 
Since we have found both Pcmt and Pcmtl to catalyse the same biochemical reaction, we decided to 
knock down both genes simultaneously (pcmt/l) in order to study the phenotypic effects of isoaspartyl 
methyltransferase downregulation. We continued with the titration of the MOs by co-injection of 7 ng 
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of each MO (14 ng in total), but this led to death of all the larvae. Amounts were reduced to 5 ng of 
each MO, which also led to severe dysmorphology in a large proportion of larvae and finally we used 
co-injection of 3.5 ng of each MO as an efficient and minimally toxic working amount for simultaneous 
knockdown of both genes. 
3.1.3.3.2 Morpholino-mediated knockdown of pcmt/l leads to loss of methyltransferase activity 
and limited accumulation of isoaspartyl residues in the pcmt/l morphants 
In order to determine the impact of simultaneous pcmt and pcmtl knockdown on isoaspartyl 
methyltransferase activity and accumulation of isoaspartyl levels, we used the vapour diffusion assay 
as described for mammalian cells. We injected AB eggs with pcmt/l MO (3.5 ng of each pcmt e5i5 and 
pcmtl e4i4) followed by protein extraction at 2 and 4 dpf (Section 2.2.5.3). Independently of the day 
of sampling, the methyltransferase activity was drastically decreased in pcmt/l morphant larvae 
compared to age-matched uninjected or MO control-injected larvae (Figure 3-17 a). Concerning the 
isoaspartyl levels, at 2 dpf we observed a slight but not significant increase in pcmt/l morphant 
extracts, which could be due to the residual methyltransferase activity detected at this stage. At 4 dpf, 
where the methyltransferase activity was not detectable, we observed a statistically significant, 1.5-
fold increase in isoaspartyl residues in the pcmt/l morphant extracts (Figure 3-17b). 
 
Figure 3-17: Isoaspartyl methyltransferase activity and isoaspartyl levels in protein extracts of zebrafish larvae at 2 and 4 dpf. 
(a) Isoaspartyl methyltransferase activity in zebrafish estimated by incubation of protein extracts with methyl 
acceptor KASAisoDLAKY and [3H]SAM. (b) Isoaspartyl levels in protein estimated by incubation of protein extracts 
with recombinant human PCMT1 and [3H]SAM (done at Clarke’s lab). The values shown are means ± SEM of 4 
biological replicates (ns, not significant; * p-value < 0.05; *** p-value < 0.001). 
We were also interested to see if the isoaspartyl residues detected in the zebrafish protein extracts 
were uniformly distributed among proteins of all sizes or were found more specifically in certain 
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proteins only, with a special interest in the proteins accumulating more isoaspartyl residues in the 
pcmt/l morphants. We therefore implemented fluorography experiments in collaboration with Prof. 
Steven Clarke’s laboratory at UCLA (Los Angeles, CA). At LCSB, we prepared the protein extracts from 
zebrafish larvae at 2 and 4 dpf (uninjected, control MO-injected or pcmt/l MO-injected). In the Clarke 
lab, isoaspartyl residues were labelled with radioactive methyl groups from [3H]SAM using 
recombinant human PCMT1 enzyme and the labelled proteins were resolved by SDS-PAGE. The 
protein gels were then incubated in EN3HANCE, dried and exposed to a film for 1 day for detection of 
the labelled protein bands as described by Patananan et al (PATANANAN et al. 2014). 
Interestingly, Coomassie blue staining of the SDS-PAGE gels showed decreased staining intensity for 
all proteins above 31 kDa in the protein extracts from 2 dpf pcmt/l morphant embryos (Figure 3-18b), 
despite loading the same amount of protein (as normalized based on Bradford assay). This could be 
due to increased protease activity levels specifically in the pcmt/l morphants at this developmental 
stage. Indeed, isoaspartyl accumulation and PCMT downregulation was reported to activate protease 
activity (SZYMANSKA et al. 1998; DAI et al. 2013; DHO et al. 2013). Accordingly, the fluorography also 
showed lower radioactive labelling after incubation with human recombinant PCMT1 for the 2 dpf 
pcmt/l morphant embryos (Figure 3-18a). Given that, when measuring total isoaspartyl levels in 
protein extracts derived from embryos at that stage, we detect equal or even slightly higher levels of 
isomerized residues in the pcmt/l morphants compared to the control embryos (Figure 3-17b), this 
suggests again that the lower labelling in the fluorograph for the pcmt/l morphants does not reflect 
overall lower accumulation of isoaspartyl residues in their proteins, but higher rates of proteolysis 
with formation of small labelled peptides that are not detected by fluorography, but are well 
measurable in the isoaspartyl assay in total protein extracts. In strong contrast, nothing points at this 
increased proteolysis in extracts derived from pcmt/l morphant larvae 2 days later (equal Coomassie 
blue staining intensities in all the lanes for 4 dpf samples, as expected given equal loading amounts 
for all the samples to be compared (Figure 3-18b). In addition, fluorography confirmed the increase in 
the isoaspartyl levels in the pcmt/l morphant larvae at 4 dpf observed also during isoaspartyl assays 
in total protein extracts (Figure 3-17b), but was, at first sight, not associated to specific proteins (Figure 
3-18a). 
Our results confirm the efficiency of the combined pcmt/l MO knockdown strategy, with a profound 
downregulation of the isoaspartyl methyltransferase activity and higher accumulation of isoaspartyl 
residues in pcmt/l morphant larvae. Both effects were more pronounced at 4 dpf than at 2 dpf. It is 
noteworthy that in the Pcmt1 knockout mice, isoaspartyl levels are positively correlated with age (KIM 
et al. 1997b). To our knowledge, isoaspartyl level measurements have not been reported for mice at 
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developmental stages that would correspond to the early stages of life investigated here in zebrafish 
due to practical constraints (MO efficiency decreases after 5 dpf due to dilution by cell division; 
experiments have thus to be performed before that time point). One concern was therefore that the 
zebrafish model could from that point of view limit us to see phenotypic impacts of isoaspartyl 
methyltransferase deficiency. The results obtained with the 4 dpf larvae indicate, however, that the 
zebrafish model should allow to also investigate consequences of increased isoaspartyl damage 
accumulation, at least to a certain extent. 
 
Figure 3-18: Fluorography and SDS-PAGE analysis of isoaspartyl in protein extracts from zebrafish Protein extracts from 
uninjected, Ctrl MO-injected and pcmt/l MO-injected of 2 dpf and 4 dpf were labelled with [3H]-SAM and 
recombinant human PCMT1 then resolved in SDS-PAGE. Fluorography (a) showed lower incorporation levels of 
[3H]-methyl in protein extract from pcmt/l morphants at 2 dpf compared to control but higher levels at 4 dpf. 
Coomassie blue staining (b) showed same protein levels loaded in all sample except for 2 dpf pcmt/l morphant 
where lower staining intensity was observed. 
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3.2 IGF-1 and MAPK Signalling pathways in PCMT1 deficient cells 
A number of previous findings support a connection between PCMT1 and growth signalling pathways 
such as the insulin/IGF-1 signalling pathway (FARRAR et al. 2005a; KHARE et al. 2011; MACKAY et al. 2012) 
or the mitogen-activated protein kinase pathway (MAPK) (DOYLE et al. 2003; KOSUGI et al. 2008). The 
IGF-1 pathway is conserved across almost all eukaryotes and plays a central role in the regulation of 
several downstream signalling cascades such as the well-documented TOR pathway. The latter is 
notably associated with macromolecule biosynthesis, autophagy or specific phenotypes such as aging. 
Investigations in a number of model organisms, including mice and C. elegans, showed that silencing 
of genes associated with the IGF-1 pathway can induce a lifespan extension (HOLZENBERGER et al. 2003; 
KENYON 2010). As already mentioned several times in this thesis before, homozygous Pcmt1 knockout 
mice exhibit a shortened lifespan. Combined with the observed hyperphosphorylation of 
intermediates of the IGF1 pathway in these mice, it is tempting to link Pcmt1 deficiency to accelerated 
aging via activation of the IGF1 signalling pathway. In this part, we aimed at reproducing these effects 
of PCMT1 on growth signalling pathways in the different PCMT1 deficient cell models established and 
validated in section (3.1.1) and (3.1.2) in order to investigate the mechanism(s) by which PCMT1 
interacts with these pathways. 
3.2.1 Growth signalling pathways in PCMT1-knockdown cells 
We first tested the previously described HEK293 cells stably expressing an anti-PCMT1 shRNA. To 
investigate differences in phosphorylation status of intermediates in the IGF-1 and MAPK pathways 
between the PCMT1 knockdown and control cell lines, we used the known corresponding activators 
IGF-1 (insulin-like growth factor-1) and EGF (epidermal growth factor). EGF was reported before to 
activate the MAPK pathway in HEK293 cells at 1 µg/ml cell medium (KOSUGI et al. 2008); the EC50 for 
IGF-1 was reported to be around 10 ng/ml in mouse bone marrow cells (FDC-P1) (MCCUBREY et al. 
1991). Based on this, we decided to use 1 µg/ml EGF and 100 ng/ml (10× EC50) IGF-1 in the medium 
of our HEK293 cell lines. We seeded 1×106 cells, expressing either of the above defined shCtrl or 
shPCMT, per well in 6-well plates. The next day, we washed the cells with PBS and stimulated them 
with either IGF-1 or EGF. We incubated the cells with the stimulating media for different durations (5 
– 30 minutes) followed by washing with PBS and scraping of the cells into ice-cold RIPA buffer. We 
analysed the protein extracts by Western blotting as described in the methods (Section 2.2.3.2). We 
found that in the control cells, the phosphorylation levels of protein kinase B (Akt) did not change after 
exposures to IGF-1 up to 30 minutes. Also, PCMT1 knockdown did not seem to affect Akt 
phosphorylation under the conditions tested: Akt phosphorylation levels were the same in cells 
expressing shCtrl and shPCMT and exposed to 100 ng/µl IGF-1, at all the time points tested (Figure 
3-19). 
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Figure 3-19: pAkt levels in PCMT1 knockdown HEK293 cells. Western blot analysis (a) and relative band intensity 
quantification (b) showing the Akt phosphorylation levels in PCMT1 knockdown HEK293 cells and corresponding 
control cells after stimulation with IGF-1 for different durations. The values shown are means ± SEM of 3 biological 
replicates. 
We then tested if we can reproduce the activation of MAPK pathway intermediates (cRaf, Erk1/2, 
MEK) that had previously been reported in different PCMT1 deficient cell models (DOYLE et al. 2003; 
KOSUGI et al. 2008). Using a similar experimental setup as Kosugi et al (KOSUGI et al. 2008), shCtrl and 
shPCMT cells were exposed to EGF for different durations followed by protein extraction for Western 
blot analysis. We found that both cell lines show a transient response to EGF, where phosphorylation 
of Erk1/2 increases within 5 minutes from EGF addition, drops after 10 minutes and then remains 
stable up to 30 minutes (Figure 3-20). There was no difference in our experiments in Erk1/2 
phosphorylation levels between shCtrl and shPCMT cells, in contrast to what had been reported 
before (KOSUGI et al. 2008). This discrepancy may be explained by the fact that in the HEK293 cell 
model used by Kosugi et al., no residual PCMT1 protein levels could be detected by Western blot 
anymore, while in our cell line a residual PCMT1 level corresponding to 20% of control levels was still 
present (Figure 3-3). Also, in the cell line used by Kosugi et al., an about 2-fold increase in isoaspartyl 
levels was measured in cellular proteins, while we only detected a 1.1-fold increase in our cell lines 
(Figure 3-4 b). 
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Figure 3-20: pErk1/2 levels in PCMT1 knockdown HEK293 cells Western blot analysis (a) and relative band intensity 
quantification (b) showing the Erk1/2 phosphorylation levels in PCMT1 knockdown HEK293 cells and 
corresponding control cells after stimulation with EGF for different durations. The values shown are means ± SEM 
of 3 biological replicates. 
We concluded that, under our conditions, PCMT1 knockdown in HEK293 cells did not affect the 
phosphorylation levels of either Akt or Erk1/2. Farrar and colleagues had shown that Akt 
hyperphosphorylation in Pcmt1 knockout mice was particularly pronounced in the hippocampus 
(FARRAR et al. 2005a). As potential reasons for our negative results in these first trials in a HEK293 
PCMT1 knockdown cell line were (1) only partial silencing of the protein of interest, (2) lack of 
significant accumulation of isoaspartyl residues in the knockdown cells and (3) use of a cell line from 
a different species (human versus mouse) and a different tissular origin (embryonic kidney versus 
hippocampus), we decided to repeat these experiments in a mouse hippocampal cell line (HT22) in 
which the Pcmt1 gene had been knocked out using the CRISPR/Cas9 technology (Section 2.2.4.3). 
3.2.2 Growth signalling in Pcmt1 knockout HT22 cells 
As described in the first part of the results (Section 3.1.2) we successfully created a Pcmt1 knockout 
HT22 cell model and validated it in terms of total loss of isoaspartyl methyltransferase activity and 
detectable accumulation of isoaspartyl substrates (Figure 3-6 b). In this section, we used the cell model 
to test whether we can reproduce the hyperphosphorylation pattern of intermediates of the IGF-1 
pathway previously observed in Pcmt1 knockout mice (FARRAR et al. 2005a). We started by optimizing 
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the conditions for activation of the IGF-1 signalling pathway by IGF-1 and insulin (RINDERKNECHT and 
HUMBEL 1978), testing exposure of the cells to different concentrations of the activators for different 
durations. Different concentrations of both IGF-1 and insulin were added to the cell media as 
described before and stimulation was stopped 10 minutes later by washing the cells with PBS and 
addition of ice-cold RIPA buffer for subsequent Western blot analysis. 
IGF-1 stimulation induced a dose response effect where phosphorylation of Akt increased in response 
to increasing IGF-1 concentrations (Figure 3-21). However, there was no significant difference in the 
phosphorylation levels of Akt between control and Pcmt1 knockout cells.  
 
Figure 3-21: Phosphorylation levels of Akt in HT22 control and Pcmt1 KO cells in response to exposure to different 
concentrations of IGF-1 for 10 minutes. (a) Representative Western blot analysis for one of the tested replicates 
and (b) relative quantification based on band intensities. The values shown are means ± SEM of 2 biological 
replicates 
We repeated a similar experiment, but stimulating the cells for different durations with 100 ng/ml 
IGF-1. The resulting time course showed a dynamic response of Akt phosphorylation to IGF-1 with the 
highest phosphorylation levels being reached at 5 and 10 minutes after addition of the growth factor, 
followed by a progressive decrease in phosphorylation over the next 24 hours. Again, we did not find 
significant differences in Akt phosphorylation levels between control and Pcmt1 knockout cells (Figure 
3-22). 
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Figure 3-22: Phosphorylation levels of Akt in HT22 control and Pcmt1 KO cells in response to exposure to 100 ng/ml IGF-1 for 
the indicated durations. (a) Representative Western blot analysis for one of the tested replicates and (b) relative 
quantification based on band intensities. The values shown are means ± SEM of 3 biological replicates 
We then tested the effect of insulin, a hormone which should also stimulate phosphorylation of Akt. 
Exposure of the HT22 cells to one dose of insulin (10 µg/ml) for different durations also led to a 
dynamic response of Akt phosphorylation levels, but to a lesser extent and with a different time course 
as with IGF-1 (Figure 3-23) but not as strong as the IGF-1 effect. Similar to IGF-1 we did not see 
differences in the phosphorylation levels of Akt in Pcmt1 knockout cells compared to control cells in 
response to insulin either. The dynamics of the responses in Akt activation following insulin and IGF-1 
addition hint at the complexity of studying these signalling pathway in cell culture models. This may 
have prevented us from observing a potential effect of Pcmt1 deficiency on IGF-1 pathway activation. 
Other reasons may of course be linked to the fact that we tried to reproduce effects that had been 
observed in the complexity of the brain tissue environment in a living animal, in a much more simple 
monoculture cell model. 
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Figure 3-23: Phosphorylation levels of Akt in HT22 control and Pcmt1 KO cells in response to exposure to 10 µg/ml insulin for 
the indicated durations. (a) Representative Western blot analysis for one of the tested replicates and (b) relative 
quantification based on band intensities. The values shown are means ± SEM of 3 biological replicates 
In our previous experiments where we investigated the phosphorylation levels of Erk1/2 in HEK293 
cells, we stimulated the cells with 1 µg/ml EGF as in Kosugi et al. (KOSUGI et al. 2008). In the HT22 cell 
model we decided to test different concentrations of EGF in the range of 25 – 1000 ng/ml (10-minute 
exposures). Interestingly, highest phosphorylation levels of Erk1/2 were found after exposure to the 
lower EGF doses at 25 to 100 ng/ml (Figure 3-24). As opposed to all the previous trials, in this cell 
model with EGF stimulation we were now also able to detect, at all the EGF concentrations tested, 
higher ERK1/2 phosphorylation levels in the Pcmt1 knockout cells compared to the control cells (Figure 
3-24). 
We were also interested in the dynamics of the phosphorylation response, so we stimulated the cells 
with 100 ng/ml EGF for different durations from 10 minutes to 23 hours. We found that highest 
phosphorylation levels were reached at 10 minutes of stimulation and went down at 30 minutes 
(Figure 3-25). Stimulations over several hours did not lead to higher phosphorylation levels or reveal 
a second wave of phosphorylation response. These results suggested that EGF stimulation induces a 
fast phosphorylation response at the level of Erk1/2 within a few minutes. Hyperphosphorylation of 
Erk1/2 in the Pcmt1 KO versus control cells was also the most pronounced for the short 10-minute 
exposure (Figure 3-25). 
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Figure 3-24: Phosphorylation levels of Erk1/2 in HT22 control and Pcmt1 KO cells in response to a 10-minute exposure to the 
indicated concentrations of EGF. (a) Representative Western blot analysis for one of the tested replicates and (b) 
relative quantification based on band intensities. The values shown are means ± SEM of 2 biological replicates 
 
Figure 3-25: Phosphorylation levels of Erk1/2 in HT22 control and Pcmt1 KO cells in response to exposure to 100 ng/ml EGF 
for the indicated durations. (a) Representative Western blot analysis for one of the tested replicates and (b) 
relative quantification based on band intensities. The values shown are means ± SEM of 3 biological replicates 
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We therefore repeated a time course experiment with 100 ng/ml EGF, but testing shorter exposure 
times to investigate the dynamics of the Erk1/2 phosphorylation response. We confirmed that the 
effect of EGF is quite transient, with highest phosphorylation levels of Erk1/2 reached at 5 and 10 
minutes and then going down at 30 minutes (Figure 3-26). Again, the most pronounced difference in 
Erk1/2 phosphorylation levels between the Pcmt1 knockout and control cells was observed for the 10-
minute exposure. 
 
Figure 3-26: Phosphorylation levels of Erk1/2 in HT22 control and Pcmt1 KO cells in response to exposure to 100 ng/ml EGF 
for the indicated durations. (a) Representative Western blot analysis for one of the tested replicates and (b) 
relative quantification based on band intensities. The values shown are means ± SEM of 3 biological replicates 
We extended this investigation by also measuring the phosphorylation levels of another intermediate 
in the MAPK pathway, namely Mitogen-activated protein kinase (MEK), which is just upstream of 
Erk1/2 (phosphorylating the latter). We tested the phosphorylation levels of MEK after stimulation 
with 100 ng/ml EGF for 0 and 10 minutes and we found that MEK is less phosphorylated in the Pcmt1 
KO cells directly after addition of EGF (‘0 min’), but shows the same phosphorylation level as the 
control cells after 10 minutes of stimulation (Figure 3-27). In the study by Kosugi et al in the PMCT1 
knockdown HEK293 cells, both Erk1/2 and MEK were more phosphorylated in the knockdown cells 
compared to the control cells, but the fold change for phospho-Erk1/2 was higher than for phospho-
MEK (KOSUGI et al. 2008). Together with our data, this suggests that the higher phosphorylation levels 
of Erk1/2 in Pcmt1 deficient cells is not due to higher activity of upstream kinases, but may be due to 
lower activity of downstream protein phosphatases. 
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Figure 3-27: Phosphorylation levels of MEK in HT22 control and Pcmt1 KO cells in response to exposure to 100 ng/ml EGF for 
the indicated durations. (a) Representative Western blot analysis for one of the tested replicates and (b) relative 
quantification based on band intensities. The values shown are means ± SEM of 3 biological replicates. 
In summary, phosphorylation levels of Akt (an intermediate in the insulin/IGF-1 signalling pathway) 
are not affected by PCMT1 knockdown in HEK293 and U-87 cells upon IGF-1 stimulation. Similarly, in 
HT22 Pcmt1 knockout cells Akt phosphorylation levels are the same upon stimulation with IGF-1 or 
insulin. Regarding the Erk1/2 (an intermediate in the MAPK signalling pathway), PCMT1 knockdown in 
HEK293 and U-87 MG cells did its affect phosphorylation levels. However, Pcmt1 knockout seems to 
have higher phosphorylation levels of Erk1/2 than control cells upon stimulation with EGF. 
3.3 Phenotyping of pcmt/l knockdown zebrafish 
3.3.1 MO-mediated knockdown of pcmt and pcmtl leads to developmental delay and 
dysmorphology in zebrafish larvae 
We have shown previously (Section 3.1.3.2) that that the expression products of the pcmt and pcmtl 
genes, arising from the genome duplication in teleost fish evolution (TAYLOR et al. 2001), do not differ 
markedly in terms of catalytic properties and expression/tissue distribution patterns (Figure 3-9 and 
Figure 3-13). One of the implications thereof is that both genes need to be targeted for morpholino-
mediated knockdown to achieve a maximal silencing effect of the associated function. In practice, this 
was achieved by co-injection of both pcmt e5i5 MO and pcmtl e4i4 MOs (3.5 ng of each). 
Survey of morphological changes following this co-injection revealed that embryos at 2 or 4 days post 
fertilization (dpf) showed various phenotypes. We ranked the severity of dysmorphology from mild to 
severe. At 2 dpf, a slight body curvature was ranked as a mild phenotype, a curved trunk and small 
body size as a moderate phenotype, and a reduction of melanin formation and a strong malformation 
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as a severe phenotype. At 4 dpf, a lack of swimming bladder, a curved trunk, and strong malformation 
were ranked as mild, moderate, and severe phenotypes, respectively (Figure 3-28). Relative 
quantification of these phenotypes in pcmt/l MO-treated embryos highlighted an increase of 
dysmorphic trait in comparison to uninjected and control MO-treated embryos (Figure 3-29). At 2 dpf, 
15% of pmct/l morphant larvae did not survive and 22%, 26%, and 17% showed severe, moderate, and 
mild dysmorphologies, respectively; 19% of the 2 dpf morphant embryos were normal. The 
deleterious effect was even higher at 4 dpf where about 50% of the pmct/l morphant larvae were 
dead. In contrast, more than 95% and 85% of embryos injected with control MO (as well as uninjected 
embryos) showed a normal phenotype at 2 dpf and 4 dpf, respectively (Figure 3-29). 
These results suggest a crucial role for pcmt and pcmtl in embryonic zebrafish development and are 
consistent with the drastically reduced life span of Pcmt1 knockout mice (KIM et al. 1997b). However, 
they should be considered with some caution since MO treatment can lead, independently from the 
targeted gene, to similar dysmorphic phenotypes, due to off-target effects of MOs, that cannot be 
reproduced by gene deletion strategies (KOK et al. 2015).  
 
Figure 3-28: Morphological phenotype ranking in morphant zebrafish larvae deficient in pcmt and pcmtl 
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Figure 3-29: Morphological phenotype in morphant zebrafish deficient in pcmt and pcmtl as well as rescuing attempt by 
exogenous expression of both genes either by direct injection of mRNAs or of plasmids carrying the coding 
sequence of pcmt and pcmtl genes. 
In order to confirm these morphological phenotypes to be specifically caused by pcmt/l deficiency, 
rescue experiments were carried out using two different approaches: by direct injection of pcmt and 
pcmtl mRNAs or of rescue plasmids carrying the coding regions of either pcmt or pcmtl. To generate 
the mRNAs, the coding sequences of both pcmt and pcmtl were cloned into the pCS2+ plasmid and 
the recombinant plasmids were used for IVT production of both transcripts. For creation of the rescue 
plasmids, the coding sequences of pcmt and pcmtl were cloned into the pGEMT vector under the 
control of eukaryotic elongation factor 1 α (eEF1α) ubiquitous promoter to be injected directly. Both 
the prepared transcripts and plasmids were first titrated to find the maximum tolerated amounts to 
be injected without causing toxicity and we ended up with 100 pg for mRNA transcripts and 20 pg 
plasmid DNA as the maximum safe amount to be injected. To perform the rescue experiments we 
injected either 100 pg of the pcmt and pcmtl transcripts or 20 pg of the pcmt and pcmtl rescue 
plasmids simultaneously with the pcmt/l MOs into AB eggs. 
For the 2 dpf larvae, neither the mRNA transcripts nor the plasmids expressing pcmt and pcmtl showed 
a rescue effect; at the contrary, they even amplified the severity of the dysmorphology (Figure 3-29). 
By contrast, for the 4 dpf larvae, both rescue strategies reversed, although only very partially, the 
deleterious effects of the pcmt/l MOs, with a higher proportion of normal larvae and a lower 
proportion of dead larvae (Figure 3-29). The most straightforward explanation for these observations 
would be that most (4 dpf), if not all (2 dpf) of the dysmorphology phenotype is due to non gene 
specific, off-target effects of the pcmt/l MOs. It could, however, also be hypothesized that the MO 
knockdown effect takes place faster than the rescue effect through the exogenous expression of both 
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genes and that reversion of the phenotypes can therefore only be observed at later time points after 
injection (starting at 4 dpf and maybe even more pronounced at later stages, but not detectable yet 
at 2 dpf). 
3.3.2 Seizure quantification by locomotor tracking system 
As a reminder, it had previously been shown that Pcmt1 knockout mice develop epileptic seizures 
starting at a young age and that their premature death coincided with a final massive epileptic episode 
(YAMAMOTO et al. 1998; KIM et al. 1999). In preliminary tests conducted on pcmt/l morphant embryos, 
we observed twitching events at 2 dpf, reminiscent of epileptic seizures (a personal communication 
by Alexander Crawford). The twitching events were characterized by abnormal fast moving of the tail 
which occurs irregularly over different durations of time making it difficult to quantify. Our 
observations indicated that they were substantially more frequent in the pcmt/l morphants than 
control MO injected larvae and suggested that isoaspartyl methyltransferase deficiency may induce 
seizure-like events in young zebrafish larvae (or embryos). 
Tracking of the locomotor behaviour has been shown to be a good read-out for the epilepsy 
phenotype in zebrafish PTZ epilepsy model (AFRIKANOVA et al. 2013). DanioVision is a high-throughput 
locomotor tracking system that is based on a camera placed on top of a 96-well plate and recording 
the movement of zebrafish larvae in each well. Based on the movements, the system can measure the 
total distance each larva traveled during the time of the experiment and its velocity which correlates 
positively with increased seizure activity. By combination of the DanioVision system and stimulation 
with pentylenetetrazol (PTZ), a gamma-aminobutyric acid (GABA) receptor antagonist that induces 
seizures (HUANG et al. 2001; BARABAN et al. 2005), we aimed at investigating the impact of pcmt/l 
knockdown on seizure development in zebrafish. As a proof-of-concept experiment, uninjected 
embryos were placed in a 96-well plate (one larva per well containing each 100 µl of Danieau). The 
plate was incubated for one hour in the dark prior to recording. Results showed that both the total 
distance travelled and the velocity were increased in embryos treated with 20 mM PTZ as compared 
to non-treated control larvae (Figure 3-30). This pilot experiment confirmed that the experimental 
setup allowed for detection of PTZ-induced seizures and that it was suitable for further 
characterization of the pcmt/l morphants. 
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Figure 3-30: Locomotor behaviour of wild type zebrafish larvae without or with exposure to PTZ. Larvae were incubated in 
96-well plate and their movements tracked using the DanioVision system. PTZ dose dependency of the total 
distance travelled (left panel) and the mean velocity (right panel) of zebrafish larvae is shown. Values are the 
mean ± SEM of 20 biological replicates. 
Using the same protocol, control and pcmt/l morphant larvae were surveyed at 4 dpf in three 
conditions, without PTZ, with 0.5 mM PTZ or with 20 mM PTZ. Only mild and normally looking larvae 
(Figure 3-28) were selected for the experiment. Larvae injected with control MO showed a similar 
profile as the ones observed for the proof-of-concept experiment where both total distance and 
velocity were increased in a dose-dependent manner in response to PTZ. In the absence of PTZ, the 
pcmt/l morphant larvae showed a similar locomotor behaviour as the control larvae. In the presence 
of 0.5 mM or 20 mM PTZ, the total distance travelled by pcmt/l morphants was drastically reduced 
compared to the control larvae although the mean velocity was only slightly decreased (Figure 3-31). 
The results indicate that pcmt/l deficiency reduces the overall locomotor activity of the zebrafish 
larvae, but that the residual movements are performed at the same speed as for control larvae. These 
observations do therefore not support that those young zebrafish larvae deficient in isoaspartyl 
methyltransferase activity, as opposed to Pcmt1 knockout mice (KIM et al. 1997b) , experience 
epileptic seizure events (lack of increased velocity of movements in response to PTZ), but the 
decreased total distance travelled shows that they experience an impairment of locomotor behaviour. 
The decreased locomotor activity of the pcmt/l morphants could be due to neurological deficits due 
to the impaired brain development that we observed in these morphants (Figure 3-36). A more trivial 
explanation would be locomotor constraints imposed by the more general developmental delay 
caused by the pcmt/l MOs, with for instance an underdeveloped swimming bladder and trunk 
curvatures, which may of course affect the swimming behaviour of the larvae. 
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Figure 3-31: Locomotor behaviour of control MO and pcmt/l MO injected zebrafish larvae without or with exposure to PTZ. 
(a) Total distance travelled with exposure to 0.5 mM PTZ (b) Mean velocity with exposure to 0.5 mM PTZ (c) Total 
distance travelled with exposure to 20 mM PTZ (d) Mean velocity with exposure to 20 mM PTZ. Values are the 
mean ± SEM of 20 biological replicates. 
3.3.3 Brain electrical activity by tectal field potential recordings 
It has been shown previously that Pcmt1 knockout mice experience abnormal electrical brain activity 
(KIM et al. 1999) and our pcmt/l morphant zebrafish model opened the perspective to provide more 
insights into this phenotype. Given the difficulty to interpret the locomotor tracking results obtained 
in the previous section due to the potential bias introduced by dysmorphologies of the morphant 
larvae potentially limiting swimming movements, it was also important to use a second approach, free 
of this bias, to try to detect and quantify seizure activity in the morphants. We therefore decided to 
proceed to measurements of the electrical brain activity in the brain using the technique of tectal field 
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potential recordings. At 5 dpf, larvae were immobilized into 2% low melting agarose and an electrode 
was placed into the optic tectum (Figure 3-32a) for local field potential recording as previously 
described (Section 2.2.5.8). As a proof of concept, tectal field potential recording of 5 dpf wild type AB 
larvae exposed to 20 mM PTZ showed massive electrical discharges indicating seizure development in 
response to PTZ that was detectable with our experimental setup (Figure 3-32b).  
 
Figure 3-32: Tectal field potential recording. (a) Representative image of an agar-immobilized 5dpf wild type AB larva with 
the electrode placed in the optic tectum. (b) representative trace of the electric field potential (in mV) in the optic 
tectum over a 10-minute recording of a 5-dpf zebrafish larvae incubated with PTZ 20mM for 30 minutes. 
We then proceeded to tectal field potential recordings, electroencephalography in the optic tectum, 
in control MO and pcmt/l MO injected larvae. As expected for control MO-injected larvae, we detected 
no epileptiform events in those animals (Figure 3-33 a). These recordings did not provide any evidence 
for increased epileptic activity in the brains of pcmt/l morphant larvae either (Figure 3-33 b). Despite 
our preliminary observations indicating increased twitching events reminiscent of epileptic seizures in 
the pcmt/l morphant larvae, the above described more quantitative methodologies for detecting 
epileptic activity in our model (locomotor tracking and tectal field potential recordings) did not lend 
further support to the assumption that isoaspartyl methyltransferase deficiency may trigger abnormal 
epileptic seizures in zebrafish, at least at the early developmental stages that were testable in our 
morpholino knockdown model. 
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Figure 3-33: Tectal field potential recordings in control MO and pcmt/l MO larvae at 5 dpf. Traces of the electric field potential 
(in mV) in the optic tectum over a 10-minute recording in a control larva (a) and a pcmt/l morphant larva (b). A 
representative experiment out of 5 independent similar experiments with similar observations is shown. 
3.4 Interplay between PCMT and calcium signalling 
Calmodulin, a major regulator of calcium levels in the cell, was reported to be a major substrate for 
Pcmt1 (REISSNER et al. 2006; VIGNESWARA et al. 2006). It was also shown that calmodulin loses its activity 
upon deamidation of Asn residues, but recovers its activity when repaired by PCMT1 (JOHNSON et al. 
1987a). Moreover, a yeast 2-hybrid system revealed that calmodulin doesn’t only serve as a substrate 
for PCMT1, but that they seem to share other types of complex interactions (O'CONNOR and O'CONNOR 
1998). Calcium homeostasis is essential for many physiological functions in the cells. The cytosolic 
concentration of calcium is generally very low and tightly regulated and a disturbance in that 
regulation can lead to many neurological disorders (WOJDA et al. 2008). Finally, there is also a link 
between calcium signalling and epilepsy and actually another approach to detect epileptic seizures is 
to monitor calcium fluxes in the brain as a result of the activation of voltage-gated calcium channels 
during neuronal firing (GRIENBERGER and KONNERTH 2012; LILLIS et al. 2015). Also, it appears that PTZ-
induced seizures are calcium dependent, since calcium channel blockers attenuated the PTZ effect on 
seizure development (GATCH et al. 2001). One may assume that isoaspartyl accumulation in calmodulin 
in PCMT1-deficient models (or a missing regulatory interaction between calmodulin and PCMT1) 
affects calcium homoeostasis in the cell, contributing thereby to the neurological disturbances 
observed for example in the Pcmt1 knockout mice. These observations motivated us to investigate 
the effects of PCMT deficiency on calcium fluxes in our zebrafish and mammalian cell models. 
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3.4.1 Calcium signalling in pcmt/l knockdown zebrafish 
GCaMP6f is a genetically encoded calcium indicator consisting in a fusion protein between calmodulin 
and a circularly permuted GFP connected through an M13 peptide (CHEN et al. 2013). When 
calmodulin binds to calcium it undergoes conformational changes leading to increasing fluorescence 
intensity of the fused GFP. We took advantage of the beta-actin:GCaMP6f transgenic zebrafish line to 
monitor cytoplasmic calcium levels in the brain in the context of PCMT deficiency. We injected eggs 
from the beta-actin:GCaMP6f line at the 1 – 2 cell stage with either control or pcmt/l MOs. Larvae at 
4 dpf were immobilized in 1.5% low melting agarose on a glass slide and covered with 0.3× Danieau’s 
containing 20 mM PTZ. Time-lapse image acquisition was started 5 minutes after addition of the PTZ-
containing solution for 15 minutes and the mean fluorescence intensity measured using the ImageJ 
software. 
A shown by the oscillations of the fluorescence signal in the brain of larvae injected with control MO, 
PTZ induced large calcium transients over the whole duration of the experiment (Figure 3-34). 
Interestingly, pcmt/l deficient larvae showed no major calcium peaks during the whole time-lapse 
imaging, indicating much less transient calcium fluxes into the cytoplasm of the brain cells of these 
larvae 
 
Figure 3-34: Calcium transients in 4 dpf beta-actin:GCaMP6f pcmt/l morphants. Calcium signalling in 4 dpf larvae either 
control (a) or pcmt/l (b) morphants n=5. Larvae exposed to 20 mM PTZ 5 minutes prior to fluorescence signal 
acquisition for 15 minutes. Signal (F) was extracted using ImageJ and normalized to the 35th percentile signal (F0). 
Normalized signal (F/F0) were plotted against time. 
In order to confirm these results, we performed rescue experiments in which we injected beta-
actin:GCaMP6f eggs with mixtures of pcmt/l MOs and pGEMT expression plasmids containing the 
coding sequences for wild type pcmt and pcmtl or mutated coding sequences leading to the expression 
of D83V mutant proteins that correspond to catalytic null mutants lacking isoaspartyl 
methyltransferase activity (CIMMINO et al. 2008). In the rescue experiment, we pre-incubated the 
larvae for 30 minutes in 20 mM PTZ prior to acquiring the fluorescence signal over another 30-min 
period. Clearly, restoring expression of wild type Pcmt and Pcmtl, but not expression of the 
catalytically inactive proteins, rescued the calcium transients induced by PTZ (Figure 3-35), similarly 
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to what was previously observed in control MO injected larvae. These observations suggest that the 
strong calcium signalling defect observed in the pcmt/l morphant larvae is specifically caused by the 
down-regulation of the pcmt and pcmtl gene expression (and not due to off-target effects) and 
moreover, that this effect is dependent on the methyltransferase activity of the enzymes. 
 
Figure 3-35: Calcium signalling in beta-actin:GCaMP6f zebrafish larvae – rescue experiment. Calcium signalling in 4 dpf pcmt/l 
morphant larvae either control (a) D83V mutant pcmt/l (b) wt pcmt/l n=5. Larvae exposed to 20 mM PTZ 30 
minutes prior to fluorescence signal acquisition for 30 minutes. Signal (F) was extracted using ImageJ and 
normalized to the 35th percentile (F0). Normalized signal (F/F0) were plotted against time. 
Another interesting observation in the pcmt/l MO injected larvae was the small size of the head. We 
noticed during the first experiments that the pcmt/l MO injections resulted in a general developmental 
delay and smaller body size, which seemed consistent with the smaller body size observed for the 
Pcmt1 knockout mice (YAMAMOTO et al. 1998). However, the latter mice displayed increased brain size, 
which contrasts with the smaller brains observed in pcmt/l morphant larvae (Figure 3-36). It should 
be noted though that a direct comparison between the zebrafish model and the mouse model is again 
not possible, since our observations in zebrafish were made in the first days of life while body and 
brain size measurements were reported for mice that were 4 – 7 weeks old (YAMAMOTO et al. 1998; 
FARRAR et al. 2005a).  Our observation in the zebrafish larvae suggested that pcmt/l deficiency 
interferes with normal brain development, which may contribute to the strongly decreased calcium 
fluxes observed in these same larvae. 
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Figure 3-36: Brain developmental delay in pcmt/l morphant larvae shown for different ages. The profile pictures taken at 2 
and 3 dpf show a smaller head size as compared to the age-matched control MO injected larvae. The top-down 
view pictures allow to see the smaller size of the developing optic tectum (blue arrows) in the pcmt/l morphant 
larvae as compared to the control larvae. In the 6 dpf larvae, the most obvious difference between pcmt/l 
morphants and controls was the underdeveloped swimming bladder (red arrows), while the differences in head 
and brain size had become less pronounced at that developmental stage. 
As a main conclusion, the results from this subsection indicate that the isoaspartyl methyltransferase 
activity of Pcmt/l plays an important role in the regulation of calcium fluxes towards the cytoplasm in 
brain cells during early zebrafish development. Via this hypothetical function, the isoaspartyl 
methyltransferases may therefore affect a panoply of downstream calcium-dependent pathways. 
3.4.2 Calcium signalling in HT22 Pcmt1 knockout cells 
To test whether this effect of Pcmt on calcium fluxes is conserved and to understand more about the 
underlying mechanism, we went back to our HT22 Pcmt1 knockout cell model (see section 3.1.2). To 
monitor calcium movements in our mouse cell line, we used the chemical fluorescent calcium 
indicator Fluo-4 from ThermoFisher scientific. We seeded 25,000 control or Pcmt1 knockout HT22 cells 
per well in 12-well plates and incubated them under standard conditions for 48 hours. Cells were then 
washed with PBS and fresh media without phenol red added in addition to 250 µl of Fluo-4 staining 
solution. Cells were stained for 30 minutes before we place the plate under the microscope and 
acquire signal. We acquired signal for 20 minutes followed by stimulation with 20 µM ATP and 
continuation of signal acquisition for another 40 minutes and finally stimulated them a second time 
with 40 µM ATP. 
We found that both control and Pcmt1 knockout cells responded to the first ATP stimulation by a spike 
in cytosolic calcium concentration while upon the second ATP stimulation only the control cells 
responded with a similar calcium transient (Figure 3-37a). Comparison of the first spike between 
control and Pcmt1 knockout cells showed a smaller peak area with a lower amplitude but with a larger 
width in the knockout cells (Figure 3-37 b – d). The lower peak area and amplitude indicate lower 
calcium concentration; in addition, the larger width of the peak indicates a slower decrease in the 
intracellular calcium concentration back to basal levels. This delay suggests a lower buffering capacity 
in the knockout cells, which could be due to a lower calcium binding capacity or affinity of calmodulin 
or to a defect in the ion channels releasing the calcium extracellularly. These results are reminiscent 
of the observations in the pcmt/l morphant zebrafish larvae in that they point towards Pcmt being 
important to sustain cellular calcium fluxes. 
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Figure 3-37: Calcium transients in HT22 cells in response to ATP stimulation. (a) Fluo-4 fluorescence signal acquired by 
microscopy in control (blue trace) and Pcmt1 KO (red trace) cells to monitor intracellular calcium concentrations 
in response to ATP stimuli. (b – d) Analysis of the first spike in response to the 20 µM ATP stimulation showing a 
decrease in spike area (b) and amplitude (c), but an increase in spike width in the KO cells compared to control 
cells. (**** p-value <0.0001; **p-value <0.001) 
Intracellular calcium release from the endoplasmic reticulum to the cytosol in response to ATP is 
mediated through the G-protein coupled receptor and phospholipase C (PLC) activation that in turn 
catalyses the cleavage of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) into inositol (3,4,5)-
trisphosphate (IP3) and diacylglycerol (DAG) (SALTER and HICKS 1995). To try to understand why the 
Pcmt1 knockout cells are less responsive to ATP stimulation in terms of calcium transients, we aimed 
to quantify GTP, GDP and IP3 levels in Pcmt1 knockout and control cells. Polar metabolites were 
extracted from the cells using a cold methanol extraction protocol followed by phase separation as 
described in the methods (Section 2.2.4.6) and metabolite extracts were analysed using a targeted LC-
MS-based approach (Section 2.2.4.7). These analyses did not reveal any significant difference in the 
GTP/GDP ratio, but a 4-fold decrease in intracellular IP3 concentration in the Pcmt1 knockout cells 
compared to the control cells (Figure 3-38). In addition, we found that the ATP/ADP ratio was lower 
in the Pcmt1 knockout cells compared to the control cells (Figure 3-38 b), which is consistent with 
previous results showing lower ATP levels in A549 cells deficient in PCMT1 (OGASAWARA et al. 2016). In 
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the latter study, a 70% decrease in cellular ATP levels was reported upon PCMT1 knockdown. Our 
results suggest that Pcmt1 deficiency may lead to a metabolic state that is less responsive to stimuli 
normally inducing spikes in cytosolic calcium concentrations. Due to reasons that remain currently 
unclear, lower isoaspartyl methyltransferase activity in cells seems to lead to lower intracellular 
concentrations of IP3, which is an important second messenger for intracellular calcium release. 
 
 
Figure 3-38: Comparison of nucleotide and inositol-3,4,5-trisphosphate (IP3) levels in control and Pcmt1 KO HT22 cells. 
Targeted LC-MS analyses showed no change in the GTP/GDP ratio, a 1.5-fold decrease in the ATP/ADP ratio and 
a 4-fold decrease in IP3 levels in the Pcmt1 knockout cells compared to the control cells. The values shown 
correspond to peak areas of m/z ions of interest normalised to the corresponding peak areas in control cells and 
are means ± SEM of 3 biological replicates (ns, non-significant; ***p-value < 0.001; ****p-value < 0.0001). 
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4 Discussion 
The Protein L-isoaspartyl methyltransferase (PCMT) recognizes isoaspartyl residues arising from 
aspartyl as well as asparaginyl residues in proteins and initiates their reconversion to aspartyl residues. 
The work described in the present thesis aimed to understand more about molecular mechanisms 
involving PCMT and which are vital for cellular homeostasis, more specifically in the brain. Although 
the only known catalytic function of PCMT is the transfer of a methyl group from the cofactor SAM to 
isoaspartyl residues in proteins initiating their ‘repair’ back to aspartyl residues, this methylation can 
lead to different outcomes as follows: (1) inhibition of protein aggregation through limiting isoaspartyl 
content in specific proteins (β-amyloid (Aβ) aggregability has for example been shown to be 
suppressed by PCMT in vitro (JUNG et al. 2011)); (2) modulation of catalytic activity of enzymes (e.g. 
creatine kinase B activity is decreased in the absence of Pcmt1 in mice due to formation of isoaspartyl 
residues (DIMITRIJEVIC et al. 2014)); (3) modulation of susceptibility to proteolysis of certain proteins 
(e.g. deamidation of asparaginyl residues in Bcl-xL and in calmodulin enhances their proteolysis 
(SZYMANSKA et al. 1998; DHO et al. 2013)); (4) modulation of protein function as conversion of 
asparaginyl to aspartyl residues can activate certain functions (e.g. deamidation of an asparaginyl 
residue in the N-terminal region of fibronectin is required to generate a binding site for αvβ3-integrin 
for activation of extracellular matrix (CURNIS et al. 2006)); (5) D/L racemization of aspartyl residues 
(e.g. PCMT was found to be necessary for racemization of Asp25 in histone H2B (YOUNG et al. 2005). 
The diversity of these outcomes and of the protein substrates on which PCMT can act, the high 
conservation of PCMT among many species, and its wide distribution in various tissues indicate that 
this enzyme plays a fundamental role in living organisms and has the potential to interfere with 
numerous cellular pathways and processes.  
4.1 PCMT differentially regulates growth signalling pathways 
Among the different pathways found to be affected by PCMT are the IGF-1 and the MAPK signalling 
pathways. The insulin/IGF-1 signalling pathway has become a hallmark pathway of the aging process 
since the discovery that it’s downregulation extends lifespan of C. elegans, but also in other organisms 
such as mice (KENYON et al. 1993; HOLZENBERGER et al. 2003; KENYON 2010). PCMT also has been shown 
to affect lifespan in mice, C. elegans, and D. melanogaster (KIM et al. 1997b; CHAVOUS et al. 2001; 
BANFIELD et al. 2008); in addition, Pcmt1 knockout mice show hyperactivation of the IGF-1 pathway 
(FARRAR et al. 2005a). Therefore, a potential mechanism of lifespan regulation by PCMT could be 
through modulation of the IGF-1 signalling pathway. Interestingly, PCMT was also found to interact 
with the MAPK pathway, as PCMT1 knockdown in HEK293 cells resulted in the transient activation of 
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different kinases in the MAPK pathway (KOSUGI et al. 2008). Nevertheless, the mechanism by which 
PCMT affects the IGF-1 and MAPK signalling pathways remains completely unknown. 
One possible mechanism through which PCMT could interact with several signalling cascades is by 
modulation of the activity of one or several protein phosphatases; these phosphatases could be 
inactivated (or more rapidly degraded) due to the presence of one or several isoaspartyl residues in 
their sequence and lack of repair of those residues in PCMT-deficient organisms or cells could then 
lead to the hyperphosphorylation pattern of several signalling intermediates that has been observed 
(DOYLE et al. 2003; FARRAR et al. 2005a; KOSUGI et al. 2008) (Figure 4-1). Another more indirect 
mechanism could involve modulation of feedback regulations in affected signalling pathways (Figure 
4-1). For example, a downstream target of Akt is the translational initiation repressor factor 4E-BP1/2 
through the mTOR pathway. 4E-BP1/2 isolated from Pcmt1 knockout mouse brain was found to 
accumulate isoaspartyl residues and be less active than the native form (BIDINOSTI et al. 2010) Lower 
activity of other downstream targets of Akt, e.g. the FOXO transcription factor, can lead to pathway 
activation via a positive feedback mechanism (PUIG et al. 2003). Similarly, Pcmt deficiency could thus 
lead to activation of intermediates of the IGF-1 pathway by lack of repair and inactivation of 4E-BP1/2. 
Also, proteomic analyses of Pcmt1 knockout mice showed differential up- and downregulation of 
many proteins which are not direct substrates for Pcmt1. An example of this is the nonspecific 
serine/threonine-protein kinase DCLK1, which was found to be significantly upregulated in the Pcmt1 
knockout mouse brains (YANG et al. 2013) and could also contribute to activation of signalling 
pathways. 
 
Figure 4-1: Possible interactions of PCMT with signalling pathways. Green arrows represent activation; red lines represent 
inhibition; black arrows point towards direct PCMT substrates; gray arrows represent potential regulatory 
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interactions. IGF-1: Insulin growth factor-1; IGFR: IGF-1 receptor; InsR: Insulin receptor; PIP2: Phosphatidylinositol 
4,5-bisphosphate; PIP3: Phosphatidylinositol (3,4,5)-trisphosphate; PI3K: Phosphatidylinositol 4,5-bisphosphate 
3-kinase; PDK1: Phosphoinositide-dependent kinase-1; Akt: protein kinase B; GSK3: Glycogen synthase kinase 3; 
mTOR: mechanistic target of rapamycin; 4E-BP1: Translation repressor protein EGF: Epidermal growth factor; 
EGFR: EGF receptor; RKIP: Raf kinase inhibitor protein; MEK: Mitogen-activated protein kinase kinase Erk1/2: 
extracellular signal–regulated kinase; MKP-3: MAP Kinase Phosphatase 3. 
To interrogate the mechanism underlying IGF-1 pathway activation in PCMT deficiency, we have 
established stable HEK293 and U-87 MG cell lines expressing low levels of PCMT1 using lentiviral 
transduction of shRNAs. Unlike to what has been reported before by Farrar et al (2005a), i.e. 
hyperphosphorylation of IGF-1 pathway intermediates, including Akt and GSK3, in Pcmt1 knockout 
mouse brain compared to wild-type (FARRAR et al. 2005a), we did not detect a difference in the 
phosphorylation levels of Akt in our PCMT1 knockdown cell models compared to control cells. We 
reasoned that two major differences might be at the basis of this discrepancy. First, the complete 
absence of Pcmt1 protein in the knockout mouse model as opposed to our knockdown models, where 
cells still retained 20 – 40% of isoaspartyl methyltransferase activity. Second, immunohistochemistry 
experiments in the Farrar et al. study showed that Akt hyperphosphorylation is by far the most 
pronounced in the hippocampus, indicating that our negative results might be related to the choice 
of cell type. We therefore switched to the HT22 cell line, an immortalized mouse hippocampal cell 
line, and, instead of using shRNA methodology to knock down PCMT1 transcription levels, we used 
the CRISPR/Cas9 technology to completely suppress enzyme expression. The latter strategy led to the 
creation of a cell line in which no residual isoaspartyl methyltransferase activity was detectable, 
confirming total knockout of Pcmt1. Nevertheless, similar to what we had observed in the HEK293 and 
U-87 MG knockdown cells, Pcmt1 knockout did not affect the phosphorylation levels of Akt in the 
HT22 cell line.   
It appears therefore that the connection between PCMT and phosphorylation of Akt or IGF-1 signalling 
more generally is affected not only by cell type but by other factors like external stimulation factors, 
cell-cell interactions or cell state, differentiated or not. PCMT1 knockdown in bone osteosarcoma cells 
(U2OS), similarly to our results, did not affect the phosphorylation levels of Akt (LEE et al. 2012). On 
the other hand, Pcmt1 knockdown in adrenal gland  pheochromocytoma cells (PC12) led not to up-, 
but downregulation of Akt phosphorylation in response to basic fibroblast growth factor (bFGF) during 
the differentiation process and the Pcmt1 deficient cells showed poor differentiation (DUNG et al. 
2016). The latter observations also suggest that PCMT might be involved in neuronal cell 
differentiation and that the PCMT effect on Akt phosphorylation levels also depends on the 
differentiation state of the cell. Unfortunately, our trials to differentiate HT22 cells to mature neurons 
failed and we therefore could not check whether this would have revealed effects of Pcmt1 deficiency 
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on IGF-1 signalling. When Dung et al (DUNG et al. 2016) looked at the phosphorylation levels of Akt, 
they stimulated the cells with bFGF while Lee et al (LEE et al. 2012) did not use any stimulators and we 
tested both IGF-1 and insulin in our experiments; this could again lead to different outcomes, to not 
mention the complexity of the extracellular environment that cells are exposed to in the brain of a 
living animal and that we may just have missed critical factors in our cell culture models to reproduce 
what had been found in the brains of a whole organism mouse model. 
Simultaneously, we wanted to validate our cell models by testing another signalling pathway, namely 
the MAPK pathway, reported previously to be activated in PCMT1 knockdown HEK293 cells (KOSUGI et 
al. 2008). In our HEK293 PCMT1 knockdown cell model, we did not find upregulation in the 
phosphorylation levels of Erk1/2 upon stimulation of the cells with 1 µg/ml EGF similar to their 
experimental set up. It seems that in the study by Kosugi et al (KOSUGI et al. 2008), they had a more 
efficient shRNA-mediated knockdown of PCMT1 in HEK293 cells, since based on Western blot analysis 
they did not find detectable residual PCMT1 protein, while in our HEK293 knockdown cell line, an 
‘only’ 80% reduction in PCMT1 protein levels was estimated using the same technique. In addition, in 
their model, PCMT1 knockdown resulted in a 2-fold increase in the isoaspartyl levels in the knockdown 
cells compared to the control cells, while we only measured a 1.1-fold increase (Figure 3-4b). When 
we switched to Pcmt1 knockout HT22 cells, we found higher phosphorylation levels of Erk1/2, but not 
MEK (also hyperphosphorylated in the Kosugi study), in the knockout cells compared to the control 
cells. The difference in results obtained in our two models, the PCMT1 knockdown HEK293 and the 
Pcmt1 knockout HT22 cells, suggests that the MAPK pathway is sensitive to enzyme and/or isoaspartyl 
levels in the cells in the sense that the lower the isoaspartyl methyltransferase activity levels and/or 
the higher the isoaspartyl levels, the more pronounced the effects on activation status of the MAPK 
signalling pathway will be (at least at the level of Erk1/2). Taken together, the observations also 
suggest that the effect of Pcmt1 deficiency on the MAPK signalling pathway is not so strongly 
dependent on cell type, cell state and/or cell environment than the effect on IGF-1 signalling and that 
the former effect may therefore be mechanistically investigated further in a cell culture model. 
A possible regulatory mechanism of the MAPK pathway by Pcmt is through the Raf kinase inhibitory 
protein (RKIP), which directly interacts with the Raf kinase, leading to less activation of the MAPK 
pathway (Figure 4-1). As already mentioned before (Table 1-1), RKIP was found to be a substrate for 
Pcmt1 through the proteomics analysis of Pcmt1 mouse knockout brains (VIGNESWARA et al. 2006). 
Assuming that isoaspartyl accumulation would decrease its activity in Pcmt1 deficient cells, this could 
lead to the activation of the MAPK pathway observed in these cells. In that scenario, one would expect, 
however, to find higher phosphorylation levels of MEK, which was not the case in our experiments, 
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and in the study by Kosugi et al. (KOSUGI et al. 2008), the effect on phosphorylation levels was also 
more pronounced on Erk1/2 than on MEK. The observation that a more downstream intermediate of 
the signalling cascade is the most hyperphosphorylated in PCMT deficient cells indicates that a 
decrease in protein phosphatase activity rather than an increase of protein kinase activity is a more 
likely mechanism involved in the effect of PCMT on the MAPK pathway. 
In summary, PCMT interaction with growth signalling pathways, and more particularly with the IGF-1 
signalling pathway, is affected by many factors and simple cell culture seems in this case not to allow 
to model an effect that has been observed in the much more complex brain environment. In addition 
to the potential influence of cell type, cell-cell interaction and differentiation state already mentioned 
above, absence of crucial extracellular signals may be a critical limitation in the cell culture model. For 
example, EGF was found to accumulate isoaspartyl residues (DIAUGUSTINE et al. 1987) and could 
contribute to abnormal signalling via the MAPK pathway in the absence of PCMT. Moreover, PCMT1 
was originally discovered in the pituitary gland where many hormones were found to be substrates 
for the enzyme, including growth hormone and the hormonal carrier neurophysins (DILIBERTO and 
AXELROD 1974; EDGAR and HOPE 1974). The effect of PCMT deficiency on growth signalling might 
therefore depend on the presence of both the cells producing the growth factors as well as the target 
cells, which is more challenging to reproduce in simple cell culture. 
4.2 Protein L-isoaspartyl methyltransferase in zebrafish 
Pcmt1 knockout mice experience fatal epileptic seizures (KIM et al. 1997b; KIM et al. 1999). However, 
the interplay between Pcmt1 and seizure development is still unclear. Zebrafish is emerging as a new 
model to study epilepsy for several reasons: both zebrafish larvae and adults recapitulate some 
features of the epileptic phenotype as described for humans and rodent models, namely convulsive 
behaviours associated with epileptiform brain discharges resulting from genetic mutations or after 
exposure to proconvulsant drugs; zebrafish larvae are highly amenable for genetic and/or 
pharmacological manipulations/treatments with implications for in vivo gene function and drug 
discovery; zebrafish larvae are optically transparent enabling the in vivo live imaging of neuronal 
activity and/or other cellular/molecular processes in the brain as reviewed by Cunliffe (CUNLIFFE 2016). 
For these reasons, zebrafish seemed like a valuable vertebrate model to investigate the role of 
isoaspartyl methyltransferase during brain development and susceptibility to epileptic seizures. 
However, the isoaspartyl methyltransferase function had not yet been reported in zebrafish. 
In our search for homologs of human PCMT1 in zebrafish, we found two proteins annotated as Pcmt 
and Pcmtl and predicted to catalyse the same reaction as PCMT1, based on their amino acid sequence 
similarity to the human protein. Amino acid sequence analysis showed that human PCMT1 shares 85% 
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and 69% sequence identity with Pcmt and Pcmtl, respectively. In addition, the SAM-dependent 
methyltransferase domains as well as amino acids predicted to bind to the co-factor based on crystal 
structure data were highly conserved in both zebrafish proteins (KAGAN and CLARKE 1994; SMITH et al. 
2002). Pcmt and Pcmtl proteins in zebrafish arise from two genes located on two different 
chromosomes (20 and 17, respectively). This duplication is common for many genes in zebrafish as a 
result of a genome duplication that occurred in the teleost fish lineage (TAYLOR et al. 2001). Our results 
showed that both pcmt and pcmtl are expressed during zebrafish development and at adult stage. 
Expression of two genes for the same function can, however, represent an energy burden for the cell 
and we wanted to first test whether both proteins catalyse the same reaction as human PCMT1 or if 
they had diverged in terms of molecular function and/or localization of expression. 
4.2.1 Pcmt and Pcmtl catalyse the transfer of methyl group to isoaspartyl residues 
For functional assay of both Pcmt and Pcmtl we expressed both enzymes in E. coli and successfully 
purified them to high homogeneity. To assay the catalytic activity of the two purified enzymes, we 
used a nonapeptide Lys-Ala-Ser-Ala-isoAsp-Leu-Ala-Lys-Tyr (KASAisoDLAKY) to serve as a substrate. 
Although many substrates have been identified for PCMT1, KASAisoDLAKY has proven to be a high 
affinity substrate for PCMT1 and was used to assay the activity of PCMT homologs from many different 
species (ICHIKAWA and CLARKE 1998). An advantage of also working with this substrate was thus to allow 
for direct comparison with previous studies. We assayed the enzymatic activity of Pcmt and Pcmtl in 
vitro using a radioactivity-based methyltransferase assay described before (PATANANAN et al. 2014). 
We found that both proteins catalyse the transfer of a methyl group from the co-factor SAM to 
isoaspartyl as revealed by the methanol release from the reaction product under alkaline conditions, 
thus suggesting that both Pcmt and Pcmtl are isoaspartyl methyltransferases. The slight difference in 
substrate affinity between Pcmt and Pcmtl may be explained by a difference in the amino acid residue 
in position number 120, i.e. in one of the highly conserved isoaspartyl methyltransferase domains, 
which corresponds to Ile in case of Pcmt and Val in case of Pcmtl. Human polymorphism at this amino 
acid residue showed higher substrate affinity in case of Val (RUTHERFORD and DAGGETT 2009). 
Compared to PCMT homologs from other species, the substrate affinity of both zebrafish enzymes can 
be classified as intermediate among homologs with higher affinity, like human PCMT1, and lower 
affinity, like the C. elegans PCM-1, based on the reported KM values (Table 4-1). The almost 10-fold 
lower substrate affinity of the zebrafish proteins compared to human PCMT1 cannot be attributed to 
differences in the isoaspartyl methyltransferase domains, since those are highly conserved between 
the proteins (see Figure 3-7 ‘multiple sequence alignment’ in the Results section 3.1.3). Even more 
strikingly, the affinity of human PCMT1 for KASAisoDLAKY is 160-fold higher than the one of A. thaliana 
PCMT although the isoaspartyl methyltransferase domains are highly conserved between the two 
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proteins. Thus it appears that the affinity for the peptide substrate is highly influenced by amino acid 
residues outside of the isoaspartyl methyltransferase domains. 
Table 4-1: KM values of PCMT from different species for KASAisoDLAKY 
Species KM [µM] Reference 
A. thaliana 80 ± 18 (THAPAR and CLARKE 2000) 
C. elegans PCM-1 9.12 (KAGAN and CLARKE 1995) 
D. Rerio Pcmt 4.2 ± 0.51 This work 
D. Rerio Pcmtl 3.6 ± 0.48 This work 
E. coli pcm 50.6 (FU et al. 1991) 
H. sapiens PCMT1 0.52 ± 0.08 (LOWENSON and CLARKE 1991) 
Wheat germ 12.7 (MUDGETT and CLARKE 1993) 
T. maritima pcm 2.8 ± 0.24 (ICHIKAWA and CLARKE 1998) 
 
4.2.2 Pcmt and pcmtl are expressed during early development 
When we tested the presence of pcmt and pcmtl transcripts in fish eggs (i.e. eggs at 1-cell stage) we 
found that both of them are expressed as a result of maternal mRNA transmission through the oocyte. 
Following the transcript levels of both pcmt and pcmtl during development, we found that the pcmt 
transcript decreased up to 12 hpf followed by a gradual increase up to 3 dpf, and then stable levels up 
to 6 dpf. The variation in pcmt transcript level during the first day of development can be explained 
by the fact that the maternal contribution of the transcript is decreasing during the first hours of 
development and the embryos start expressing endogenous pcmt at later stages. On the other hand, 
pcmtl presents more stable transcription levels from 7 hpf to 2 dpf, and from 3 dpf the levels are 
doubled and become more stable up to 6 dpf. 
Since PCMT plays a protein repair role, the presence of pcmt/l transcript in the eggs can represent a 
molecular function of PCMT in rejuvenation, a process taking place during gametogenesis where all 
damaged molecules are removed, yet the underlying mechanisms are still unclear (UNAL et al. 2011). 
Independently of this possible contribution to the rejuvenation process, the subsequent expression of 
pcmt/l during early developmental stages is interesting since isoaspartyl levels have been shown to 
positively correlate with age (KIM et al. 1997b; LOWENSON et al. 2001); such an early expression of the 
repair enzyme might thus indicate an alternative function, for instance a regulatory function via 
methylation of specific proteins as opposed to the more global housekeeping protein repair role that 
might become more important again during the aging process. In rats, the Pcmt transcript levels also 
increased in the brain from embryonic day 15 (E15) up to 28-week-old (28W) (SHIRASAWA et al. 1995). 
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This early expression of Pcmt in several species thus suggests a conserved role of this protein during 
embryonic development and this may be further supported by its importance for neuronal 
differentiation (Pcmt1-deficient fibroblasts fail to differentiate in vitro; (DUNG et al. 2016) and the 
developmental delay and lack of neuronal maturation in Pcmt1 knockout mice (FARRAR et al. 2005b). 
4.2.3 pcmt and pcmtl tissue distribution 
Since we found that the catalytic function of zebrafish Pcmt and Pcmtl is very similar, one possible 
explanation that both of them are nevertheless actively expressed is a differential tissue distribution. 
We aimed at investigating the tissue distribution of both transcripts at different embryonic stages as 
well as in adult animals. Tissue distribution of PCMT homologs in other species were, to the best of 
our knowledge, not reported before at embryonic stage and the ex-uterus development of zebrafish 
offers in principle a unique opportunity to visualize gene expression during early development. The 
results obtained from the whole mount in situ hybridization of 1 dpf embryos for the pcmtl transcript 
agrees with previous results from a highthroughput expression analysis, which reported that the pcmtl 
transcript is not spatially restricted to a specific tissue (THISSE and THISSE 2004). Similar results were 
also obtained for pcmt showing ubiquitous expression in all tissues of the embryo. Yet, the high 
background in our negative controls during those experiments made it difficult to derive solid 
conclusions about the tissue localization of the pcmt and pcmtl transcripts during embryogenesis, 
since it might indicate a poor specificity of the hybridization probes used. 
Our qRT-PCR results from adult zebrafish showed also ubiquitous expression of both transcripts, but 
with differential tissue expression levels. We found that both transcripts are present in all tested 
tissues, with the highest expression levels in the brain and testes or ovaries. A similar expression 
pattern, detected by transcript levels and isoaspartyl methyltransferase activity levels, was also found 
in rats (KIM et al. 1997b; LOWENSON et al. 2001). In addition, in Pcmt1 knockout mice, the brain is the 
most affected organ with the mice dying due to fatal epileptic seizures. Interestingly, these seizures 
as well as the short lifespan phenotypes in Pcmt1 knockout mice were rescued by adenoviral mediated 
expression of exogenous Pcmt1 under the control of a neuron-specific promoter (KIM et al. 1997b; 
LOWENSON et al. 2001). These findings suggest that Pcmt1 knockout in the organs other than the brain 
has much less critical pathological effects in mice. Moreover, many of the identified major substrates 
for PCMT are brain specific proteins (e.g. synapsin and dynamin 1; (VIGNESWARA et al. 2006; ZHU et al. 
2006b)). Taken together these observations indicate a general support function of PCMT for all the 
tissues in the analysed species, including now zebrafish, but more critical roles in the brain. 
The high levels of expression of PCMT in testes might be important to preserve fertilization competent 
sperm for several weeks of storage (CHAVOUS et al. 2000). Similarly, in plants protein homoeostasis in 
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seeds is essential since seeds experience long periods of quiescence before they start to germinate. In 
Arabidopsis thaliana, Pcmt affects seed longevity and germination vigor and protects the seeds from 
heat stress (OGE et al. 2008). And as mentioned before, like in the female eggs, the high expression 
levels of PCMT in the gametes of many species suggests a role in the rejuvenation process through 
removal of damaged molecules (UNAL et al. 2011). 
While all the above helps justifying high expression of Pcmt and Pcmtl in brain, testes and ovaries, the 
reason for the conserved expression of two enzymes that catalyse the same reaction, with very similar 
kinetic parameters and spatial distribution in zebrafish is not clear yet. However, it is not the first 
organism in which the expression of two PCMT transcripts has been maintained. Arabidopsis thaliana 
expresses two genes encoding two active isoaspartyl methyltransferase enzymes and the one 
difference found so far is the subcellular localization, as one of the forms is targeted to the nucleus 
(XU et al. 2004; VILLA et al. 2006). Another difference for the two A. thaliana genes has been identified 
at the level of the regulation of expression: while one of them is constitutively expressed, the other 
one is expressed under stress or abscisic acid treatment (MUDGETT and CLARKE 1994; XU et al. 2004). 
We also saw differences in the transcription dynamics of the pcmt and pcmtl genes in zebrafish during 
early development. Further investigations on transcriptional regulation and subcellular localization of 
Pcmt and Pcmtl in zebrafish might provide rational explanations for the two corresponding genes 
being still actively expressed in this organism. 
4.2.4 Physiological implication of pcmt/l knockdown in zebrafish 
To assess the function of Pcmt and Pcmtl in vivo, we used MO technology to knock down the 
expression levels of both genes. We selected two splice blocking MOs targeting the pcmt and pcmtl 
transcripts and validated their knockdown efficiency. We can see clearly that both MOs interfere with 
the normal splicing as PCR amplification using primers flanking the region targeted by the MOs and 
gel analysis showed smaller PCR amplicons from the transcripts of both genes following MO injection 
(Figure 3-15). Sequencing of those transcripts confirmed the skipping of the MO-targeted exons. 
Moreover, the morphant larvae co-injected with both the pcmt- and pcmtl-targeting MOs showed a 
more than 73% decrease in the isoaspartyl methyltransferase activity at 2 dpf and no detectable 
activity at 4 dpf (Figure 3-17). All of these results confirmed the efficiency of the MO strategy used to 
simultaneously reduce the expression levels of pcmt and pcmtl. 
Despite the drastic decrease in isoaspartyl methyltransferase activity in the pcmt/l morphant larvae, 
there was no increase in isoaspartyl levels at 2 dpf and only a 1.5-fold increase at 4 dpf. The absence 
of isoaspartyl accumulation at 2 dpf and the low accumulation at 4 dpf as compared to an up to 8-fold 
increase of isoaspartyl levels measured in the Pcmt1 knockout mice (KIM et al. 1997b) can be due to 
Discussion 
108 
 
many reasons. First, the age difference of the analysed fishes and mice: the accumulation of 
isoaspartyl residues is age-dependent and the higher accumulation observed in the Pcmt1 knockout 
mice might simply be due to the fact the samples were obtained from older animals (30 – 40 days old 
mice (KIM et al. 1997b)). Two or four days of development might not have been enough time for 
reaching isoaspartyl levels that would lead to clearly identifiable phenotypes, but this time constraint 
is imposed by MO technology as knockdown efficiency is going down starting at 5 dpf. Second, 
knockdown of the isoaspartyl methyltransferase activity might lead to activation of proteolytic 
pathways limiting the accumulation of isoaspartyl residues in proteins by an independent mechanism 
(PATANANAN et al. 2014). Indeed, SDS-PAGE analysis of protein extracts from 2 dpf pcmt/l morphants 
indicated increased proteolysis in those samples and comparison of results obtained by isoaspartyl 
assay in total protein extracts versus fluorography supported the idea of increased proteolysis of 
isoaspartyl-containing proteins specifically induced in the pcmt/l knockdown animals (Section 
3.1.3.3.2). The latter might therefore be an interesting model for further investigations on proteases 
more specifically acting on isoaspartyl-containing proteins. 
MO-mediated double knockdown of both pcmt and pcmtl led to morphological abnormalities in 
zebrafish larvae. The most obvious phenotypes in the pcmt/l morphants were the small size, curved 
trunk and a delayed swim bladder development. A recent publication showed disagreements between 
some phenotypes observed with MO-mediated knockdown and TALEN- or CRISPR/Cas9-mediated 
knockout of the same genes, suggesting that a number of phenotypes induced by MOs are due to off-
target effects (KOK et al. 2015). The most common MOs off-target phenotypes reported by the latter 
study included curved and shortened trunk, and stalled intersegmental vessels. However, the poor 
correlation between gene knockout and knockdown in this study could have been due to several 
reasons. For example, gene knockout, but not to the same extent knockdown, can activate 
compensatory mechanisms masking phenotypic effects of the gene silencing; from this point of view 
it seems actually advantageous to use MO knockdown methodology over knockout technologies (ROSSI 
et al. 2015). Another reason for different results obtained with knockout versus knockdown strategy 
can be gene redundancy in knockout models due to gene duplication, alternative start codon, or 
partial overlapping function, especially in zebrafish where the genome duplication event has resulted 
in numerous paralogous gene pairs; this could again lead to rescue of effects caused by the knockout 
gene (BARBARIC et al. 2007). Therefore, despite the recent controversies around MOs as a good tool 
for gene knockdown in zebrafish, we believe that it remains a valuable strategy, especially if the 
injected MO concentrations are well titrated and used at a concentration where the targeted genes 
are efficiently downregulated, but where toxic, likely off-target effects are not seen yet. We did these 
titration efforts where we tried different amount of each MO individually and selected the maximum 
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amounts that does not lead to sever dysmorphology by itself. Even when combining the two MO 
against pcmt and pcmtl together we went more down with the MO amounts combined together. In 
addition, the gene specificity of phenotypic effects induced by MOs can be tested using rescue 
strategies, by exogenous expression of the target gene either by transcript injection or DNA vector 
carrying the coding sequence of the target gene. Although our trails to rescue the dysmorphological 
phenotype in the larvae did not lead to a significant recovery of those phenotypes, still pcmt/l 
knockdown could be the reason behind the observed morphological abnormalities since mice 
deficient in Pcmt1 also experience growth retardation (KIM et al. 1997b). 
The delay of development of the swim bladder was another interesting phenotype in the pcmt/l 
morphant larvae, specially it not a common off-target effect induced by many other MOs (KOK et al. 
2015). The swim bladder development was found to be regulated by various signalling pathways like 
Notch and Hey2 (HOLTZINGER and EVANS 2005), but so far none of these pathways were investigated in 
the context of PCMT deficiency. Interestingly, swim bladder development hindrance has been recently 
reported in the context of other neurological disorders modelled in zebrafish (ZHANG et al. 2015; 
WAGER et al. 2016). Since PCMT is important for normal brain functioning (as also supported by work 
in zebrafish in this thesis), there could be a specific link to the swimming bladder development. This 
indicates that the zebrafish may be a valuable new model to explore interactions of PCMT with 
signalling pathways involved in development in addition to the growth signalling pathways to which 
connections have already been established in other models. The work performed in this thesis lays 
solid grounds to start these investigations. 
MO-mediated knockdown studies of genes associated with epilepsy in humans were found to induce 
seizures in zebrafish larvae, which could be detected using electroencephalography in the optic 
tectum (EEG) (ZHANG et al. 2015; WAGER et al. 2016). Likewise, we pursued to use the same technique 
to analyse brain electrical activity and to test whether our pcmt/l morphant zebrafish larvae present 
a similar seizure phenotype as observed in Pcmt1 knockout mice (KIM et al. 1999). Our EEG results did 
not reveal brain electrical activity reminiscent of epileptic discharges in the pcmt/l morphant larvae. 
We also performed locomotor tracking experiments in the same larvae; locomotor tracking is another 
method for the detection of abnormal brain activity as it can result in atypical movement behaviours 
(AFRIKANOVA et al. 2013). Locomotor tracking of 4 dpf larvae deficient in pcmt/l showed neither 
differences in their total distance travelled nor in the velocity of their movements under control 
conditions; even when using a sub-convulsant concentration of PTZ (0.5 mM), no difference was 
detected. Interestingly, with 20 mM PTZ stimulation, pcmt/l morphant larvae showed much less 
locomotor activity in terms of total distance travelled during the assay, although the velocity of the 
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remaining movements was similar to that of control larvae. On the one hand, these observations 
indicate that PCMT deficiency does not lead to seizure development in young zebrafish larvae. On the 
other hand, the locomotor tracking experiments revealed that PCMT deficiency in those larvae leads 
to abnormally low locomotor activity, which may be explained by delays in swimming bladder and/or 
brain development. 
Despite both showing developmental abnormalities(YAMAMOTO et al. 1998), it is interesting to think 
about the possible reasons for the discrepancy between Pcmt1 knockout mice and pcmt/l morphant 
larvae in terms of seizure development. One possible reason is that the downregulation of PCMT 
activity in the morphant zebrafish larvae is probably only effective at later stages than in the mouse 
knockout model. The MOs we used for pcmt/l knockdown interfere with mRNA splicing. This means 
that the maternal mRNA, which is already spliced, is not affected by those MOs and our results indeed 
indicated that wild type pcmt/l transcripts are present in the pcmt/l morphant embryos up to 12 hpf 
(data not shown). By contrast, in Pcmt1 knockout mice, the enzyme is absent from the very start (1-
cell zygote stage). It can be speculated that some critical events in terms of brain development are 
differentially affected depending on the presence or absence of PCMT in these first hours of life, which 
will later on lead (or not) to the development of seizures. Also, the Pcmt1 knockout mice were 
reported to have a 15% increase in brain size compared to wild type littermates (YAMAMOTO et al. 
1998), whereas pcmt/l morphant larvae actually showed smaller brain size compared to control 
larvae. Finally, a straightforward comparison between the zebrafish and mouse model may be 
hampered again by the difference in age of the analysed animals. Given the decrease in MO 
knockdown efficiency beyond 5 dpf, we tried to detect seizures via EEG recordings at 4 dpf in the 
zebrafish model, whereas the seizure events detected in the mice occurred at the age of 4 – 12 weeks 
(YAMAMOTO et al. 1998). 
Despite all these observations pointing at the absence of seizure development in PCMT deficient 
zebrafish, some further deeper investigations may be required to fully formulate conclusions. Due to 
some developmental delays, interpretation of the locomotor tracking experiments is difficult in terms 
of epileptic seizure development and EEG recordings seem to be better adapted to pursue the epilepsy 
analyses in the pcmt/l morphant larvae. EEG recordings were so far only performed in control 
conditions. It might be worth repeating such recordings after exposure of the larvae to proconvulsant 
agents. However, given the apparent irresponsiveness of the pcmt/l morphants to the commonly used 
proconvulsant PTZ (see calcium signalling experiment and also the absence of increased locomotor 
activity after exposure to high doses of PTZ), different agents like pilocarpine and kainate should be 
tested here. Finally, it is worth considering that the epileptic seizures in the Pcmt1 knockout mice may 
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be a secondary effect of Pcmt1 deficiency whereas the primary effect is impaired brain development. 
Similarly, mutations in the phenylalanine hydroxylase (PAH) gene lead to seizures in a mouse model 
and humans, but the primary effect of phenylalanine accumulation is a delay in brain development 
which then renders these animals prone to seizures (KAYAALP et al. 1997; MARTYNYUK et al. 2007). 
4.3 Calcium signalling 
4.3.1 Calcium homeostasis in the cell 
Regulation of intracellular Ca2+ concentration is important for many cellular processes like 
differentiation, apoptosis and transcription (BERRIDGE et al. 2003). These processes depend on the 
dynamics of cytosolic Ca2+ concentrations as well as downstream targets. Most of the Ca2+ binding 
proteins are characterized with helix-loop-helix motives (also called EF-hands), which contain the 
conserved sequence Asp-X-Asp-X-X-Gly. Ca2+ binds to this motif causing conformational changes in the 
Ca2+ binding proteins that will allow the binding to their downstream (FRIEDBERG 1988). Well known 
examples of Ca2+ binding proteins are calmodulin, which regulates for example phosphorylation 
cascades via interactions with Ca2+-calmodulin dependent kinases (CaMK), protein kinase C and 
protein kinase A and the Ca2+-dependent phosphatase calcineurin B (BERRIDGE et al. 2003). Since 
intracellular Ca2+ concentration critically impacts many cellular processes, it is tightly controlled by a 
range of regulatory mechanisms. 
Upregulation of cytosolic Ca2+ concentrations is achieved through either influx from extracellular space 
or release from intracellular Ca2+ pools, mainly the ER, but also other organelles like sarcoplasmic 
reticulum (SR), Golgi apparatus and mitochondria. Ca2+ influx from the extracellular space occurs 
through voltage-operated as well as ligand-gated Ca2+ channels upon stimulation. N-methyl-D-
aspartate receptors (NMDARs) are one class of ligand-gated Ca2+ channels activated upon ligand 
binding like the excitatory neurotransmitter glutamate (RAO and FINKBEINER 2007). Voltage-operated 
Ca2+ channels, e.g. N and P/Q channels, are present on excitable neurons and are activated upon 
membrane depolarization and will lead to Ca2+ influx and neurotransmitter release (BURNASHEV and 
ROZOV 2005). Intracellular Ca2+ release in response to GPCR stimulation is achieved through the 
production of inositol 1,4,5 trisphosphate (IP3), which binds to IP3 receptors (IP3R) on the ER 
membrane, leading to calcium release from the ER to the cytosol (SALTER and HICKS 1995). 
Downregulation of cytosolic Ca2+ concentrations was found to be kinetically controlled. Cells evolved 
mechanisms for rapid decrease in cytosolic Ca2+ concentration and others for slower decrease, in order 
to bring the Ca2+ concentration back to its basal levels following stimulation. Rapid decrease 
mechanisms depend on protein buffers like calbindin D-28k, calretinin, and calmodulin, present in the 
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cytosol and binding instantly to Ca2+ reducing its cytosolic free concentration (SCHWALLER 2007). Slower 
mechanisms are based on Ca2+ pumps and exchangers. Mitochondria also were found to be sensitive 
to cytosolic Ca2+ concentration and play an important role in its downregulation where they tend to 
take up Ca2+ to protect the cells from apoptosis (COLLINS et al. 2001; GIACOMELLO et al. 2007). 
This brief summary illustrates that intracellular Ca2+ concentration is regulated through different 
mechanisms and should make it clear that interfering with one or more of those checkpoints would 
lead to perturbed Ca2+ homeostasis affecting many Ca2+-dependent cellular functions. 
4.3.2 Interplay between PCMT and calcium 
Calmodulin is one of the early discovered substrates for PCMT. It accumulates high levels of isoaspartyl 
levels during in vitro as well as in vivo aging (GAGNON et al. 1981; JOHNSON et al. 1985; POTTER et al. 
1993). In addition, one of the isoforms of PCMT1 contains the RDEL ER retention signal, suggesting a 
possible localization of the enzyme also in this Ca2+ hub organelle. Supporting this hypothesis is the 
isoaspartyl formation in calreticulin, an endoplasmic reticulum resident protein and Ca2+ regulator, 
which is one of the major substrates for Pcmt1 found through the proteomic analysis of Pcmt1 
knockout mouse brains (VIGNESWARA et al. 2006). Moreover, it has recently been reported that PCMT1 
may play an important role in the preservation of mitochondrial function and that its knockdown leads 
to a significant decrease in ATP levels (OGASAWARA et al. 2016), which we confirmed in our Pcmt1 
knockout cell model. Finally, the EF-hand (Asp-X-Asp-X-X-Gly) in Ca2+ binding proteins contains two 
aspartate residues which are prone to isoaspartyl formation affecting Ca2+ binding (FRIEDBERG 1988). 
Due to all these established or potential connections between PCMT and Ca2+ homeostasis as well as 
known connections between the latter and epilepsy development, we were tempted to test the effect 
of PCMT on Ca2+ signalling in the PCMT deficient models created in this thesis. 
We used a transgenic zebrafish line that encodes the GCaMP6f protein, a cytosolic Ca2+ indicator 
whose fluorescence intensity increases upon intracellular Ca2+ release. PTZ was reported to induce 
seizures through release of Ca2+ from intracellular pools like the endoplasmic reticulum (ER) (SUGAYA 
and ONOZUKA 1978; ONOZUKA et al. 1989). The knockdown of pcmt/l in zebrafish drastically hindered 
Ca2+ fluxes in the brain in response to PTZ stimulation, an effect that was rescued with exogenous 
expression of pcmt/l but not catalytically inactive forms of the enzymes. This observation strongly 
suggested that the isoaspartyl methyltransferase activity plays an important role to support Ca2+ 
movements in the cell. We sought further support for this role in our HT22 cell model where we used 
the Fluo-4 dye (GEE et al. 2000), a fluorescent Ca2+ indicator. Upon stimulation of the cells with ATP, 
both control and Pcmt1 knockout cells showed a transient increase in intracellular Ca2+ concentrations. 
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Interestingly, upon a second stimulation with ATP, the control cells again responded with a spike in 
intracellular Ca2+ concentration, which was not observed in the Pcmt1 knockout cells. 
Even though the HT22 knockout cells responded to the first ATP stimulation, the Ca2+ spike area and 
width showed that a lower intracellular Ca2+ concentration was reached and that the subsequent Ca2+ 
buffering (to recover original Ca2+ concentrations) was less efficient as compared to control cells. As 
mentioned before, cytosolic Ca2+ binding proteins like calmodulin and organelles like the mitochondria 
are important players in Ca2+ buffering or downregulation. Non-repaired calmodulin in Pcmt1 
knockout cells could be one of the reasons behind the poor buffering of Ca2+ since the Ca2+ binding 
affinity of calmodulin might be affected with the accumulation of isoaspartyl residues (BILLINGSLEY et 
al. 1985b; OTA and CLARKE 1990). Another possibility of poor Ca2+ buffering could be mitochondrial 
dysfunction. Our results showed lower ATP/ADP ratios in Pcmt1 knockout HT22 cells and a recent 
study also provided evidence for mitochondrial dysfunction in PCMT1 knockdown A549 
cells(OGASAWARA et al. 2016). 
To further investigate the mechanism involved in the crosstalk between PCMT and Ca2+ signalling, we 
used LC-MS analysis to measure the levels of Ca2+ related metabolites in HT22 Pcmt1 knockout cells. 
The release of Ca2+ from the ER in response to ATP was found to be phospholipase C (PLC) dependent 
following activation of GTP-dependent GPCR. PLC catalyses the hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PIP2) to diacylglycerol (DAG) and IP3, which in turn binds to the IP3 receptor (IP3R) in 
the ER membrane leading to the release of Ca2+ (SALTER and HICKS 1995). The GTP/GDP ratio was not 
affected by Pcmt1 knockout, suggesting that GPCR activity may not be affected but rather a 
downstream target to it. By contrast, IP3 levels in the Pcmt1 knockout HT22 cells were found to be 4-
fold lower as compared to control cells, which could contribute to the lower cytosolic calcium levels 
reached after ATP stimulation in the knockout cells. A possible reason for decreased IP3 concentrations 
in the knockout cells could be a deficiency in PLC activity due to isoaspartyl residue accumulation in 
the enzyme, but this has not been investigated so far. Noticeably, similar to Pcmt1 knockout mice, PLC 
knockout mice experience epilepsy, (KIM et al. 1997a) suggesting that the epileptic seizures in the 
Pcmt1 knockout mice may be mechanistically connected to PLC function, although this remains highly 
speculative for the time being. 
In summary, our work in PCMT deficient cell and zebrafish models suggests that the isoaspartyl 
methyltransferase activity of PCMT plays an important role in the calcium response of the cell to 
extracellular stimuli, that is conserved in fish and mammals. Possible mechanisms underlying this role 
of PCMT are as follows: 1) supporting PLC activity for the adequate production of IP3 and Ca2+ release 
from the ER; 2) maintaining calmodulin levels or calcium affinity to guarantee adequate calcium 
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buffering capacity in the cytosol; and 3) preserving mitochondrial function and thereby its role in 
calcium re-uptake through an as yet unknown mechanism (Figure 4-2). Some evidence has been found 
to support the first mechanistic line proposed. However, this list is not exhaustive and further work is 
needed to better understand how PCMT contributes to regulating calcium uptake and/or 
downregulation after exposure of the cell to extracellular stimuli. 
 
Figure 4-2: Possible mechanisms underlying the role of PCMT in supporting the cellular calcium response to extracellular 
stimuli.PCMT deficiency may lead to lower PLC activity and IP3 production and/or mitochondrial dysfunction and 
lower ATP production. In addition, PCMT deficiency could affect the Ca2+ buffering capacity of the cytosol via 
effects on calmodulin levels or Ca2+affinity. CaM: Calmodulin; DAG: diacylglycerol; IP3: inositol (3,4,5)-
trisphosphate; PIP2: Phosphatidylinositol 4,5-bisphosphate; PLC: phospholipase C. 
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5 Conclusions and perspectives 
Our work aimed at elucidating the mechanism by which the protein repair enzyme PCMT interacts 
with growth signalling pathways such as the insulin/IGF-1 and MAPK pathways. To address this aim, 
new models to investigate this and other physiological roles of PCMT have been established and 
validated and for the first time in vivo evidence could be produced to support and important role for 
PCMT in the cellular calcium response to extracellular stimuli in the brain. 
PCMT1 knockdown in HEK293 and U-87 MG cells did not affect either Akt or Erk1/2 phosphorylation 
levels under our experimental conditions. Pcmt1 knockout in HT22 mouse hippocampal cells did not 
produce detectable effects on Akt phosphorylation either, but we could find a transient increase in 
ERK1/2 phosphorylation levels in the knockout cells compared to control cells after exposure to EGF. 
Our main conclusions from this work are that the regulation of the insulin/IGF-1 signalling pathway by 
PCMT seems to rely on interactions that are too complex to reproduce in simple cell culture models 
and that can only be meaningfully addressed in the context of the living brain. This is less the case for 
the effect of PCMT on the MAPK signalling pathway, which can be observed in simple cell culture. 
However, type of stimulator used, stimulator concentration, exposure time to the stimulator, and 
extent of reduction of PCMT expression are all factors critically impacting this effect. We ended up 
finding conditions under which ERK1/2 hyperphosphorylation could be reproducibly observed in 
PCMT knockout cells; these conditions can now be used to investigate molecular mechanisms 
underlying the observed effect in a convenient experimental setting. 
We have also established a new vertebrate whole organism model for investigation of the 
physiological role of PCMT. After demonstrating that zebrafish expresses two PCMT homologs (Pcmt 
and Pcmtl) with isoaspartyl methyltransferase activity, we characterized their expression during 
development and their tissular distribution. Maternal transcript for both genes are transmitted to the 
progeny, reflecting the importance of both genes during the very first stages of development. Both 
enzymes were ubiquitously expressed in all organs tested with the highest levels in the brain and 
testes or ovaries, consistent with what has been reported for other species. Both enzymes catalyse 
the transfer of a methyl group from the cofactor SAM to isoaspartyl residues with very similar kinetics. 
MO-meditated knockdown of both genes simultaneously led to developmental abnormalities, 
locomotor impairment, and a perturbed calcium response. 
For future perspectives, it would be interesting to reveal the differences between Pcmt and Pcmtl that 
justify conservation of expression of both the proteins by zebrafish. The data that we gathered so far 
revealed no large differences between Pcmt and Pcmtl in terms of gene expression, tissue distribution 
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and catalytic function. However, we did not investigate the subcellular localization of the enzymes. 
Such studies may reveal different compartmentalization of both enzymes similar to what has been 
found in A. thaliana, where one of the PCMT paralogs is targeted to the nucleus. It could also be that 
after gene duplication, both Pcmt and Pcmtl retained the isoaspartyl methyltransferase function, but 
that one of them retained another ancestral function, which was lost in the other. Further enzymatic 
and functional analyses of the zebrafish proteins may shed more light on possible alternative functions 
of PCMT. 
Concerning the effect of PCMT on the calcium response that we uncovered in the zebrafish model and 
subsequently confirmed in the HT22 cell model, the low intracellular IP3 levels that we detected upon 
Pcmt1 knockout in the HT22 cells suggest that phospholipase C may be an interesting enzyme to study 
with respect to its susceptibility to isoaspartyl damage and a protective function of PCMT. It is 
currently not known whether PCMT interacts with PLC and whether or not this interaction plays a role 
in the effect of PCMT deficiency on the cellular calcium response. Another possible mechanistic 
explanation for the effects of PCMT deficiency on calcium fluxes, which cannot be ignored given a 
body of pre-existing evidence, involves the calcium binding protein calmodulin. As the isoaspartyl 
methyltransferase activity seems to be required for the role of PCMT in calcium regulation, based on 
our observations in the zebrafish model, the most straightforward calmodulin-associated mechanism 
would be that PCMT deficiency decreases the calcium binding affinity of calmodulin (due to non-
repaired isoaspartyl residues) or its calcium binding capacity (due to increased proteolytic degradation 
of calmodulin because of higher isoaspartyl content). Support for these hypotheses could be obtained 
for example by measuring calmodulin protein levels as well as isoaspartyl content in calmodulin (by 
mass spectrometry; (YANG et al. 2013)) in pcmt/l morphant larvae versus control larvae. 
Moreover, a recent proteomic study supports a role of PCMT in glutamate metabolism that might lead 
to seizures as well (YANG et al. 2013). We also obtained, during the work of this thesis, some 
preliminary data in our Pcmt1 knockout HT22 cell line supporting differential response to glutamate 
toxicity compared to control cells. While 3 mM glutamate was found to be toxic and affects HT22 cell 
viability, Pcmt1 knockout were resistant to the same concentration of glutamate. One possible 
explanation could be a damage in glutamate receptor in cells deficient in Pcmt1 leading to lower 
sensitivity to glutamate. It would be interesting to pursue the investigation of glutamate toxicity in 
our cell model which might reveal new findings on the effect of PCMT on glutamate metabolism.  
Generation of a pcmt/l double knockout zebrafish line using CRISPR/Cas9 technology would enable us 
to study the effect of isoaspartyl residue accumulation, which is positively correlated with age, on 
physiological functions at later stages of development. The high expression levels of PCMT in the brain 
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and its interaction with various proteins associated to neurodegenerative diseases, which typically 
develop at later age stages, suggest that PCMT may play a protective role in neurodegenerative 
diseases. In this context, the study of the effects of PCMT deficiency certainly makes more sense at 
later age stages. Towards this end, it would also be interesting to study PCMT deficiency in 
combination with a neurodegenerative disease model such as for example zebrafish lines expressing 
α-synuclein. A pcmt/l knockout line would maybe also enable the study of seizures associated with 
PCMT deficiency and which may only develop at later age. The lower efficiency of MOs at 
developmental stages later than 5 dpf limited us from this point of view in this thesis, where we did 
not detect a difference in electrical brain activity by EEG in the young animals tested. Finally, a pcmt/l 
knockout zebrafish model may be instrumental in investigating the role of PCMT in insulin/IGF-1 
signalling in the brain, given a number of afore mentioned practical advantages over the mouse model 
and that it addresses the apparent requirement for these studies to be implemented in the context of 
a living brain, as suggested by the work in this thesis. 
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6 Appendix 
6.1 Plasmid maps 
6.1.1 Plasmids for lentivirus production and shRNA 
6.1.1.1 pENTR™/U6 
 
 
Feature Bases Benefit 
rrnB T1 and T2 
transcription 
terminators 
427-470 
268-295 (C) 
Reduces potential toxicity in E. coli by preventing basal 
expression of the double-stranded oligonucleotide of interest. 
M13 forward (-20) 
priming site 
537-552 Allow sequencing of the insert. 
attL1 and attL2 sites 569-668 (C) 
979-1078 
Bacteriophage λ-derived recombination sequences that allow 
recombinational cloning of a gene of interest in the entry 
construct with a Gateway® destination vector (Landy, 1989). 
Human U6 promoter 705-968 Allows RNA polymerase III-dependent expression of the short 
hairpin RNA (shRNA) (Kunkel et al., 1986; Kubkel and Pederson, 
1988). 
U6 forward priming 
site 
 Allow sequencing of the insert. 
5’ overhangs 965-968 (C) 
969-972 
Allows ligase-mediated directional cloning of the double-
stranded oligonucleotide of the insert. 
Pol III terminator 969-974 Allows efficient termination of RNA Polymerase III-dependent 
transcription. 
M13 reverse priming 
site 
1119-1135 Allow sequencing of the insert. 
Kanamycin resistance 
gene 
1248-2057 Allows selection of the plasmid in E. coli. 
pUC origin of 
replication (ori) 
2178-2851 Permits high-copy replication and maintenance in E. coli. 
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6.1.1.2 pLenti6/BLOCK-iT™ 
 
Feature Bases Benefit 
Rous Sarcoma Virus (RSV) 
enhancer/promoter 
1-229 Allows Tat-independent production of viral mRNA 
(Dull et al., 1998). 
HIV-1 truncated 5’ LTR 230-410 Permits viral packaging and reverse transcription of 
the viral mRNA (Luciw, 1996). 
5’ splice donor and 3’ 
acceptors 
520 Enhances the biosafety of the vector by facilitating 
removal of the Ψ packaging sequence and RRE such 
that expression of the gene of interest in the 
transduced host cell is no longer Rev-dependent (Dull 
et al., 1998). 
HIV-1 psi (Ψ) packaging signal 521-565 Allows viral packaging (Luciw, 1996). 
HIV-1 Rev response element 
(RRE) 
1075-1308 Permits Rev-dependent nuclear export of unspliced 
viral mRNA (Kjems et al., 1991; Malim et al., 1989). 
attR1 and attR2 sites 1868-1992 
4008-4132 
Bacteriophage λ-derived recombination sequences 
that permit recombinational cloning of the gene of 
interest from Gateway. 
ccdB gene 2421-2726 (C) Permits negative selection of the plasmid. 
Chloramphenicol resistance 
gene (CmR) 
3068-3727 (C) Allows counterselection of the plasmid. 
SV40 early promoter and origin 4281-4590 Allows high-level expression of the selection marker 
and episomal replication in cells expressing the SV40 
large T antigen. 
EM7 promoter 4645-4711 Synthetic prokaryotic promoter for expression of the 
selection marker in E. coli. 
Blasticidin (bsd) resistance 
gene 
4712-5110 Permits selection of stably transduced mammalian cell 
lines (Kimura et al., 1994). 
ΔU3 
HIV-1 truncated 3’ LTR 
5916-5430 Allows viral packaging but self-inactivates the 5’ LTR 
for biosafety purposes (Dull et al., 1998). The element 
also contains a polyadenylation signal for transcription 
termination and 
polyadenylation of mRNA in transduced cells. 
SV40 polyadenylation signal 5502-5636 Allows transcription termination and polyadenylation 
of mRNA. 
bla promoter 6492-6590 Allows expression of the ampicillin resistance gene. 
Ampicillin resistance gene (β-
lactamase) 
6591-7451 Allows selection of the plasmid in E. coli. 
pUC origin 7596-8269 Permits high-copy replication and maintenance in E. 
coli. 
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6.1.1.3 pLP1 
 
Feature Bases Benefit 
Human cytomegalovirus (CMV) 
promoter 
1-747 Permits high-level expression of the HIV-1 gag and pol 
genes in mammalian cells (Andersson et al., 1989; 
Boshart et al., 1985; Nelson et al., 1987). 
Human β-globin intron 880-1320 Enhances expression of the gag and pol genes in 
mammalian cells. 
HIV-1 gag coding sequence 1355-2857 Encodes the viral core proteins required for forming 
the structure of the lentivirus (Luciw, 1996). 
HIV-1 pol coding sequence 2650-2857 Encodes the viral replication enzymes required for the 
replication and integration of the lentivirus (Luciw, 
1996). 
HIV-1 Rev response element 
(RRE) 
5686-5919 Permits Rev-dependent expression of the gag and pol 
genes. 
pUC origin of replication (ori) 6995-7668 (C) Permits high-copy replication and maintenance in E. 
coli. 
Ampicillin (bla) resistance gene 7813-8673 (C) Allows selection of the plasmid in E. coli. 
6.1.1.4 pLP2 
 
Feature Bases Benefit 
RSV enhancer/promoter 1-271 Permits high-level expression of the rev gene (Gorman et 
al., 1982). 
HIV-1 Rev ORF 391-741 Encodes the Rev protein that interacts with the RRE on 
pLP1 and on the pLenti6/BLOCK-iT™-DEST expression 
vector to induce Gag and Pol expression, which promotes 
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the nuclear export of the unspliced viral RNA for packaging 
into viral particles. 
HIV-1 LTR polyadenylation 
signal 
850-971 Allows efficient transcription termination and 
polyadenylation of mRNA. 
Ampicillin (bla) resistance gene 2015-2875 Allows selection of the plasmid in E. coli. 
pUC origin of replication (ori) 3020-3693 Permits high-copy replication and maintenance in E. coli. 
 
6.1.1.5 pLP/VSVG 
 
 
Feature Bases Benefit 
Human CMV promoter 1-747 Permits high-level expression of the VSV-G gene in 
mammalian cells (Andersson et al., 1989; Boshart et al., 
1985; Nelson et al., 1987). 
Human β-globin intron 880-1320 Enhances expression of the VSV-G gene in mammalian 
cells. 
VSV G glycoprotein (VSV-G) 1346-2881 Encodes the envelope G glycoprotein from Vesicular 
Stomatitis Virus to allow production of a pseudotyped 
retrovirus with a broad host range (Burns et al., 1993; Emi 
et al., 1991; Yee et al., 1994) 
Human β-globin 
polyadenylation signal 
3004-3769 Allows efficient transcription termination and 
polyadenylation of mRNA. 
pUC origin of replication (ori) 3927-4600 
(C) 
Permits high-copy replication and maintenance in E. coli. 
Ampicillin (bla) resistance gene 4745-5606 
(C) 
Allows selection of the plasmid in E. coli. 
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6.1.2 Plasmid for CRISPR/Cas9 pX459 
 
Feature Benefit 
U6 promoter Allows RNA polymerase III-dependent expression of the gRNA 
Human CMV promoter Permits high-level expression of the Cas9 gene in mammalian cells. 
Cas9 Encodes Cas9 
PuroR Permits selection of transfected mammalian cell lines 
Human β-globin polyadenylation 
signal 
Allows efficient transcription termination and polyadenylation of 
mRNA. 
Ampicillin (bla) resistance gene Allows selection of the plasmid in E. coli. 
pUC origin of replication (ori) Permits high-copy replication and maintenance in E. coli. 
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6.1.3 Plasmid for recombinant protein expression: pET100 
 
Feature Bases Benefit 
T7 promoter 209-225 Permits high-level, IPTG-inducible expression of your 
recombinant protein in E. coli strains expressing the T7 
RNA polymerase. 
T7 forward priming site 209-228 Allow sequencing in the sense orientation 
lac operator (lacO) 228-252 Binding site for lac repressor that serves to reduce basal 
expression of your recombinant protein. 
Ribosome binding site 282-288 Optimally spaced from the TOPO® Cloning site for efficient 
translation of PCR product. 
N-terminal 6×His tag 309-326 Permits purification of recombinant fusion protein on 
metal-chelating resin (i.e. ProBond™ or Ni-NTA). In 
addition, allows detection of recombinant protein with 
the Anti-HisG Antibodies. 
Xpress™ epitope (Asp-Leu-Tyr-
Asp-Asp-Asp-Asp-Lys) 
366-389 Allows detection of the fusion protein by Anti-Xpress™ 
Antibodies. 
Enterokinase (EK) recognition 
site (Asp-Asp-Asp-Asp-Lys) 
375-389 Allows removal of the N-terminal tag from your 
recombinant protein using an enterokinase such as 
EKMax™. 
T7 Revers priming site 466-485 Allows sequencing of the insert. 
T7 transcription termination 
region 
427-555 Sequence from bacteriophage T7 which permits efficient 
transcription termination. 
bla promoter 856-954 Allows expression of the ampicillin resistance gene. 
Ampicillin resistance gene (β-
lactamase) 
955-1815 Allows selection of the plasmid in E. coli. 
ROP ORF 3001-3192 
(C) 
Interacts with the pBR322 origin to facilitate low-copy 
replication in E. coli. 
lacI ORF 4507-5595 
(C) 
Encodes lac repressor which binds to the T7lac promoter 
to block basal transcription of the gene of interest and to 
the lacUV5 promoter in the host chromosome to repress 
transcription of T7 RNA polymerase 
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6.1.4 Plasmids for zebrafish 
6.1.4.1 pCS2+ 
 
Feature Bases Benefit 
Sp6 primer 35-52 Allows in vitro transcription of ORF 
SV40_PA_terminator 145-273 (C) Allows transcription termination and polyadenylation of 
mRNA. 
Ampicillin resistance gene (β-
lactamase) 
1591-2451 
(C) 
Allows selection of the plasmid in E. coli. 
f1 origin 2600-2905 
(C) 
Permits high-copy replication and maintenance in E. coli. 
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6.1.4.2 pZFF001 
 
Feature Benefit 
MiniTol2 Permits transgenesis of exogenous gene into the zebrafish genome 
Her4.1 promoter Permits expression in neuronal cells 
P2A peptide Self-cleaving peptide that allow cleavage of expressed protein of interest 
from reporter fluorescent protein AmCyan 
AmCyan Fluorescence reporter protein 
SV40 polyadenylation signal Allows transcription termination and polyadenylation of mRNA. 
Ampicillin resistance gene (β-
lactamase) 
Allows selection of the plasmid in E. coli. 
 
6.1.4.3 pGEMT 
 
Feature Benefit 
MiniTol2 Permits transgenesis of exogenous gene into the zebrafish genome. 
eEF1α promoter Permits expression in eukaryotic cells 
dsRED Fluorescence reporter protein 
Ampicillin resistance gene (β-
lactamase) 
Allows selection of the plasmid in E. coli. 
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6.2 LCMS 
6.2.1  Ionisation 
• Sheath gas flow rate   20 AU 
• Auxiliary gas flow rate   5 AU 
• Sweep gas flow rate   3 AU 
• Spray voltage    2.5 kV 
• Capillary temperature   250°C 
• S-lens RF level    50 V 
• Auxiliary gas heater temperature 100°C 
6.2.2 Nucleotides method 
• Targeted single ion monitoring (tSIM) 
• Runtime   10 minutes 
• polarity    negative 
• Mass resolution  35000 
• AGC Target 200000  200000 
• Maximum injection time 200 ms 
• Isolation window  0.4 m/z 
  Adduct neg 
mode 
Mass adduct neg 
mode 
detection 
window 
AMP C10H14N5O7P  -H 346.0552594  0 - 3 
ADP C10H15N5O10P2  -H 426.0215899 2 - 3.7 
ATP C10H16N5O13P3  -H 505.9879205 2.7 - 5 
GMP C10H14N5O8P  -H 362.050174 2.3 - 4.1 
GDP C10H15N5O11P2  -H 442.0165046 3.4 - 5.6 
GTP C10H16N5O14P3  -H 521.9828351 4.4 - 10 
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6.2.3 Inositol (3,4,5)-trisphosphate method 
 
• Targeted single ion monitoring (tSIM) 
• Runtime   20 minutes 
• polarity    positive 
• Mass resuolution  70000 
• AGC Target 200000  3000000 
• Maximum injection time 200 ms 
• Isolation window  0.4 m/z 
  Adduct neg 
mode 
Mass adduct neg 
mode 
detection 
window 
D-myo-inositol 
1,4,5-
triphosphate 
C6H15O15P3  +H 420.9702047026  
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